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Zusammenfassung
Zusammenfassung
Voraussetzung für die Induktion einer effizienten Immunantwort ist neben dem richtigen
Antigen eine effiziente Präsentation von Antigen in vitro und in vivo. Dendritische Zellen (DC)
gelten als die am besten charakterisierten antigen-präsentierenden Zellen. Allerdings
können sie kaum in großen Mengen und ausreichender Reinheit hergestellt werden, was
einen entscheidenden Nachteil bei der Nutzung von DCs in der klinischen Anwendung dar
stellt. Deshalb wurde ein alternativer Ansatz entwickelt, bei dem polyklonale B-Zellen durch
die Behandlung mit stimulierenden Zytokinen und dem CD40-Liganden als
antigenpräsentierende Zellen genutzt werden können. Die Aktivierung durch den CD40-
Liganden induziert entscheidend die Antigen-präsentation, was zu einer effizienten
Induktion von CD4+ und CD8+ T-Zellen in vitro führt. Darüber hinaus wandern diese CD40-
aktivierten (CD40)B-Zellen nicht nur in die peripheren lymphatischen Organe, sondern
induzieren auch eine anti-tumorale Immunität in Mäusen.
Die Antigen-präsentation und -prozessierung durch antigen-spezifische B-Zellen ist bis zu
tausendfach effektiver als bei polyklonalen B-Zellen. Deshalb wurden in der vorliegenden
Arbeit antigen-spezifische B-Zellen genutzt, um die antigen-präsentierende Funktion von
CD40B-Zellen zu steigern. Nach CD40-Stimulation regulieren aufgereinigte, antigen-
spezifische B-Zellen kostimulatorische Moleküle wie CD80 und CD86 signifikant hoch, was zu
einer verstärkten Antigen-präsentation und der Induktion einer spezifischen T-Zellantwort in
vitro und in vivo führt. Antigen-spezifische CD40B-Zellen induzieren eine signifikant stärkere
T-Zellanwort als polyklonale CD40B-Zellen, die mit einer DC-induzieren Reaktion vergleichbar
ist. Eine präventive Vakzinierung mit antigen-spezifischen CD40B-Zellen alleine oder in
Kombination mit antikörper-sezernierenden Plasmazellen führt zu einer Anti-Tumor
Immunität in vivo, bei der das Tumorwachstum komplett unterdrückt wird. Darüber hinaus
migrieren antigen-spezifische CD40B-Zellen in den Tumor, was neue
Anwendungsmöglichkeiten als Trägerstoff bei Imagingverfahren oder zum ‚Drug Delivery‘
ermöglicht.
Diese Ergebnisse liefern neue Einblicke in die Rolle von aktivierten antigen-spezifischen
B-Zellen als antigen-präsentierende Zellen und ihrer Nutzung in der Immuntherapie.

Abstract
Abstract
Efficient antigen presentation is a prerequisite for the development of a T-cell-mediated
immune response in vitro and in vivo. As “nature’s adjuvant”, dendritic cells (DCs) are the
most prominent professional antigen-presenting cells (APCs). However, they have several
significant disadvantages concerning application as an adjuvant in cancer immunotherapy.
They are rare in peripheral blood and the isolated population is not homogenous, since it
also contains unwanted tolerogenic DCs. Therefore, an alternative approach to DCs was
developed, in which polyclonal B cells can serve as potent APCs by treatment with the
inflammatory cytokine IL-4 and the CD40 ligand. CD40-activation dramatically improves
antigen presentation by normal and malignant B cells, efficiently inducing naïve and memory
CD4+ and CD8+ T-cell responses. Moreover, these CD40-activated (CD40) B cells do not only
home to secondary lymphoid organs, but also induce anti-tumor immunity in mice.
However, antigen-processing and -presentation by antigen-specific B cells is 1000-fold more
effective compared to polyclonal B cells. Therefore, tumorantigen-specific B cells were used
in the present study to improve the antigen-presenting function of CD40B cells. Purified
tumorantigen-specific B cells highly upregulate activation markers upon CD40-stimulation
resulting in an enhanced antigen-presentation and a specific T-cell response in vitro and in
vivo. The T cell response elicited by antigen-specific CD40B cells is significantly stronger than
that induced by polyclonal CD40B cells and comparable to the stimulation induced by
mature DCs. Alone or in combination with antibody-secreting plasma cells, preventive
vaccination with these antigen-specific CD40B cells leads to an anti-tumor immune response
in vivo resulting in complete inhibition of tumor growth. Moreover, antigen-specific B cells
home to the tumor site, thereby offering new application perspectives as vehicle for tumor
imaging and drug delivery. These results provide new insights into the role of activated
antigen-specific B cells as APCs and their use for cancer immunotherapy.
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1. Introduction
The immune system plays an essential role in the development and progression of tumors.
Several different immune cells interact with tumor cells and the surrounding non-malignant
cells of the tumor micromilieu. On the one hand, the effector immune cells prevent tumor
growth and destroy established tumors. On the other hand, tolerogenic immune cells inhibit
the anti-tumor immunity and enhance tumor growth by secretion of growth factors and
expression of inhibitory surface molecules (Popi et al. 2004).
Immunotherapy of malignant diseases is one of the most promising therapeutic approaches
in modern cancer treatment. Beside the clinically established and routinely applied therapy
with antibodies, the use of tumor vaccines could further improve treatment of malignant
diseases. Tumor vaccines aim to enhance preexisting immune responses or induce novel
tumor-directed effector mechanisms, thereby tipping the balance towards immunological
enhanced tumor control.
CD40-activated B cells provide a promising source of antigen-presenting cells for the use as
cellular adjuvant in cancer immunotherapy (Schultze et al. 1997). Most published B cell-
based immunotherapeutic approaches use polyclonal B cells which are loaded with tumor
antigens (Wennhold et al. 2013). However, this strategy does not exploit the full potential of
B cell-based cancer immunotherapy, since it does not fully exploit the advantage of antigen-
specificity conferred by the B cell receptor, i.e. enhanced antigen-uptake and production of
antigen-specific antibodies.
1.1 The Adaptive Immune System
The immune system consists of specialized systems, which provide protection against
invading pathogens and degenerated endogenous cells. The first line of defense is
represented by the innate immune system. It is phylogenetically selected and provides
immediate defense against infections. Macrophages and natural killer (NK) cells make up the
cellular defense mechanism of the innate immune system. Recognition of conserved
patterns on pathogens by their diverse receptors triggers macrophage activation resulting in
phagocytosis of the pathogens and release of cytokines and chemokines for the attraction of
other leukocytes (Mantovani and Sica 2010). NK cells on the other hand recognize the
Introduction
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absence of MHC molecules as it occurs in transformed or stressed cells (Herberman et al.
1986). However, unlike the adaptive immune system it does not provide a long-lasting or
protective immunity. The adaptive immune system, on the other hand, is acquired during
lifetime. Unlike innate immunity, adaptive immunity is characterized by the development on
immunologic memory and improves with repeated exposures to pathogens. An adaptive
immune response consists of two components: the humoral and the cellular mediated
immunity. The humoral immunity is mediated by antibodies produced by B cells (Kearney et
al. 1997). They are soluble molecules that bind to specific antigens on the surface of their
target, thereby neutralizing them or targeting them for destruction by phagocytes. Cellular
immunity involves direct effector functions of T cells directed against intracellular
pathogens, which are inaccessible to the humoral system.
1.1.1 T Cells
After developing in the thymus, T cell recirculate in the bloodstream and the lymphatic
tissues as mature naïve T cells until they encounter their specific antigen. The antigen is
presented to them in combination with major histocompatibility complex (MHC) and co-
stimulatory molecules (Bretscher 1999, Bevan 2004) leading to a cascade of signaling events
that result in the activation of naïve T cells. The activated T cells rapidly proliferate, migrate
through the tissues to the sites of antigen presence and perform effector functions, which
depend on the subtype of T cells (Broere et al. 2011).
1.1.1.1 CD8+ T Cells
CD8+ cytotoxic T cells recognize 8-10 amino acid long peptides presented on the surface of
their target cells in combination with self-MHC class I molecules (Klein and Sato 2000). Naïve
CD8+ T cells become initially activated (‘primed’) when their T-cell receptor binds to its
specific antigen presented by activated antigen presenting cells (APCs). The effector function
of CD8+ T cells includes secretion of interferon (IFN)-γ and the apoptosis inducing molecules 
perforin and granzyme B and the upregulation of the Fas ligand. Furthermore, interaction
with the specific antigen leads to differentiation into memory T cells, which respond faster
upon re-exposure to the antigen (Weninger et al. 2002).
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1.1.1.2 CD4+ T Cells
In contrast to CD8+ T cells, CD4+ helper T cells recognize 10-34 amino acid long peptides from
exogenous proteins presented in combination with MHC class II molecules by APCs (Klein
and Sato 2000). Depending on the context of antigen encounter CD4+ T cells can
differentiate into several distinct subgroups, which can be distinguished by their cytokine
profile.
Type 1 cytokine-secreting CD4+ helper T cells (Th1) develop in the presence of IL-12 and a
strong antigen-TCR interaction or high density of antigen (Fishman and Perelson 1999). Th1
cells by production of IFN-γ are responsible for directing cell-mediated immune responses 
(Mosmann et al. 1986). Furthermore, they enhance activation of APCs through engagement
of the CD40 ligand (CD40L) and its receptor CD40 (Bourgeois et al. 2002). Interleukin (IL)-4
and IL-6 secretion and a weak antigen-T cell receptor (TCR) interaction or low density of
antigen stimulates development of Th2 T cells, which secrete IL-4, IL-5, IL-6, IL-10 and IL-13.
Th2 cells thereby favor a humoral immune response by B cells, while inhibiting Th1 cellular
immune responses. Another subset of T helper cells develops in the presence of IL-23 into
IL-17A secreting T cells (Th17 cells). Th17 cells are the first T cells that are generated during
infection and their interaction with fibroblasts, epithelial cells and keratinocytes leads to the
recruitment of neutrophils and macrophages (Steinman 2007, Stockinger and Veldhoen
2007). They also play a major role in autoimmune diseases such as rheumatoid arthritis,
psoriasis and Crohn’s disease.
Regulatory CD4+ T cells (Tregs) are characterized by the constitutive expression of CD25 and
the transcription factor FoxP3 (Wing and Sakaguchi 2010). They build one arm of
immunological tolerance mechanisms.
1.1.2 Immunological Tolerance
Activation of self-reactive T cells and thus failure of the immune system to tolerate the
body’s own tissues can result in tissue-specific autoimmunity. Two essential mechanisms
account for self-non-self discrimination by the immune system, which allows productive
immunity to pathogens while minimizing the risk of autoimmunity. Central tolerance
includes clonal deletion of autoreactive T cells in the thymus according to their recognition
pattern (positive selection) and affinity (negative selection). This results in a repertoire of
Introduction
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T-cells that recognize foreign antigens presented by self-MHC molecules (Kappler et al. 1987,
Kisielow et al. 1988). Peripheral tolerance deals with auto-reactive T cells, which escape
clonal deletion. One mechanism is the induction of anergy in naïve T cells to avoid
autoimmune responses to tissue-specific proteins, which are not presented in the thymus
and thus do not lead to clonal deletion of self-reactive T cells (Albert et al. 2001). Anergy is
induced by antigen recognition of the TCR in the absence of costimulatory signals, as it
occurs with antigens expressed on the surface of tissue cells in the periphery, and is
characterized by the induction of a hyporesponsive state of self-reactive naïve T cells. More
recently, evidence for the existence of a second mechanism of immune tolerance was
provided by the identification and characterization of regulatory T cells (Fontenot et al.
2003, Sakaguchi 2005). Tregs suppress T-cell responses through direct contact with APCs or
through production of anti-inflammatory cytokines such as transforming growth factor
(TGF)-β, IL-10 and IL-35. 
1.1.3 B Cells and Humoral Immune Response
B cells develop in the bone marrow from hematopoietic stem cells to common lymphoid
progenitor cells to pro B cells and pre B cells. These different stages are characterized by
immunoglobulin gene rearrangement, changes in gene expression and the surface
phenotype (Osmond 1990, Hardy et al. 1991, Hardy 2003). Dysfunctional or autoreactive B
cells recognizing self-antigens are eliminated by receptor editing (Melchers et al. 1995,
Hardy et al. 2000) before immature B cells leave the bone marrow and enter the spleen.
Engagement of the surface B cell receptor (BCR) of the isotype M and D by its specific
antigen leads to maturation and terminal differentiation (Osmond et al. 1998, Rolink et al.
1999)
Three different B cell subsets can be defined according to their location. B-1 B cells locate
mainly in the pleural and peritoneal cavities (Kantor and Herzenberg 1993) and are involved
in the early stages of thymus-independent immune responses against bacterial patterns
(Allman et al. 2004). Upon BCR-signaling they can differentiate into short-lived IgM-
producing plasmablasts and are responsible for the majority of the physiological IgM levels
in serum (Kraal 1992, Hardy and Hayakawa 2001).
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Fig. 1.1 B cell development under physiological conditions (A) B1 B cells develop from
hematopoietic stem cells (HSCs) in the bone marrow or the fetal liver, differentiate into short-lived
plasma cells and produce natural IgM-antibodies. (B) B2 B cells develop from HSCs in the bone
marrow. Following rearrangement of their B-cell receptor and removal of autoreactive cells via
central tolerance, immature B2 B cells relocate to the spleen. Those immature B2 B cells that escape
the processes of peripheral tolerance differentiate into marginal zone (MZ) B cells or mature
follicular B cells. Upon T-cell activation, follicular B cells develop into short-lived plasma cells or form
germinal centers (GC), where they differentiate into long-lived plasma cells or memory B cells
(Dorner et al. 2009).
Marginal zone (MZ) B cells are located in the marginal sinus in the spleen at the border of
the red and the white pulp and link the innate and adaptive immune system (Martin and
Kearney 2002). MZ B cells respond early to infections due to their close contact to blood-
borne antigens (Kraal 1992). Upon stimulation of toll-like-receptors alone or in combination
with stimulation of the BCR, MZ B cells migrate to the T-cell-B-cell border of the lymphoid
follicle, where they present antigen to CD4+ T cells (Attanavanich and Kearney 2004). After
migration into the red pulp, they differentiate into plasma cells secreting large amounts of
IgM (Martin et al. 2001). B-1 and MZ B cells do not form germinal centers and thus do not
undergo somatic hypermutation. Therefore, they express only low-affinity BCRs, which
mainly distinguishes them from follicular B cells.
Follicular B cells re-circulate through the blood and the lymph to B cell follicles of the lymph
nodes, the spleen and Peyer’s patches (Allman and Pillai 2008). Encounter of their specific
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antigen and subsequent cross-linking of the BCR leads to BCR-mediated endocytosis of the
antigen, antigen processing in endosomes and its presentation in the context of MHC II
molecules (Lanzavecchia 1990). Upon antigen encounter, follicular B cells change their
chemokine receptor profile, migrate to the T-cell-B-cell border and bind to activated CD4+ T
cells that express the corresponding TCR, building a so called “immunological synapse”
(Grakoui et al. 1999, Pereira et al. 2010). Activated B cells undergo different fates after T cell
encounter depending on the strength of BCR signaling (Paus et al. 2006). B cells with a high-
affinity BCR undergo proliferation and plasmacytic differentiation into plasmablasts and
finally short-lived plasma cells that secrete high amounts of IgM but non-somatically
mutated antibodies (Jacob et al. 1993, Paus et al. 2006). B cells with an intermediate affinity
BCR follow the second developmental path by migrating into the lymphoid follicles to form
germinal centers (Thorbecke et al. 1994, Paus et al. 2006, Carter and Myers 2008). Here,
B cells highly proliferate and undergo somatic hypermutation and isotype switching resulting
in memory B cells and long-lived plasma cells that produce affinity-matured antibodies,
mainly of the IgG isotype, some IgE and IgA (Coico et al. 1983, Ziegner et al. 1994). Memory
B cells are released from the germinal centers and mount a quicker immune response upon
re-exposure to their cognate antigen.
1.1.4 Antigen-Presentation to T Cells
Efficient antigen presentation is a prerequisite for the development of a T-cell-mediated
immune response in vitro and in vivo. APCs are crucial for development of an immune
response, since T cells are only activated when they recognize their specific antigen
presented in combination with MHC and co-stimulatory molecules (Cassell and Schwartz
1994, Askew et al. 1995, Banchereau and Steinman 1998). Uptake of antigen by APCs, such
as DCs, macrophages or B cells, takes place in the peripheral tissues or the lymphatic vessels.
In the classical antigen presentation pathway, MHC class II molecules are assembled in the
endoplasmatic reticulum (ER) and are associated with an invariant chain before the complex
is transported to late endosomal compartments, called MIIC. In the endosomal
compartments, MHC II molecules require HLA-DM (one of three polymorphic MHC II genes)
to facilitate the exchange of the invariant chain with a specific peptide derived from a
protein that was degraded in the endosomal pathway. MHC II molecules are then
transported to the plasma membrane to present their peptide to CD4+ T cells (Neefjes et al.
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2011). In addition to endocytosis, B cells are able to take up antigen in a highly specific
fashion via their B cell receptor (Abbas et al. 1985, Lanzavecchia 1985). In B cells, HLA-DM
activity is restricted to acidic compartments, which is favorable for antigens internalized
through the BCR (Alfonso et al. 1999).
Usually, presentation of antigens in the context of MHC class I molecules is restricted to
endogenously derived peptides (Neefjes et al. 2011). Proteins of cytosolic and nuclear origin
are degraded by proteasomes and translocated into the ER. There, MHC I molecules are
assembled and loaded with the degraded antigens. The fully assembled peptide-MHC class I
complexes leave the ER for presentation on the cell surface. The presentation of only
intracellularly derived peptides in the context of MHC I molecules is however insufficient in
the case of naïve CD8+ T cell priming, since they need to be activated by professional APCs
before they can fulfill their cytotoxic effector function. Therefore, APCs also have the ability
to load peptides derived from exogenous antigens to MHC class I molecules by a process
called cross-presentation (Kurts et al. 2010). Cross-presentation and priming has since been
shown to be essential for vaccination with protein antigens.
Encounter of T cells and activated APCs takes place in the secondary lymphoid organs, where
organ structure brings antigen and APCs into close contact to T cells. In addition to TCR-
mediated signal induced by binding to a matching peptide-MHC II complex, activation of a
T cells requires costimulatory signals. These are provided by the costimulatory surface
molecules such as CD80 (B7-1) and CD86 (B7-2), which are highly upregulated on activated
APCs (Lenschow et al. 1994, Bretscher 1999). Their receptor on the T cell surface is CD28.
Absence of co-stimulatory signals at the time of TCR-MHC-antigen interaction results in
anergy (Schwartz 2003).
DCs are known to be the most prominent APCs, since they play a critical role in inducing
primary T cell responses, thereby leading to the establishment of immunological memory
(Steinman 1991, Hart 1997, Banchereau and Palucka 2005, Palucka et al. 2011). Since the
first report on DCs by Steinman and Cohn (Steinman and Cohn 1973) different subtypes
arising from CD34+ bone marrow progenitors have been described (Shortman and Liu 2002,
Steinman and Idoyaga 2010). DC progenitors develop in the bone marrow and migrate into
peripheral tissues, where they encounter antigen. Upon antigen uptake and processing, DCs
mature and migrate through the afferent lymphatics to the draining lymphoid organs, where
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they present antigen to CD4+ and CD8+ T cells. Moreover, DCs are able to induce a humoral
immune response or activate cells of the innate immune system, such as NK cells,
macrophages and eosinophils (Banchereau and Steinman 1998, Banchereau et al. 2000,
Steinman 2008). Hence, DCs drive all arms of the immune system and therefore have
extensively been studied for use as cellular adjuvant.
1.2 Basic Principles of Cancer Immunology
The immune system does not only protect us from invading pathogens, it also participates in
the protection from cancer development by surveilling the body for transformed cells. A
broad range of immune cell-types and immunological mechanisms are involved in this
process.
1.2.1 Cancer Immunosurveillance
An immunological response against cancer has first been proposed by Paul Ehrlich in 1909
(Ehrlich 1909), who observed that mice were protected against rechallenge with aggressive
tumor cells when previously vaccinated with slowly growing tumor cells. In 1954 Burnet and
Thomas formulated the “cancer immunosurveillance hypothesis”, which stated that innate
and adaptive immune cells permanently monitor tissues for the presence of transformed
cells and leading to their elimination (Burnet 1970, Burnet 1971, Thomas 1982). Due to a
lack of direct experimental evidence this hypothesis remained highly controversial. It was
not before the development of knock-out and immunodeficient mice that researchers were
able to show that the immune system indeed plays a vital role in the control of neoplastic
growth. These early studies identified some fundamental mechanisms of tumor
immunosurveillance. First, the contribution of the cytokine IFN-γ to protection against tumor 
formation (Kaplan et al. 1998, Street et al. 2001); second, the effect of perforin-mediated
cytotoxicity of effector lymphocytes on tumor control (van den Broek et al. 1996, Street et
al. 2001); and third, immune-deficient Rag1 and Rag2 knock-out mice, which are incapable of
producing soluble antibodies or a functional TCR, were susceptible to tumor challenge
(Shankaran et al. 2001). Further evidence for the existence of immune surveillance derived
from observations in humans. Immunocompromised humans, like HIV patients or organ
transplant recipients, are more susceptible to certain types of cancers than the general
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population (Grulich et al. 2007). Moreover, several bacterial infections were shown to be
cancer-associated and several cancer-causing viruses have been identified (Mager 2006,
Sarid and Gao 2011).
1.2.2 Immunoediting
The cancer immunosurveillance theory was extended from a simple host-protective role of
the immune system to a more complex process, in which the immunological tumor
microenvironment shapes tumor immunogenicity (Dunn et al. 2002, Schreiber et al. 2011,
He et al. 2014). This process can lead to three possible outcomes. First, the innate and
adaptive immune system recognizes and eliminates transformed cells (elimination phase).
Second, in some cases tumor cells sustain elimination, due to tumor heterogeneity and
selection pressure. This leads to an equilibrium state, in which tumor growth is controlled by
the immune system (equilibrium phase). Third, tumor cells can become resistant to immune
detection and enter the escape phase leading to the development of a malignant disease
(escape phase).
1.2.3 Tumor Evasion Strategies
Immune-evasion strategies of tumor cells are manifold. They are the focus of interest for the
development of a successful cancer immunotherapy. Active tolerance mechanisms induced
by the tumor include downregulation of MHC molecules on the surface of tumor cells or the
impairment of antigen processing. Tumor cells thereby evade recognition and destruction by
cytotoxic T cells (Ferrone and Marincola 1995). Furthermore, tumor cells are able to shape
the tumor microenvironment by release of suppressive anti-inflammatory cytokines, such as
TGF-β or IL-10 (Chen et al. 1994, Walker et al. 1998). More recently, tumor cells were shown 
to upregulate immune checkpoint proteins, like programmed cell death ligand 1 (PD-L1) or
cytotoxic T-lymphocyte associated antigen 4 (CTLA-4). Thus, they further contribute to
shaping the tumor microenvironment (Ramsay 2013). Passive tolerance mechanisms involve
the recruitment of leukocytes into the tumor stroma. This includes mostly tumor-associated
macrophages, mast cells, NK and NKT cells, T cells and B cells. The type of infiltration and the
influence on survival outcome depends on tumor type and patient (Bremnes et al. 2011).
However, regulatory T and B cells were shown to be recruited to the tumor site, negatively
influencing the outcome for the patient (Whiteside 2008, Zhang et al. 2013).
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Overcoming evasion strategies of tumor cells and inducing an effective immune response by
T cells is therefore the key to a successful treatment of cancer.
1.3 Targeted Immunotherapy
Given that cancer resists conventional surgery and nonsurgical treatment options and still
remains the major cause of death worldwide, the development of novel prophylactic and
therapeutic strategies is required. Impressive clinical success was achieved by
immunotherapy in recent years (Couzin-Frankel 2013). In various studies, active and passive
therapy approaches were shown to induce specific immune responses against various
tumors with high therapeutic potential (Mellman et al. 2011).
1.3.1 Tumor Antigens
The immune system has to distinguish between normal and neoplastic tissue to protect the
organism from malignant cells. This is often difficult, since proteins on cancer cells and
normal tissue are similar in structure and their level of expression. However, there are
certain tumor antigens, which are self derived, but trigger an immune response anyway.
Over the last 20 years a large array of immunogenic tumor antigens has been identified and
characterized. Two primary groups of antigens can be distinguished: Tumor-specific antigens
and tumor-associated antigens.
1.3.1.1 Tumor-Specific Antigens
Tumor-specific antigens are unique to the tumor tissue. They arise from genetic alterations
like point mutations, deletions or chromosomal translocation (Bielas et al. 2006) and may be
associated with tumor formation. However, their usefulness for standard immunotherapy is
limited, since they are highly patient-specific and manufacturing such a vaccine would be
costly (Sensi and Anichini 2006). Some shared tumor-specific antigens have been identified,
among them the oncogene ras and the mutated tumor suppressive gene p53 (Bos 1989,
Chiba et al. 1990).
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1.3.1.2 Tumor-Associated Antigens
Tumor-associated antigens are shared by normal and neoplastic tissue, but their level or
location of expression is differs. Tumor-associated antigens can be divided into three
subgroups. Some of these antigens are usually expressed exclusively in germ cells of the
testes. In cancer cells, those germ line genes can be aberrantly activated (Caballero and
Chen 2009). Since germ cells do not express MHC molecules and thereby do not present
antigen to T cells, such antigens can be considered as tumor-specific. One example is the
melanoma-antigen family (MAGE) of proteins. The second subgroup represents antigens
that are expressed during embryogenesis or particular stages of differentiation. Their use as
target for cancer immunotherapy is limited since it may lead to autoimmune reactions.
Some well studied examples are Melan-A, gp100 and tyrosine, which are expressed in
healthy melanocytes, but also melanoma cells. Other examples are prostate-specific antigen
(PSA) in prostate carcinoma or cell adhesion molecule (CEA) in colorectal carcinoma (Malati
2007). The third group is characterized by antigens that are overexpressed in tumor tissue,
but are expressed in very low levels in normal tissue. These overexpressions are often the
result of gene amplifications and are associated with initial tumor formation or growth. Only
a small amount of these antigens, which include for example HER2 or telomerase, is required
to elicit a T cell response and therefore the risk for autoimmunity is low (Disis and Cheever
1997).
1.3.2 Passive Immunotherapy
Exploiting the specificity of the immune system against cancer cells provides a promising
therapeutic approach against cancer diseases with low risk for toxicity and side effects.
Breaking self-tolerance and overcoming tumor-escape mechanisms as well as identifying the
appropriate target and delivery platform are the key to a successful immunotherapy.
Passive immunotherapy with monoclonal antibodies today is a well established treatment
modality. The number of clinically used monoclonal antibodies and their cancer-associated
target proteins has increased dramatically over the past years. They act by antagonizing
oncogenic signaling pathways, blocking tumor cells or initiating cell death. Great clinical
efficacy has been reported for agents inhibiting immunological checkpoints. In 2012, Toplian
et al. reported a study with 300 melanoma, kidney or lung cancer patients that were treated
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with anti-PD1 antibodies. One third of these patients showed a clinical response (Topalian et
al. 2012). In 2013, the combined therapy with Ipilimumab (anti-CTLA-4) and Nivolumab (anti-
PD-L1) resulted in tumor reduction in one third of patients with metastasized, pretreated
melanomas (Wolchok et al. 2013). One of the most recent examples of a successful
antibody-based immunotherapy is the use of Brentuximab for targeting CD30 in patients
with CD30-positive lymphomas (Theurich et al. 2013, Theurich et al. 2013, Theurich et al. in
press).
1.3.3 Active Immunotherapy
In contrast to passive immunotherapy with monoclonal antibodies, active immunotherapy
aims to induce a specific anti-tumor response by vaccination (Schlosser et al. 2014).
Strategies include non-cellular vaccines with purified tumor-antigen, synthetic peptides or
tumor lysates, and cellular vaccines. Moreover, ex vivo expanded and/or manipulated
immune cells can be adoptively transferred into cancer patients. One promising approach
are genetically engineered T cells expressing tumor-specific “chimeric antigen receptors”
(CARs) to directly target tumor cells with high specificity. In 2013, two groups reported of 75
patients with leukemia, of which 45 patients were successfully treated with CARs (Couzin-
Frankel, 2013). Prophylactic cancer vaccines, which exploit the immunological properties of
APCs to induce tumor-specific T cells, are already successfully used in the treatment of
virally-induced cancer diseases (Kanwar et al. 2011). Therapeutically used vaccines showed
first clinical success within the past years, including the first US Food and Drug
Administration (FDA)-approved cell based immunotherapy on the basis of autologous DCs
for the treatment of prostate carcinoma patients (Small et al. 2000). Strategies with ACPs
loaded with tumor-associated antigens aim at inducing effective cellular and antibody-
mediated responses specific for antigens expressed by tumors, thereby avoiding unwanted
side effects as seen by conventional approaches (Grabbe et al. 1995, Ward et al. 2002,
Banchereau and Palucka 2005). The challenges remain in identifying immunogenic tumor
antigens, overcoming tolerance and generating professional APCs that effectively and
specifically induce T cells immunity.
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1.3.4 Dendritic Cell Vaccination
Cellular-based adjuvants are the object of intensive studies since- in contrast to non-cellular
approaches- they reflect the physiological induction of a T cell response. A number of
different subtypes of dendritic cells have been identified, since their first description by
Steinman et al. and have been explored for their use as vaccine against cancer and infectious
diseases (Steinman and Cohn 2007).
In mice, vaccination with bone-marrow derived ex vivo matured antigen-loaded DCs has
been shown to induce protective and therapeutic anti-tumor immunity (Mayordomo et al.
1995, Parkhurst et al. 1996, Zitvogel et al. 1996). Several strategies to deliver antigen to DCs
have been exploited: DCs are simply loaded with peptides or proteins (Parkhurst et al. 1996,
Li et al. 2002), they are transfected with mRNA or DNA plasmids (Boczkowski et al. 1996) or
transduced with viral vectors (Ribas et al. 2002). Other strategies include tumor-DC fusions,
loading DC with dying tumor cells (Albert et al. 1998, Berard et al. 2000) or direct target of
DC surface molecules like DEC205 or DC-SIGN to facilitate antigen uptake (Gilboa 1999, Fong
and Engleman 2000).
The potential of this approach in a human setting could be demonstrated in numerous
studies. In particular, studies with healthy volunteers demonstrated that a single vaccination
dose of DCs is sufficient to induce an antigen-specific T cell response (Dhodapkar et al.
1999). However, after more than 200 clinical studies with DC-based vaccines, the response-
rate to vaccination has been disappointingly low (Draube et al. 2011). Therefore, in order to
achieve reliable responses, several questions need to be addressed before this approach can
be routinely applied in the clinic. These include the identification of the appropriate DC
subtype, the optimal activation status, the injection route, the injection interval or dose.
DCs cannot be generated in large quantities or in sufficient purity, thereby making their
development for the clinical application laborious and expensive. In most studies the purity
of the applied DCs is not determined at all or it does not reach more than 80 % (Draube et al.
2011). An insufficient purity makes it difficult to distinguish between the effect of the DCs
itself and the effect of the bystander cells (Figdor et al. 2004, Rosenberg 2004, Schultze et al.
2004). In addition, the optimal maturation status of the generated DCs is of critical
importance. Immature DCs are usually differentiated ex vivo from CD34+ progenitors by
treatment with granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-4.
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However, antigen-presentation by immature DC subsets results in undesired antigen-specific
tolerance mechanisms (Mahnke et al. 2002). Maturation or terminal differentiation of DCs
can be achieved by antagonizing their toll-like receptors with CpG-ODN (Caux et al. 1992) or
triggering tumor-necrosis factor (TNF) receptor signaling with LPS or CD40 ligation (Romani
et al. 1994, Sallusto and Lanzavecchia 1994). However, the stimulus used for maturation
results in the release of different cytokine subsets and therefore in different T cell responses,
either of tolerogenic or immunogenic nature (Steinman et al. 2003, Mailliard et al. 2004, Liu
et al. 2009).
Another critical point for the use of DCs in a clinical setting is their lack of CD62 ligand
expression, a key molecules for migration through the high endothelial venues, and their
resulting failure of lymph node homing (von Andrian and Mempel 2003). Therefore, the
optimal injection route does not only influence DC homing and T cell response, but also
determines the clinical outcome. Injection routes with easy access to the draining lymph
nodes were shown to result in an improved clinical response than for example intravenous
injections (Draube et al. 2011). Although less than 4 % of the injected DCs reach the draining
lymph nodes, intradermal or intravenous injections are preferred in clinical studies, since
intralymphatic and intranodal injections remain challenging (Ridolfi et al. 2004, Quillien et al.
2005).
The first autologous DC-based therapeutic cancer vaccine, Sipuleucel-T (PROVENGE), has
been approved by the FDA for the treatment of prostate cancer in 2010 (Cheever and Higano
2011). This therapy is based on ex vivo generated DCs that target prostate acid phosphatase
(PAP) antigen on prostate cancer cells and prolongs the median survival of men with
advanced castrate-resistant prostate cancer by 4.1 month. However, clinical studies on
Sipuleucel-T have been criticized afterwards and, taking gain of quality-adjusted life years
into account, the treatment with Sipuleucel-T has been evaluated to be cost-ineffective
(Graff and Chamberlain 2015).
Taken together, combining immunomodulatory agents and DCs with conventional treatment
like radiation and chemotherapy currently provide the most promising approaches to
improve therapeutic efficacy of vaccination against cancer (Le et al. 2010, Palucka et al.
2010).
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1.4 B Cells as Antigen-Presenting Cells
Even though B cells are less efficient than DCs at capturing antigens by pinocytosis, Fc-
Receptor (FcR)-mediated uptake or adsorption (Chesnut et al. 1982, Grey et al. 1982, Batista
and Neuberger 1998, Rodriguez-Pinto 2005), they are increasingly recognized to play a
crucial role in the initiation of T cell responses. However, to fully extend their function as
APCs, B cells require two activation signals. The first one is the crosslinking of the BCR by its
antigen, which induces growth, proliferation and survival of the B cell. Moreover, it leads to
expression of the costimulatory molecule CD86 (Lenschow et al. 1994). The second signal
results from the interaction with CD4+ T cells and is mediated by CD40-CD40 ligand (CD40L)
interaction and the secretion of IL-4 by the T cells (Ranheim and Kipps 1993, Evans et al.
2000). CD40-derived signals induce B-cell activation and promote several changes related to
their antigen-presenting function: CD40-activated B cells (CD40B cells) upregulate the
expression of MHC class I and II and costimulatory molecules CD80 and CD86, enhance
antigen processing and are able to activate naïve T cells (Kennedy et al. 1994, Faassen et al.
1995).
1.4.1 CD40-CD40L Interaction
CD40-CD40L interaction exerts profound effects on DCs, B cells, endothelial cells and many
other cells of the hematopoietic and non- hematopoietic compartments (Elgueta et al.
2009). The CD40 receptor and its ligand are both transmembrane proteins of the TNF
superfamily (van Kooten and Banchereau 2000). The CD40L is primarily expressed on T cells,
but also on activated B cells, platelets and under inflammatory conditions on other cells of
the innate and adaptive immune system (Carbone et al. 1997). The soluble form of the
CD40L was shown to express similar activities as its transmembrane form (Graf et al. 1995,
Mazzei et al. 1995). In B cells, CD40 signaling promotes germinal center formation,
immunoglobulin (Ig) isotype switching, somatic hypermutation of the Ig to enhance affinity
for antigen and the formation of long-lived plasma cells and memory B cells (Danese et al.
2004, Elgueta et al. 2009).
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Fig. 1.2 APC activation upon encounter with an antigen-specific CD4+ T cell. Interactions that control
the outcome of CD4+ T cell-APC encounter are indicated by the receptor-ligand pairs. CD40L, CD40
ligand; TCR, T-cell antigen receptor; CTLA4, cytotoxic T lymphocyte–associated protein 4; MHCII,
major histocompatibility complex type II protein (Haanen and Schumacher 2007).
More importantly, CD40 engagement promotes B cell cytokine production, the expression of
costimulatory molecules on their surface and facilitates cross-presentation of antigen
(Robson et al. 2008, de Wit et al. 2010). Furthermore, CD40 signaling supports survival of
germinal center B cells, DCs and endothelial cells (Bishop et al. 2007) and its deregulation
has been observed to play a role in multiple autoimmunity diseases (Peters et al. 2009).
The importance of this signaling pathway in acquired immune responses makes it a
promising target for pharmacological manipulations for the treatment of immunological
diseases. Interference of the CD40-CD40L interaction by use of blocking CD40-antibodies
showed positive effects on uncontrolled immune reactions like inflammation, autoimmunity
or allo-graft rejection (Larsen et al. 1996, Kirk et al. 1997, Kirk et al. 2001, Pearson et al.
2002, Grammer et al. 2003, Sidiropoulos and Boumpas 2004). Moreover, enhancement of
the CD40-CD40L interaction by use of antagonistic CD40-antibodies was shown to result in
anti-proliferative anti-tumor effects or meditation of immune response against tumors
(Mackey et al. 1998, Diehl et al. 1999, Tong and Stone 2003, Watanabe et al. 2003,
Eliopoulos and Young 2004, Vonderheide et al. 2007). Because of their potential as APC
stimulators, CD40 agonists have been selected as one of the twelve immunotherapy drugs
that could cure cancer (Cheever 2008).
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1.4.2 CD40-Activated B Cells
In 1991, Banchereau et al. discovered that long-term human B-cell lines could be established
by stimulation with the CD40L and IL-4 (Banchereau et al. 1991, Banchereau and Rousset
1991). Since then several strategies have been developed to manipulate the CD40-CD40L
interaction to activate B cells (Neron et al. 2011). Schultze et al. established a culture system,
in which human B cells can be activated and expanded by stimulation with the CD40L and
IL-4 (Schultze et al. 1997). Under constant cultivation on CD40L expressing feeder cells,
human and murine primary B cells can be expanded from small amount of peripheral blood,
upregulate costimulatory, MHC and adhesion molecules and show an increased antigen
presenting capacity in vitro (Liebig et al. 2009, Liebig et al. 2010). The expression level of
MHC and costimulatory molecules is comparable to those of CD40L/IFN-γ or TNF-α matured 
DCs (Wiesner et al. 2008). In vitro these CD40-activated B cells present antigen in an MHC
class I or II- restricted manner to induce naïve or memory CD8+ and CD4+ T cells responses,
respectively (Schultze et al. 1997, von Bergwelt-Baildon et al. 2002, Lapointe et al. 2003, von
Bergwelt-Baildon et al. 2004, Theurich et al. 2011) and overcome T cell tolerance as shown
by generating autologous tumor antigen-specific T cells in vitro by help of peptide-pulsed
CD40B cells (von Bergwelt-Baildon et al. 2002, Shen et al. 2007, Wu et al. 2010). Moreover,
CD40B cells have the capacity to attract T cells and to home to secondary lymphoid organs
(von Bergwelt-Baildon et al. 2006, Guo et al. 2009), which is essential for T cell-APC
encounter and the induction of immunity. Human and murine CD40B cells express the
respective factors and receptors crucial for homing to secondary lymphoid organs including
CD62L, C-C-chemokine receptor (CCR) 7/ CXC-Motiv-Chemokinrezeptor (CXCR) 4, and
leukocyte function antigen (von Bergwelt-Baildon et al. 2006, Klein-Gonzalez et al. accepted
2015). The receptors CCR7 and CXCR4 are functional and induce chemotaxis toward
increasing chemokine concentrations of their ligands CCL21 and CXCL12, respectively (Fig.
1.3).
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Fig. 1.3. Chemokines involved in lymphocyte positioning in the secondary lymphoid organs.
(a) CCL21/ CCL19, chemokines expressed in the T cell zones of secondary lymphoid organs and the
ligand for CCR7; (b) CXCL12, the ligand for CXCR4 mostly involved in T cell zone entry; (c) and CXCL13,
a chemokine made in B cell zones of lymphoid organs and the ligand for CXCR5. (d) The chemokine
expression pattern of CD40B cells (e) allows them to migrate towards the B/T cell boundary (Klein-
Gonzalez et al. accepted 2015).
Nevertheless, very few studies have focused on the in vivo antigen-presenting capacity of
CD40B cells and their contribution to anti-tumor immunity (Wennhold et al. 2013). In two
preventive vaccination studies, tumor growth was delayed in mice that were immunized
with CD40 B cells (Ritchie et al. 2004, Liebig et al. 2011). The group of Mason reported the
first study in out-bred large animals using tumor RNA-loaded CD40B cells as cellular adjuvant
in privately owned dogs with NHL (Sorenmo et al. 2011). However, the correlation between
the immunological response and the clinical outcome was not significant.
Taken together, CD40B cells cannot only serve to identify tumor-antigens or to generate
T cells for adoptive immunotherapy, but show also promise as a versatile platform for
cellular cancer vaccines (Fujiwara et al. 2005, Ivanov et al. 2005, Kondo et al. 2009). Most of
all, the results from preclinical studies of application as antigen presenting cells in
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preventive and therapeutic vaccination appears promising (von Bergwelt-Baildon et al. 2002,
Coughlin et al. 2004, Van den Bosch et al. 2005, Yoon et al. 2005, Shen et al. 2008, Wu et al.
2010).
1.4.3 Antigen-Specific B Cells
Antigen-processing and -presentation, and thereby T cells activation, is 1000-10,000 fold
more effective in antigen-specific B cells compared to resting or lipopolysaccharide (LPS)-
activated polyclonal B cells (Abbas et al. 1985, Lanzavecchia 1990). The BCR has a high
affinity for a given antigen and allows B cells to concentrate very small quantities of their
specific antigen and present the antigen efficiently. In contrast, presentation after uptake by
fluid phase pinocytosis in B cells requires about 5000 higher concentrations.
Specific antigen uptake via the BCR leads to three important changes in the antigen
processing machinery that facilitates the traffic of antigen and MHC class II molecules and
the generation of peptide-MHCII complexes (Rodriguez-Pinto 2005). First, BCR receptor
ligation induces its internalization and the traffic towards MHCII rich compartments (MIIC),
the site of peptide-MHCII complex formation. Second, BCR signaling upregulates MHCII
expression and trafficking through the MIIC. Finally, BCR crosslinking induces changes in the
MIIC to generate the adequate environment for loading of MHCII with peptides. A second
characteristic of antigen processing in B cells differs from that in other antigen presenting
cells. The expression of HLA-DO, a non-classical MHCII molecule that is expressed only in
B cells and thymic epithelium, modulates peptide loading of MHCII molecules by HLA-DM
and favoring presentation of peptides derived from antigens internalized through the BCR
(Alfonso et al. 1999, Denzin et al. 2005).
1.5 Purpose of this Study
Although polyclonal CD40B cells were shown to efficiently induce anti-tumor immunity in
vivo, the tumor control is still suboptimal when using polyclonal CD40B cells as cellular
adjuvant (Liebig et al. 2011). Based on the fact that antigen-specific B cells present antigen
very efficiently when the antigen concentration is low, this study aimed at investigating
whether the use of tumorantigen-specific CD40B cells instead of polyclonal CD40B cells
improves their antigen-presenting function. For this purpose polyclonal and antigen-specific
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CD40B cells were compared with regard to their potential to induce antigen-specific T cell
reactions in vitro and in vivo. Moreover, the migratory behavior of tumorantigen-specific
CD40B cells in healthy and tumor bearing mice was investigated with the purpose of
exploiting their potential as drug delivery and imaging vehicle. With regards to the use of
antigen-specific B cells as cellular adjuvant for cancer immunotherapy, their antigen-
presenting function and antibody-secreting capacity were combined for immunotherapy in
tumor bearing mice.
Material and Methods
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2. Material and Methods
2.1 Material
2.1.1 Chemical
For preparation of buffers and solutions, chemicals of analytical purity were used exclusively.
Bovine Serum Albumin (BSA) Sigma Adrich
CFSE Invitrogen
Active hepatitis b virus Hepatitis B
Surface Antigen full length protein (HBV-antigen) Abcam
Albumin from Chicken Egg White (OVA) Sigma Aldrich
Dimethyl sulfoxide (DMSO) Sigma Aldrich
D-Luciferin Regis Technologies
Ethanol Th Geyer
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich
Hygromycin B Sigma Aldrich
Isofluran Actavis
Ovalbumin peptide (aa 257-264) Thermo Scientific
Paraformaldehyde (PFA) Sigma Aldrich
Sodium hydrogen carbonate (NaHCO3) Sigma Aldrich
Sodium carbonate (Na2CO3) Sigma Aldrich
Sodium chloride (NaCl) Sigma Aldrich
Trypsin-EDTA Life Technologies
Tween-20 Sigma Aldrich
Sodium Dodecyl Sulfate (SDS) Sigma Aldrich
2.1.2 Consumables
5 ml FACS tubes Sarstedt
6-well culture dish Sarstedt
12-well culture dish Sarstedt
15 ml Falcon tube Sarstedt
26G ½ needle Beckton Dickinson
50 ml Falcon tube Sarstedt
75 cm2 culture flask (adherent) Sarstedt
75 cm2 culture flask (suspension) Sarstedt
96-well culture dish, round bottom Sarstedt
96-well high binding plate Greiner
100 µm cell strainer Greiner
Cryo Tubes Sarstedt
Glass object slides Sarstedt
MS Columns Miltenyi Biotech
LD Columns Miltenyi Biotech
LS Columns Miltenyi Biotech
Slide-A-Slizer G2 Dialysis Cassette Thermo Scientific
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2.1.3 Kits
EasySep Mouse T Cell Enrichment Kit Stem Cell Technologies
EasySep Mouse Biotin Selection Kit Stem Cell Technologies
Pierce Biotin Quantitation Kit Thermo Scientific
2.1.4 Devices
EOOS 350D digital camera Canon
Gallios Flow Cytometer Beckman Coulter
HeraCell 150i CO2 Incubator Thermo Scientific
Heraeus Megafuge 16R Thermo Scientific
HeraSafe hood ThermoScientific
Microplate Reader µQuant BIO-TEK Instruments
Neubauer Counting Chamber OptikLabor
Silk-epil FG1100 Braun
Televal 31 microscope Zeiss
Vernier Caliper Hogotex
Water bath WNB14 Set Memmert
Xenogen IVIS 200 Perkin Elmer
2.1.5 Cell Culture
If not described differently, pipette tips were obtained from BD Falcon.
2.1.5.1 Cell Culture Reagents
10 x Phosphate buffered saline (PBS) Life Technologies
AB-Human serum Biochrom
AIM-V medium Life Technologies
Anti-mouse CD40Ligand (CD40L) antibody Novus Biologicals
Anti-mouse IgM(mu-chain), unconjugated Sigma Aldrich
β-Mercaptoethanol (β-ME)     Sigma Adrich 
CpG ODN 2395 Miltenyi Biotech
Cyclosporin A Sigma Adrich
DMEM medium Life Technologies
Fetal Bovine Serum (FBS) Lonza
G418 Biochrom
GM-CSF Immunotools
HEPES Life Technologies
IMDM medium Life Technologies
Incomplete Freund’s Adjuvant Sigma Aldrich
LPS from Escherichia coli 055:B5 Sigma Aldrich
MEM Life Technologies
Penicillin/ Streptomycin Life Technologies
rh Insulin Novo Nordisk
rh Interleukin-4 Immunotools
rh Transferrin Sigma Aldrich
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rm Interleukin-4 Immunotools
rm Interleukin-21 Immunotools
RPMI 1640 medium Life Technologies
Trypan Blue Stain 0.4 % Life Technologies
VLE-RPMI medium Biochrom
2.1.5.2 Media
DC medium VLE-RPMI medium
+ 5 % FBS
        + 50 µM β-ME 
+ 10 % Pen/Strep
Freezing medium FBS + 10 % DMSO
HeLa standard medium RPMI 1640
+ 300 µg/ml L-Glutamine
+ 10 % FBS
+ 10 mM HEPES
+ 10 % Pen/Strep
HeLa selection medium RPMI 1640
+ 300 µg/ml L-Glutamine
+ 10 % FBS
+ 10 mM HEPES
+ 10 % Pen/Strep
+ 0.2 mg/ml Hygromycin B
Human CD40B medium IMDM
+ 584 µg/ml L-Glutamine
+ 25 mM HEPES
+ 10 % AB-Human serum
+ 50 µg/ml rh Transferrin
+ 5 µg/ml rh Inuslin
+ 10 % Pen/Strep
Murine CD40B medium DMEM
+ 580 µg/ml L-Glutamine
+ 4.5 mg/ml Glucose
+ 10 % FBS
+ 10 mM HEPES
+ 0.1 mM MEM
+ 10 % Pen/Strep
NIH standard medium DMEM-Ham’s/ F12
+ 365 µg/ml L-Glutamine
+ 10 % FBS
+ 10 mM HEPES
+ 10 % Pen/Strep
Tumor medium DMEM
+ 580 µg/ml L-Glutamine
+ 10 % FBS
+ 10 mM HEPES
+ 10 % Pen/Strep
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2.1.6 Reagents
ABTS Peroxidase Substrate KPL
Biotin anti-mouse IgG1 Biolegend
CD19 MicroBeads human Miltenyi Biotech
CD19 MicroBeads mouse Miltenyi Biotech
Cell wash Beckton Dickinson
EZ-Link NHS-Biotin Reagent Thermo Scientific
HRP Avidin Biolegend
Pancoll Human (density 1.077 g/l) PAN Biotech
Pancoll Mouse (density 1.086 g/l) PAN Biotech
Purified anti-chicken Ovalbumin Biolegend
2.1.7 Solutions and Buffers
1x PBS 1 L 10x PBS, 9 L Ampuwa
Blocking solution 1x PBS, 10 % FBS
Coating buffer 8.4 g NaHCO3, 3.56 g Na2CO3, add
H2O up to 1.0 L, pH to 9.5
EasySep medium 1x PBS, 2 % FBS, 1 mM EDTA
MACS buffer 1x PBA, 0.5 % BSA, 2 mM EDTA
PBS/Tween 1 L 1x PBS, 0.5 ml Tween-20
2.1.8 Software
FlowJo Software TreeStar
GraphPad Prism GraphPadPrism
Kaluza Software Beckman Coulter
Living Image Software Perkin Elmer
2.2 Methods
2.2.1 Cell Subset Enrichment
2.2.1.1 Purification of Murine Lymphocytes from Spleen
Spleens were removed from 7-12 week old mice. A single suspension was prepared by
squeezing the tissue through a 100 µm cell strainer. For purification of murine lymphocytes
density-gradient centrifugation was performed. Cells of two spleens were resuspended in 8
ml murine CD40B medium and added onto a layer of 5 ml mouse Pancoll separation
medium. Cells were centrifuged at 1080 x g for 15 min without break. Afterwards, the
interphase, containing the splenocytes (lymphocytes from the spleen), was carefully
collected with a 20 G needle and cells were washed with 10 ml PBS.
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2.2.1.2 Purification of Murine Lymphocytes from Lymph Nodes
Single cell suspensions from mesenteric and inguinal lymph nodes of 7-12 week old mice
were prepared by squeezing the organs through a 100 µm cell strainer into a culture dish.
Cells were collected by washing the culture dish with 8 ml murine CD40B medium.
2.2.1.3 Purification of Human Lymphocytes from Blood
Buffy coat preparations were obtained from healthy donors at the blood bank of our
institution. The donors gave their consent and all the experiments were approved by our
institutional ethical board.
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats by
density-gradient centrifugation. 15 ml blood was mixed with 20 ml 1 x PBS and layered on
top of 15 ml human Pancoll separation medium. Cells were centrifuged at 1080 x g for 15
min without break. Afterwards, the interphase, containing the lymphocytes, was carefully
collected and cells were washed with 10 ml PBS.
2.2.1.4 Purification of Murine CD3+ T Cells
Murine CD3+ T cells were negatively enriched from splenocytes (chapter 2.2.1.1) of 7-12
week old OT-I or OT-II mice using EasySep Mouse T Cell Enrichment Kit (Stem Cell
Technologies, Canada) according to manufacturer’s protocol. Briefly, cells were resuspended
in EasySep medium at a concentration of 1 x 108 cells/ml. Cells were incubated for 10 min at
RT with 50 µl/ml of Normal Rat Serum and 50 µl/ml of EasySep Mouse T Cell Enrichment
Cocktail and for additional 2.5 min with 75 µl/ml of EasySep Streptavidin RapidSpheres.
Afterwards, the tube with the cells was placed into the EasySep magnet for 2.5 min. After
the incubation time, the desired cell fraction was poured off into a new tube by inverting the
magnet. The desired cell suspension was washed with 10 ml AIM-V medium. T cell purity
was determined by FACS analysis for CD3+ versus CD19+ cells.
2.2.1.5 Purification of CD34+ Bone Marrow Progenitor Cells
Murine CD34+ progenitor cells were purified from bone marrow of hind limbs of C57BL/6N
mice by positive selection with EasySep Biotin Selection Kit.
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Hind limbs of mice were isolated by cutting above the hip joint. The foot pad was cut below
the ankle joint and femur and lower leg were divided. Muscle tissue was removed and bones
put onto ice until further use. Bone tips were cut off and the bone marrow was washed from
each side with a 26G ½ needle by thorough rinsing with 4 ml cold EasySep buffer into a
falcon tube containing a buffer reservoir. The resulting cell suspension was washed through
a 100 µm cell strainer and centrifuged at 270 x g for 5 min. The cells were resuspended in
EasySep medium at a concentration of 1 x 108 cells/ml and incubated with 10 µl/ml EasySep
FcR-Block and 15 µl/ml anti-murine CD34-biotinylated antibody (0.5 mg/ml) for 15 min at RT.
Afterwards, the cells were washed, resuspended in EasySep Medium at concentration of 1 x
108 cells/ml and incubated with 100 µl/ml EasySep Biotin Selection Cocktail for 15 min at RT.
Afterwards, 50 µl/ml EasySep magnetic nanoparticles were added for additional 10 min. The
tube with the cells was placed into the EasySep magnet for 5 min. After the incubation time,
the supernatant fraction was poured off by inverting the magnet. The desired cell fraction
was collected by washing the tube 3 times with 1 ml DC-medium.
2.2.1.6 Purification of Murine and Human CD19+ B Cells
Murine CD19+ B cells were positively enriched from splenocytes (chapter 2.2.1.1) of 7-12
week old C57BL/6N or Luc+ mice using murine CD19 MACS microbeads. Human CD19+ B cells
were positively enriched from PBMCs (chapter 2.2.1.3) using human CD19 MACS
microbeads. Both isolations were performed according to manufacturer’s protocols
(Miltenyi Biotech, Germany) with minor modifications. Briefly, murine splenocytes or human
PBMCs were resuspended in MACS buffer at a concentration of 17 x 107 cells/ml. Murine or
human CD19 microbeads were added at a concentration of 127.5 µl/ml and cells were
incubated for 15 min at 4 °C. Afterwards, cells were washed with 10 ml MACS buffer and the
pellet was resuspended in 5 ml MACS buffer before the suspension was applied to the MACS
LS column. After the column was washed two times with 3 ml MACS buffer, the desired cell
fraction was removed by firmly pushing the plunger into the column. Cells were washed with
additional 10 ml murine or human CD40B medium by centrifuging them at 270 x g for 5 min.
B cell purity was determined by FACS analysis for CD19+ B220+ cells.
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2.2.1.7 Purification of Murine and Human Antigen-Specific B Cells
Murine and human antigen-specific B cells were isolated from splenocytes of 7-12 week old
immunized C57BL/6 or Luc+ mice or from blood (chapter 2.2.1.3) of vaccinated healthy
donors. Antigen-specific B cells were enriched by labeling them with antigen tetramers and
subsequent positive selection using the EasySep Biotin Selection Kit.
2.2.1.7.1 Generation of Protein-Biotin Conjugates for Antigen Tetramers
The antigens were biotinylated by using the EZ-Link NHS-Biotin Reagent (Thermo Scientific,
Rockford, USA) according to manufacturer’s protocol. 135.5 µl of a 10 µM biotin solution
were added to 1.5 ml of a 2 mg/ml protein solution. The mixture was incubated on ice for
two hours. To remove excess non-reacted biotin, the solution was applied to a Slide-A-Lyzer
G2 Dialysis Cassette (Thermo Scientific, Rockford, USA) over night at 4 °C in 1 L 1x PBS with
one complete change of the buffer after 2 h.
OVA (albumin from chicken egg white) was purchased from Sigma Aldrich (St. Louis, USA)
and HBV antigen (Active hepatitis b virus Hepatitis B Surface Antigen full length protein) was
purchased from Abcam (Cambridge, UK).
2.2.1.7.2 Quantification of Biotinylation
Biotinylation of antigens was checked using the Pierce Biotin Quantitation Kit (Thermo
Scientific, Rockford, USA) according to manufacturer’s protocol. 100 µl of HABA/Avidin
Premix were added to 800 µl 1x PBS and the absorbance of the solution at 500 nm was
recorded as A500 HABA/avidin. 100 µl of the antigen-biotin solution were added to the
mixture and once the value of the absorbance at 500 nm was stable, it was recorded as A500
HAB/avidin/ biotin sample. The number of moles of biotin per mole of protein was
calculated as follows according to manufacturer’s protocol:
1. Calculation # 1 is for the concentration of biotinylated protein in mmol/ml (before
any dilution for the assay procedure (MW = molecular weight):
2. Calculation # 2 is for the change in absorbance at 500 nm in a cuvette:
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3. Calculation # 3 is for the concentration of biotin in mmol per ml of reaction mixture:
4. Calculation # 4 is for the mmol of biotin per mmol of protein:
2.2.1.7.3 Enrichment of Antigen-Specific B Cells
OVA-specific B cells from splenocytes and HBV-specific B cells from blood were isolated
using the EasySep Biotin Selection Kit. The cells were resuspended in EasySep medium at a
concentration of 1 x 108 cells/ml and incubated with 10 µl/ml EasySep FcR-Block and 0.1 -0.3
µg/ml (depending on the concentration of mmol biotin per mmol protein calculated in
chapter 2.2.1.7.2) antigen-biotin conjugate for 10 min at RT. Afterwards, the cells incubated
with 100 µl/ml EasySep Biotin Selection Cocktail and 4 µl/ml Streptavidin-PE for 15 min at RT
and for another 10 min with 50 µl/ml EasySep magnetic nanoparticles. The tube with the
cells was placed into the EasySep magnet for 5 min. After the incubation time, the
supernatant fraction was poured off by inverting the magnet. The cells were resuspended in
2.5 ml EasySep medium. This procedure was repeated at least two times. The desired cell
fraction was collected by washing the tube 3 times with 1 ml murine or human CD40B
medium. The purity of murine or human antigen-specific B cells was determined by FACS
analysis of antigen-specific CD19+ B220+ or CD19+ CD20+ cells, respectively.
2.2.1.8 Purification of Murine Memory B Cells
Murine memory B cells were enriched from splenocytes (chapter 2.2.1.1) of 7-12 week old
C57BL/6N mice using murine Memory B Cell Isolation Kit (Miltenyi Biotech., Bergisch
Gladbach, Germany). The isolation was performed according to manufacturer’s protocol.
Murine splenocytes were resuspended in MACS buffer at a concentration of 33 x 107
cells/ml. 100 µl of Memory B Cell Biotin-Antibody Cocktail, 50 ml of Anti-IgG1-APC and 50 µl
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of Anti-IgG2ab-APC were added per 108 cells and incubated for 5 min at 4 °C. 300 ml MACS
buffer and 200 µl of Anti-Biotin microbeads were added per 108 cells for additional 10 min.
Afterwards, cells were applied to the MACS LD column. Unlabelled cells were collected and
centrifuged at 270 x g for 5 min. Cells were resuspended In 400 µl MACS buffer and 100 µl of
Anti-APC microbeads were added for 15 min at 4 °C. The cells were washed at 270 x g for 5
min, resuspended in 500 µl buffer and applied to the MACS MS column. After the column
was washed two times with 500 µl MACS buffer, the desired cell fraction was removed by
firmly pushing the plunger into the column.
2.2.2 Cell Culture
If not described differently, all cell lines were incubated at 37 °C in a humidified atmosphere
with 5% CO2. Cell culture was performed at sterile conditions under a safety cabinet with
sterile solutions, glass and plastic ware. All centrifugation steps in cell culture were
performed in a Heraeus Megafuge 16R (Thermo Scientific).
2.2.2.1 Counting of Cells
For counting, an aliquot of the cell suspension was diluted with 10x with Trypan Blue Stain
0.4 % and counted using a Neubauer Counting Chamber. 10 µl of the cell suspension were
applied to the counting chamber and bright cells within one big quadrant of the Neubauer
chamber were counted as viable using a light optical microscope with 20 fold magnification.
The average cell number of per quadrant was multiplied by the dilution factor and by the
chamber factor 104, resulting in the number of cells per 1 ml. The relative growth a cultures
during a whole cultivation period was assessed by calculating the relative increase between
two passages.
2.2.2.2. Cryopreservation and Thawing of Cells
For cryopreservation, cells were suspended in freezing medium, at a density of 3-10 x 106
cells/ml. The cell suspension was aliquoted into cryo tubes and slowly frozen at -80 °C in a
freezing chamber. 24 h later, tubes were transferred into liquid nitrogen for long-term
storage.
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Frozen cells were rapidly thawed in a water bath at 37 °C until a small ice clump was left in
the tube. Cells were transferred to an excess of medium and centrifuged at 270 x g for 5 min.
2.2.2.3 Trypsinization of Adherent Cells
The medium was removed and the adherent cells were washed with 10 ml of 1x PBS. After
removing the PBS, 4 ml of Trypsin-EDTA were added to a 75 cm2 flask. Cells were incubated
at 37 °C for 5-10 min. To stop trypsinization, 10 ml of medium were added to the cells. Cells
were harvested and centrifuged at 200 xg for 5 min and resuspended in standard medium.
2.2.2.4 Assessment of Morphology by Microscopy
Representative sections of cultures were photographed by using an inverted phase Zeiss
Televal 31 microscope fitted with a Canon EOOS 350D digital camera.
2.2.2.5 Assessment of Morphology by Pappenheim Staining
10 µl of a cell suspensions were placed at a density of 1 x 106 cells/ml on a glass object slide.
The cell suspension was allowed to dry over night. Pappenheim staining according to
standard protocols were kindly performed in the Laboratory for Hematological Diagnostic in
the Department for Internal Medicine I at the University Hospital Cologne, Germany.
Pictures were taken using a Zeiss AxioPhot microscope at a magnification of x63. Pictures
were taken using dhs-Bilddatenbank.
2.2.2.6 Cell Lines
2.2.2.6.1 Culture of the tmuCD40L HeLa Cell Line
The tmuCD40L HeLa cell line, an adherent human epithelial cell line, was kindly provided by
Clemens Wendtner (Klinikum Schwabing, Munich, Germany). Cell passaging was performed
twice a week. Adherent tmuCD40L HeLa cells were trypsinized (chapter 2.2.1.3) and
resuspended in 10 ml HeLa standard medium in order to determine cell number (chapter
2.2.1.1). 2 x 106 cells in 10 ml selection medium were seeded in a 75 cm2 culture flask and
incubated at standard conditions. Stable expression of the CD40L was tested once a week by
flow cytometry using a PE-conjugated anti-mouse CD154 (CD40L) antibody.
For generation of murine CD40B cells, tmuCD40L HeLa cells were lethally irradiated 3 times
with 26 Gy and subsequently plated on sterile 6-well culture plate at a density of 0.4 x 106
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cells/well in 2 ml HeLa standard medium. After 4-24 h of incubation at standard conditions,
cells became adherent and were used for co-cultures with murine CD40B cells.
2.2.2.6.2 Culture of the NIH3T3/tCD40L Cell Line
The NIH3T3/tCD40L cell line, an adherent murine fibroblast cell line, was kindly provided by
Gordon Freeman (DFCI, Boston, USA). Cell passaging was performed twice a week. Adherent
NIH3T3/tCD40L cells were trypsinized (chapter 2.2.1.3) and resuspended in 10 ml NIH
standard medium in order to determine cell number (chapter 2.2.1.1). 1.5 x 106 cells in 10 ml
NIH standard medium supplemented with G-418 (0.7 mg/ml) were seeded in a 75 cm2
culture flask and incubated at standard conditions. Stable expression of the CD40L was
tested once a week by flow cytometry using a PE-conjugated anti-human CD154 (CD40L)
antibody.
For generation of human CD40B cells, NIH3T3/tCD40L cells were lethally irradiated 2 times
with 26 Gy and subsequently plated on sterile 6-well culture plate at a density of 0.2 x 106
cells/well in 2 ml NIH standard medium. After 4-24 h of incubation at standard conditions,
cells became adherent and were used for co-cultures with human CD40B cells.
2.2.2.6.3 Culture of the E.G7 Lymphoma Cell Lines
The murine suspension lymphoma cell line EL4 and the OVA-expressing E.G7 cell line (EL4
background) were kindly provided by the Laboratory of Tomo Šarić (Department for 
Neurophysiology, University Hospital Cologne, Germany). Cell passaging was performed
three times a week by harvesting the cell suspension. Cells were centrifuged at 270 x g for 5
min and resuspended in 10 ml tumor medium for counting (chapter 2.2.1.1). Cells were
culture at a concentration of 0.1 x 106 cells/ml in a 75 cm2 culture flask and incubated at
standard conditions. E.G7 cells were supplemented with G-418 (1 mg/ml).
2.2.2.7 Generation of Murine and Human CD40B Cells
Murine or human CD40B cell cultures were generated as described previously (Liebig et al.
2009, Liebig et al. 2010). In short, CD19+-purified (chapter 2.2.1.6) or antigen-enriched B cells
(chapter 2.2.1.7) were resuspended at a concentration of 1.25 x 106 cell/ml in murine or
human CD40B medium, respectively. The human medium was freshly supplemented with 1
U/ml of IL-4 and 0.63 µg/ml cyclosporin A. The murine medium was additionally
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supplemented with 100 µM β-ME. For co-cultures, the supernatant of the previously 
prepared 6-well feeder cell plates (chapter 2.2.2.6.1 and 2.2.2.6.2, respectively) were
removed and the plates were washed with 1x PBS. 4 ml of the lymphocyte cell suspension
were gently added to each well of the 6-well plate and incubated at standard conditions.
Feeder cells of CD40B cultures were refreshed twice a week. CD40B cells were harvested by
vigorously pipetting the cell suspension up and down. The cells were washed at 270 x g for 5
min and resuspended at a concentration of 1.25 x 106 cells/ml in murine or human CD40B
medium. IL-4, β-ME and cyclosporin A were freshly supplemented at the concentrations 
mentioned above. The cell suspension was applied to fresh cultures of feeder cells and
cultivated at standard conditions. The expression of co-stimulatory and MHC-molecules and
surface immunoglobulins was determined twice a week by fluorescence-associated cell
sorting (FACS) analyses.
2.2.2.8 Generation of Murine Dendritic Cells
For in vitro generation of murine dendritic cell cultures, CD34+ bone marrow progenitor cells
(chapter 2.2.1.5) were used. The enriched cells were cultivated at a concentration of 0.25 x
106 cell/ml in murine DC medium supplemented with 500 U/ml of murine GM-CSF and 1
U/ml murine IL-4. 2 ml of the cell suspension was applied to each well of a 12-well plate and
incubated at standard conditions. On days 3, and 5 of the cultivation period, 1 ml medium
from each well was carefully removed and replaced by 1 ml DC medium supplemented with
1000 U/ml of murine GM-CSF and 2 U/ml of murine IL-4. For maturation of DCs, the medium
was replaced as described above, supplemented with either 10 ng/ml LPS or 1 µg/ml anti-
mouse CD40L antibody and cultivated over night at standard conditions. For further use, DCs
were harvested by gently detaching them from the culture plate with a cell scraper. Purity of
DC cultures was determined by FACS analyses of the CD11c+ CD11b+ cell population and
checked for the expression of co-stimulatory molecules.
2.2.2.9 Generation of Antibody-Secreting Plasma Cells
For in vitro generation of antibody-secreting plasma cells, CD19+-purified (chapter 2.2.1.6) or
antigen-enriched B cells (chapter 2.2.1.7) were resuspended at a concentration of 1 x 106
cells/ml in CD40B medium. The medium was supplemented with different stimuli, including
IL-4 (1 U/ml), IL-21 (50 ng/ml), anti-mouse CD40L (1 µg/ml), anti-mouse IgM (5 µg/ml), LPS
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(10 µg/ml) and OVA-biotin tetramers (0,2 µg/ml + 0.5 µg/µl Streptavidin-PE). 200 µl of the
cell suspension were applied to a round bottom 96-well plate and incubated for 72 h at
standard conditions. Differentiation into plasma cells was assessed by FACS analyses of
surface immunoglobulin and plasma cell markers, as well as Enzyme Linked Immunosorbent
Assay (ELISA) of specific immunoglobulins.
2.2.3 Phenotypical and Functional Analyses
2.2.3.1 Fluorescence Activated Cell Sorting
Acquisition and enumeration of cells were performed by using a Gallios Flow Cytometer
(Beckman Coulter, Pasadena, USA). Single-cell analyses were performed by use of the FlowJo
software (Tree Star, Ashland, USA) or the Kaluza software (Beckman Coulter, Pasadena,
USA). All washing steps were performed with cell wash in a Heraeus Megafuge 16R (Thermo
Scientific) at 270 x g for 5 min at RT.
2.2.3.1.1 Surface Staining with Monoclonal Antibodies
Surface staining with monoclonal antibodies for FACS analyses was performed by washing
0.1 – 1 x 106 cells in 4 ml cell wash. Cells were resuspended in 100 µl cell wash and stained
with 1 µl of antibody solution for 20 min at 4 °C. Afterwards, cells were washed and
resuspended in 150 - 300 µl cell wash depending on the cell number. Monoclonal antibodies
used for staining, conjugates and companies are listed in table 2.1.
Table 2.1. Monoclonal antibodies used for FACS analyses.
Antibody Conjugate Company
Murine Antibodies
B220 Alexa Fluor 750 Life Technologies
Pacific Blue Biolegend
CD3 APC-Cy7 BD
CD4 PE-Cy7 BD
CD8 PerCP-Cy5.5 BD
CD11b APC-Cy7 BD
CD11c PE BD
CD19 Alexa Fluor 700 Biolegend
PE-Texas Red Life Technologies
CD27 PE-Cy7 Biolegend
CD80 APC BD
CD86 FITC BD
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2.2.3.1.2 Staining of Antigen-Specific B Cells with Antigen Tetramers
Antigen-specific B cells were identified by staining with antigen tetramers. In order to form
tetramers, 0.2 µg of biotinylated OVA- or HBV-protein was pre-incubated with 0.5 µg of
Streptavidin-PE for 5 min at RT. Afterwards, antigen-tetramers were incubated together with
surface antibodies (chapter 2.2.3.1.1).
Alexa Fluor 700 Biolegend
CD138 PerCP-Cy5.5 Biolegend
IgG1 FITC BD
PE-Vio770 Miltenyi Biotech
IgM APC Biolegend
IgD PerCP-Cy5.5 Biolegend
VioBlue Miltenyi Biotech
MHCI FITC eBioscience
IAb (MHC II) FITC Biolegend
Vß 5.1, 5.2 PE BD
Human Antibodies
CD3 APC-Cy7 Beckman Coulter
CD4 ECD Beckman Coulter
CD8 FITC BD
CD11b Alexa Fluor 700 Biolegend
CD11c APC Biolegend
CD19 APC eFluor 780 eBioscience
CD20 Pacific Orange Life Technologies
CD21 APC Biolegend
CD27 PE-Cy7 Biolegend
CD80 FITC BD
CD86 Pacific Blue Biolegend
CD138 Alexa Fluor 700 Biolegend
IgD FITC BD
IgG1 ECD Beckman Coulter
IgM PerCP-Cy5.5 Biolegend
HLA-DR Alexa Fluor 700 eBioscience
Species Independent Antibodies
Annexin PE BD
Streptavidin PE BD
APC Biolegend
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2.2.3.2 Mixed-Lymphocyte Reaction
To study the APC capacity of CD40B cells and DCs, antigen-specific autologous mixed-
lymphocyte reactions (MLR) were performed.
APCs were incubated with the specific antigen at a concentration of 75 nM for 24 h prior to
incubation with the T cells. Afterwards, APCs were harvested and resuspended in HeLa
standard medium at a concentration of 1 x 106 cells/ml. Cells were irradiated once with 26
Gy to stop them from proliferation. Serial dilutions were performed for incubation with T
cells at APC-to-T cell ratios 3:1, 1:1, 1:5, 1:10, 1:20 and 1:50 in 100 ml HeLa standard
medium.
CD3+ T cells were isolated from spleens of OT-I or OT-II mice by positive selection (chapter
2.2.1.4). For detection of T cell proliferation, the T cells were stained with the fluorescent
proliferation marker CFSE. For this purpose, CD3+ T cells were resuspended at a
concentration of 5 x 106 cells/ ml in 1 x PBS with 5 % FBS, stained with 10 µM CFSE and
incubated for 5 min in the dark with constant agitation. The staining reaction was stopped by
adding 5 ml of pure FBS and cells were centrifuged at 270 x g for 5 min. T cells were
resuspended at a concentration of 1 x 106 cells/ml in HeLa standard medium. T cells were
plated in 100 µl at indicated APC-to-T cell ratios on a round bottom 96-well plate. Co-
cultures were incubated for 5 days at standard culture conditions. CFSE segregates equally
between daughter cells upon cell division, resulting in sequential reduction of cellular
fluorescence intensity with each successive generation. Therefore, proliferation of T cells
was detected by determining the percentage of proliferating CFSElow CD3+CD4+ or CD8+ T
cells by FACS analysis (chapter 2.2.3.1). Activation of T cells was determined by positive
staining for the T cell activation marker CD25.
2.2.3.3 Enzyme-Linked Immunosorbent Assay
Secretion of specific antibodies in plasma cell differentiation assays was determined in
ELISAs for OVA-specific IgG1 antibodies. For this purpose, 96-well high-binding plates were
incubated with OVA-protein at a concentration of 40 µg/ml in a volume of 50 µl Coating
Buffer. The plate was sealed and incubated over night at 4 °C. The day after, the protein
solution was discarded into a sink and the plate was washed three times with PBS/Tween.
Afterwards, non-specific binding was blocked by incubating the plate with 100 µl Blocking
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Solution for 1 h at RT. The plate was washed three times with PBS/Tween before applying 50
µl of standards and samples in doublets. Samples were diluted 1:5 in Blocking Solution.
Standards were applied at 5 ng/ml, 10 ng/ml, 50 ng/ml, 100 ng/ml, 250 ng/ml, 500 ng/ml,
1000 ng/ml, 2500 ng/ml and 5000 ng/ml in Blocking Solution. The plate was sealed and
incubated at RT for 2-4 h. Afterwards the plate was washed three times with PBS/Tween and
50 µl of the detection antibody anti-mouse IgG1 was added at a concentration 100 ng/ml in
Blocking Solution. The plate was sealed and incubated at RT for 1 h. The plate was washed
three times before adding the avidin-horseradish peroxidase (Av-HRP) at a dilution of 1:1000
in Blocking Solution. The plate was incubated for 30 min at RT. Afterwards, the plate was
washed 5 times with PBS/Tween before applying 50 µl of the premixed ABTS substrate
solution A and B. The enzymatic reaction was stopped with 50 µl 1 % SDS and the extinction
at 405 nm was measured in a µ-Quant microplate reader.
2.2.4 In Vivo Experiments
The animal experiments were performed in accordance with the national and European
guidelines for laboratory animal keeping with permission from the local government
authorities (permission number 84-02.04.2011.A226). Mice were bred in the animal facility
of the Department of Pathology at the University Hospital Cologne under specific pathogen-
free conditions.
C57BL/6NRj wild type mice were obtained from Janvier Labs (France) and then further bred
in our own animal facility.
C57BL/6-Tg(TcraTcrb)1100Mjb/Crl (OT-I) mice contain inserts for mouse Tcra-V2 and Tcrb-V5
genes and express transgenic T cell receptors (TCR) that recognize ovalbumin residues 257-
264 in the context of H2Kb. OT-I mice were routinely monitored for expression of TCR-chain
Vβ5 on CD3+CD8+ T cells by FACS analysis.
C57BL/6-Tg(TcraTcrb)425Cbn/Crl (OT-II) mice express the mouse alpha-chain and beta-chain
T cell receptor that pairs with the CD4 coreceptor and is specific for chicken ovalbumin 323-
339 in the context of I-Ab. They show a four-fold increase in the CD4+ to CD8+ peripheral T
cell ratio. OT-II mice were routinely monitored for expression of TCR-chain Vβ5 on CD3+CD4+
T cells by FACS analysis.
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Luciferase+ (Luc+) mice were on a C57BL/6N background and were kindly provided by Prof.
Dr. Robert Zeiser (Laboratory for Allo-Immunregulation, Department for Internal Medicine I,
University Hospital Freiburg). These mice express the firefly luciferase under control of the
β-actin promoter in many leukocyte subsets including CD19+B220+ B cells.
2.2.4.1 Vaccination Strategies
2.2.4.1.1 Immunization with Peptide-Loaded Cell Subsets
In order to immunize CD57BL/6N mice with CD40B cells or mature DCs, cell subsets were
exogenously loaded with OVA protein. For this purpose, CD40B cells or DCs were harvested
and washed with serum-free medium at 270 x g for 5 min. Cells were suspended in serum-
free medium at a concentration of 1 x 106 cells/ml and incubated with 10 µM OVA-Protein
for 1 h at standard culture conditions. Before injection, cells were washed three times with
20 ml 1 x PBS. Cells were injected in 100 µl 1 x PBS. Cell numbers and injection routes were
as indicated in experiments.
2.2.4.1.2 Immunization with Incomplete Freund’s Adjuvant
C57BL/6N or Luc+ mice were immunized with 20 µM OVA-Protein in Incomplete Freund’s
Adjuvant (IFA) for generation of OVA-specific B cells. In order to prepare the IFA/protein
emulsion, OVA-Protein was dissolved in PBS and added to the IFA in a ratio of 1:1. The
solution was strongly vortexed until it appeared white and viscous. The emulsion was
transferred to the syringes without attaching the needle. The needle was added immediately
prior to injection. 100 µl of the protein/IFA solution was injected i.p.
As positive control for in vivo cytotoxicity assays and tumor control, mice were immunized
with OVA-Protein/ IFA solutions in addition of 7 µM immunomodulatory CpG-ODN 2395
(oligodeoxynucleotide with non-methylated cytosine-guanine motifs). Positive controls were
injected i.p.
2.2.5 In Vivo Cytotoxicity Assays
In vivo cytotoxicity (cytotox) assays aim to detect in vivo killing of antigen-presenting target
cells by recognition through cognate CD8+ T cells induced by immunization (chapter
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2.2.4.1.1). Five to seven days after the last immunization, mice were injected with CFSE-
labeled target cells from naïve syngeneic mice loaded with OVA-peptide (aa 257 – 264).
2.2.5.1 Injection of Target Cells
Target cells were prepared from single cell suspension from spleens of 7-18 week old
C57BL/6 mice (chapter 2.2.1.1). Splenocytes were washed two times with 1x PBS at 270 x g
for 5 min. Afterwards, cells were resuspended in 1x PBS with 5 % FBS at a concentration of
100 x 106 cells/ml. Splenocytes were split into fractions. One fraction was labeled with a low
amount of CFSE (2 µM) and one fraction was labeled with high amount of CFSE (20 µM) by
constantly agitating the tubes for 5 min in the dark. The labeling reaction was stopped by
adding 5 ml pure FBS. The cells were washed at 270 x g for 5 min and resuspended in serum-
free medium at a concentration of 1 x 107 cells/ml. The CFSE high fraction was pulsed with
10 µM OVA-peptide, the CFSE low fraction was left unpulsed. Cells were incubated for 1 h at
standard conditions. Afterwards, both fractions were washed extensively by resuspending
them in 20 ml PBS and centrifuging at 270 x g for 5 min. For injection, cells were
resuspended at a concentration of 10 x 107 cells/ml in 1x PBS and both fractions were
2.2.5.2 Detection of Specific Cytolysis
To analyze remaining CFSE-positive target cell fractions in immunized mice, spleens were
isolated 24 hours after target cell injection. Spleen were minced through a 100 µm cell
strainer and resuspended in 1 x PBS. Splenocytes were counted and 4 x 106 cells were filled
in a FACS tube, washed and resuspended in 300 µl cell wash. Cells were analyzed by FACS
immediately. The ratio of unpulsed versus pulsed (RatioUP) target cells was determined by
dividing the percentage of CFSE low cells by the percentage of CFSE high cells. The
percentage of the specific lysis was then calculated by the following formula:
2.2.6 In Vivo Homing Studies
For in vivo migrations studies of polyclonal B cells, B cells were isolated from spleens of Luc+
mice (chapter 2.2.1.1) and activated in the CD40 culture system (chapter 2.2.2.7). For
migration studies of OVA-specific B cells, Luc+ mice were immunized with OVA-Protein 14
% Specific Lysis = (1-(RatioUP Negative Control/RatioUP Immunized))*100
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days before isolation (chapter 2.2.4.1.2). Luc+ mice were injected i.v. into 7-12 weeks old
C57BL/6N wild type mice. Detection of Luc+ B cells was performed by injecting 7.5 mg D-
luciferin in 250 ml 1x PBS i.p. into wild type mice. The luciferin was allowed to distribute in
the mouse for 5 min before mice were narcotized with 1.5-4 % isofluran. Mice were shaved
prior to imaging in order to minimize interference by the fur. Imaging was performed in the
Xenogen IVIS 200 (Perkin Elmer). Mice were constantly kept under narcosis with 1.5-4 %
isofluran at 37 °C. Bioluminescence pictures were analyzed with the Living Image Software
(Perkin Elmer).
2.2.7 Tumor Formation
For tumor control experiments, E.G7 lymphoma cells (chapter 2.2.2.6.3) were kept at a low
concentration of 1 x 106 cells/ml prior to injection. For tumor formation, cells were
harvested and resuspended at a concentration of 4 x 106 cells/ml in 1x PBS. 100 µl (0.4 x 106
cells) were injected s.c. into the right flank of immunized or naïve C57BL/6N mice. Tumor
size was determined daily from day 7 after inoculation by measuring tumor diameter in two
dimensions using a vernier caliper. The tumor volume was calculated using the following
formula:
Tumors were allowed to grow for 40 days or until one diameter reached a size of 15 mm.
2.2.8 Statistics
Significant differences were calculated by ordinary one-way ANOVA or ordinary two-way
ANOVA were appropriate using GraphPad Prism Software. P-values of less than 0.05 were
considered statistically significant and marked with asterisks: * p ≤ 0.05, ** p ≤ 0.01,      *** p 
≤ 0.001, **** p ≤ 0.0001. Mean values and standard deviations (SD) were calculated from at 
least 3 independent experiments.
Tumor volume = 0.5 x (length × width2)
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3. Results
3.1 Antigen-Specific B Cells can be Isolated by Antigen Tetramers
Study of antigen-specific B cells is challenging, because of low frequencies in peripheral
blood or spleens and low signaling by fluorescently labeled antigens
However, a sensitive method enabling the detection of B cells with defined specificity in
FACS analyses are antigen tetramers. They are produced by biotinylation of the soluble
antigen and tetramerization with fluorescently labeled streptavidin (Fig. 3.1).
Fig. 3.1 Overview of the antigen tetramer staining.
with fluorescently labeled streptavidin to form tetramers. B cells are stained with antigen tetramers
and a panel of surface antibodies.
3.1.1 Murine Antigen-Specific B Cells can be Purified by Antigen
Under normal conditions, the frequency of B cells with defined specificity in spleen is below
1 % (Oshiba et al. 1994, Kodituwakku et al. 2003
specific B cells, C57BL/6 mice were im
increased the percentage of OVA
spleens (Fig. 3.2A, middle plot) and to about 30 % in inguinal lymph nodes (Fig. 3.2B, right
plot), which was determined by labeling with antigen tetramers and FACS analyses (Fig. 3.1).
However, the percentage of OVA
greatly from 20 to 90 % (data not shown).
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Fig. 3.2 Percentage of OVA-specific B cells. (A) Splenocytes from mice were stained for OVA-specific
B cells among the CD19+ B220+ B cell population with OVA-Biotin tetramers. Representative flow
cytometry analyses out of at least 10 independent experiments with non-immunized mice (control,
left plot) or immunized mice (middle plot) are shown. Splenocytes from immunized mice were
purified by positive selection with OVA-Biotin tetramers (right plot). (B) Single cell suspensions from
inguinal and axillary lymph were stained for OVA-specific B cells among the CD19+ B220+ B cell
population with OVA-Biotin tetramers. Representative flow cytometry analyses out of at least 10
independent experiments of inguinal lymph nodes (draining LN, right plot) and axillary lymph nodes
(non-draining LN, middle plot) with immunized mice are shown. Inguinal lymph nodes of non-
immunized mice served as control (left plot). Numbers indicate the percentage of OVA+ B cells.
OVA-specific B cells could be enriched from splenocytes by positive selection via antigen
tetramers. The efficiency of the enrichment strongly depended on the grade of biotinylation
and therefore varied between 20 and 70 %. However, under optimal conditions an OVA-
specific B cell purity of above 60 % of all CD19+ B220+ B cells could be reached (Fig. 3.2A,
right plot). The overall purity of CD19+ B220+ B cells was around 80 % (Fig. 3.3), but was
never higher than 85 % unlike with CD19+ selection of B cells. Higher B cell purity could also
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not be reached by negative B cell selection prior to OVA-specific enrichment (data not
shown).
B cells of other specificities could also be generated and isolated, which was demonstrated
by isolation of Keyhole Limpet Hemocyanin (KLH)-specific B cells. According to the
generation of OVA-specific B cells, KLH-specific B cells were isolated from immunized mice
and stained with KLH tetramers. About 2-9 % of all CD19+ B220+ B cells in spleens were
specific for KLH (Fig. 3.4, middle plot). KLH-specific B cells were enriched using a Memory B
cell Isolation Kit, which resulted in a purity of KLH-specific B cells of about 7 % (Fig. 3.4, right
plot).
Fig. 3.4 Percentage of KLH-specific B cells. Splenocytes from mice were stained for KLH-specific B
cells among the CD19+ B220+ B cell population with KLH-Biotin tetramers. Representative flow
cytometry analyses out of 3 independent experiments with non-immunized mice (control, left plot)
or immunized mice (middle plot) are shown. Splenocytes from immunized mice were purified by
memory B cell selection (right plot). Numbers indicate the percentage of KLH+ B cells.
Fig. 3.3 B cell purity of OVA-enriched B cells.
Representative flow cytometry analysis of
purified OVA-specific B cells out of at least 10
independent experiments is shown. Splenocytes
from immunized mice were purified by positive
selection with OVA-Biotin tetramers and stained
for CD19+ B220+ B cells. Numbers indicate the
percentage of CD19+ B220+ B cells.
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3.1.2 Murine Antigen-Specific B Cells Show a Class-Switched Phenotype
The isolated antigen-specific B cells were characterized by FACS analyses for several surface
markers defining their activation status and developmental state. Bar charts represent
results of at least three independent experiments. Expression levels of B cells of immunized
mice were normalized to the expression levels of B cells of non-immunized (control) mice.
There was no difference in expression of the B cell marker B220 in OVA-specific CD19+ B220+
B cells compared to control B cells of non-immunized mice or OVA-negative B cells of
immunized mice (Fig. 3.5).
Fig. 3.5 B220 expression in OVA-specific B cells. OVA-specific B cells from immunized mice were
stained for their expression of B220 and analyzed by flow cytometry. (A) Representative analyses out
of 5 independent experiments are shown. OVA-specific B cells (black line) were compared to B cells
of non-immunized (control) mice (left plot, grey line) and OVA-negative B cells of immunized mice
(right plot, grey line). Cells that were analyzed without antibody staining served as unstained control
(filled histogram). (B) The mean fluorescent intensity (MFI) of B220 of OVA-specific (OVA+) and OVA-
negative (OVA-) B cells in immunized mice were normalized to the expression levels in B cells of
control mice. Bar charts show mean values ± SEM of three independent experiments. Significant
differences calculated with ordinary one-way ANOVA were not detected.
Although the B cell marker CD19 was upregulated in immunized mice, the difference was not
significant (Fig. 3.6). Phenotyping of KLH-specific B cells revealed similar results (data not
shown).
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Fig. 3.6 CD19 expression in OVA-specific B cells. OVA-specific B cells from immunized mice were
stained for their expression of CD19 and analyzed by flow cytometry. (A) Representative analyses out
of 5 independent experiments are shown. OVA-specific B cells (black line) were compared to B cells
of non-immunized (control) mice (left plot, grey line) and OVA-negative B cells of immunized mice
(right plot, grey line). Cells that were analyzed without antibody staining served as unstained control
(filled histogram). (B) The mean fluorescent intensity (MFI) of CD19 of OVA-specific (OVA+) and OVA-
negative (OVA-) B cells in immunized mice were normalized to the expression levels in B cells of
control mice. Bar charts show mean values ± SEM of three independent experiments. Significant
differences calculated with ordinary one-way ANOVA were not detected.
Interestingly, the percentage of IgD+ and IgM+ OVA-specific CD19+ B220+ B cells was
significantly decreased (22.41 % ± 18.81 and 26.37 % ± 19.91, respectively) compared to
control B cells of non-immunized mice (90.33 % ± 1.74 and 82.09 % ± 14.98, respectively)
and OVA-negative B cells of immunized mice (60.20 % ± 20.93 and 77.16 % ± 13.44,
respectively; Fig. 3.7 and Fig. 3.8). In contrast, IgG1+ OVA-specific B cells were significantly
increased (77.25 % ± 18.17) compared to control B cells of non-immunized mice (6.98 % ±
7.98) or OVA-negative B cells of immunized mice (51.95 % ± 2.90; Fig. 3.9). This clearly
demonstrated a class-switched phenotype of the isolated B cells, confirming the assumption
that they are antigen-specific B cells. KLH-specific B cells showed similar percentaged
distribution of immunoglobulins (data not shown).
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Fig. 3.7 Percentage of IgD+ B cells. OVA-specific B cells from immunized mice were stained for their
expression of IgD and analyzed by flow cytometry. (A) Representative analyses out of 5 independent
experiments are shown. OVA-specific B cells (black line) were compared to B cells of non-immunized
(control) mice (left plot, grey line) and OVA-negative B cells of immunized mice (right plot, grey line).
Cells that were analyzed without antibody staining served as unstained control (filled histogram). (B)
The percentage of IgD+ B cells among OVA-specific (OVA+), OVA-negative (OVA-) or B cells of control
mice are shown. Bar charts show mean values ± SEM of three independent experiments. Significant
differences were calculated with ordinary one-way ANOVA are marked by an asterisk. ** p ≤ 0.01, 
**** p ≤ 0.0001. 
Fig. 3.8 Percentage of IgM+ B cells. OVA-specific B cells from immunized mice were stained for their
expression of IgM and analyzed by flow cytometry. (A) Representative analyses out of 5 independent
experiments are shown. OVA-specific B cells (black line) were compared to B cells of non-immunized
(control) mice (left plot, grey line) and OVA-negative B cells of immunized mice (right plot, grey line).
Cells that were analyzed without antibody staining served as unstained control (filled histogram). (B)
The percentage of IgM+ B cells among OVA-specific (OVA+), OVA-negative (OVA-) or B cells of control
mice are shown. Bar charts show mean values ± SEM of three independent experiments. Significant
differences were calculated with ordinary one-way ANOVA are marked by an asterisk. ** p ≤ 0.01, 
*** p ≤ 0.001. 
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Fig. 3.9 Percentage of IgG+ B cells. OVA-specific B cells from immunized mice were stained for their
expression of IgG and analyzed by flow cytometry. (A) Representative analyses out of 5 independent
experiments are shown. OVA-specific B cells (black line) were compared to B cells of non-immunized
(control) mice (left plot, grey line) and OVA-negative B cells of immunized mice (right plot, grey line).
Cells that were analyzed without antibody staining served as unstained control (filled histogram). (B)
The percentage of IgG+ B cells among OVA-specific (OVA+), OVA-negative (OVA-) or B cells of control
mice are shown. Bar charts show mean values ± SEM of three independent experiments. Significant
differences were calculated with ordinary one-way ANOVA are marked by an asterisk. * p ≤ 0.05, 
**** p ≤ 0.0001. 
OVA-specific B cells show significantly higher expression of the MHC molecules I (190.00 % ±
6.17; Fig. 3.10) and II (202.20 % ± 3.43; Fig. 3.11) compared to control cells of non-
immunized mice or OVA-negative B cells of immunized mice (106.80 % ± 13.20 and 84.96 %
± 3.22, respectively).
Fig. 3.10 MHC I expression in OVA-specific B cells. OVA-specific B cells from immunized mice were
stained for their expression of MHC I and analyzed by flow cytometry. (A) Representative analyses
out of 5 independent experiments are shown. OVA-specific B cells (black line) were compared to B
cells of non-immunized (control) mice (left plot, grey line) and OVA-negative B cells of immunized
mice (right plot, grey line). Cells that were analyzed without antibody staining served as unstained
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control (filled histogram). (B) The mean fluorescent intensity (MFI) of MHC I of OVA-specific (OVA+)
and OVA-negative (OVA-) B cells in immunized mice were normalized to the expression levels in B
cells of control mice. Bar charts show mean values ± SEM of three independent experiments.
Significant differences were calculated with ordinary one-way ANOVA are marked by an asterisk. ** p
≤ 0.01, *** p ≤ 0.001. 
Fig. 3.11 MHC II expression in OVA-specific B cells. OVA-specific B cells from immunized mice were
stained for their expression of MHC II and analyzed by flow cytometry. (A) Representative analyses
out of 5 independent experiments are shown. OVA-specific B cells (black line) were compared to B
cells of non-immunized (control) mice (left plot, grey line) and OVA-negative B cells of immunized
mice (right plot, grey line). Cells that were analyzed without antibody staining served as unstained
control (filled histogram). (B) The mean fluorescent intensity (MFI) of MHC II of OVA-specific (OVA+)
and OVA-negative (OVA-) B cells in immunized mice were normalized to the expression levels in B
cells of control mice. Bar charts show mean values ± SEM of three independent experiments.
Significant differences were calculated with ordinary one-way ANOVA are marked by an asterisk. * p
≤ 0.05, **** p ≤ 0.0001. 
Moreover, the expression of the costimulatory molecules CD86 was significantly higher in
OVA-specific B cells (182.60 % ± 15.30; Fig. 3.12) than in control B cells or OVA-negative B
cells (110.50 % ± 10.49). Although OVA-specific B cells also upregulated the expression of
CD80 (129.90 % ± 49.06; Fig. 3.13), the differences to control B cells or OVA-negative B cells
(128.6 % ± 14.02) was not significant. KLH-specific B cells showed similar upregulation of the
activation markers (data not shown).
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Fig. 3.12 CD86 expression in OVA-specific B cells. OVA-specific B cells from immunized mice were
stained for their expression of CD86 and analyzed by flow cytometrry. (A) Representative analyses
out of 5 independent experiments are shown. OVA-specific B cells (black line) were compared to B
cells of non-immunized (control) mice (left plot, grey line) and OVA-negative B cells of immunized
mice (right plot, grey line). Cells that were analyzed without antibody staining served as unstained
control (filled histogram). (B) The mean fluorescent intensity (MFI) of CD86 of OVA-specific (OVA+)
and OVA-negative (OVA-) B cells in immunized mice were normalized to the expression levels in B
cells of control mice. Bar charts show mean values ± SEM of three independent experiments.
Significant differences were calculated with ordinary one-way ANOVA are marked by an asterisk. ** p
≤ 0.01. 
Fig. 3.13 CD80 expression in OVA-specific B cells. OVA-specific B cells from immunized mice were
stained for their expression of CD80 and analyzed by flow cytometry. (A) Representative analyses out
of 5 independent experiments are shown. OVA-specific B cells (black line) were compared to B cells
of non-immunized (control) mice (left plot, grey line) and OVA-negative B cells of immunized mice
(right plot, grey line). Cells that were analyzed without antibody staining served as unstained control
(filled histogram). (B) The mean fluorescent intensity (MFI) of CD80 of OVA-specific (OVA+) and OVA-
negative (OVA-) B cells in immunized mice were normalized to the expression levels in B cells of
control mice. Bar charts show mean values ± SEM of three independent experiments. Significant
differences calculated with ordinary one-way ANOVA were not detected.
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The percentage CD138+ B cells in OVA-specific B cells varied greatly in the different mice, but
overall was increased (7.18 % ± 5.07; Fig. 3.14) compared to control B cells (1.85 % ± 0.50)
and OVA-negative B cells (2.48 % ± 0.73). However, the difference was not significant. KLH-
specific B cells showed similar increase in CD138+ cells (data not shown).
Fig. 3.14 CD138+ OVA-specific B cells. OVA-specific B cells from immunized mice were stained for
their expression of CD138 and analyzed by flow cytometry. (A) Representative analyses out of 5
independent experiments are shown. OVA-specific B cells (black line) were compared to B cells of
non-immunized (control) mice (left plot, grey line) and OVA-negative B cells of immunized mice (right
plot, grey line). Cells that were analyzed without antibody staining served as unstained control (filled
histogram). (B) The percentage of CD138+ B cells among OVA-specific (OVA+), OVA-negative (OVA-)
or B cells of control mice are shown. Bar charts show mean values ± SEM of three independent
experiments. Significant differences calculated with ordinary one-way ANOVA were not detected.
These data clearly indicate a class-switched, activated phenotype of the isolated B cells as
expected for antigen-specific B cells of recently immunized mice (Good-Jacobson and
Shlomchik 2010).
3.1.3 Efficient Purification of Human Antigen-Specific B Cells Depends on Initial HBV-
Specific B Cell Frequency
Hepatitis-B-Virus (HBV) antigen was chosen as model antigen for the isolation of antigen-
specific B cells in a human setting. Blood donors vaccinated against HBV are easily accessible,
since by 2012 79 % of children in 183 World Health Organization (WHO) member states had
received HBV vaccination (WHO 2015). Nevertheless, non-vaccinated donors are still
available, since HBV vaccination only became a standard treatment in children in 1982.
The percentage of HBV-specific B cells among all CD19+ CD20+ B cells was determined by
labeling with antigen tetramers and FACS analyses (Fig. 3.1). For identification of the positive
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population, gates were adjusted to negative control donors. The percentage of HBV-specific
B cells varied greatly from 0.60 to 2.50 % in vaccinated donors normalized to control donors
(Fig. 3.15 middle plot and Fig. 3.16, lower left plot, respectively).
HBV-specific B cells could be enriched from PBMCs by positive selection via antigen
tetramers. The efficiency of the enrichment strongly depended on the grade of biotinylation
of the antigen as well as the initial frequency of HBV-specific B cells. Therefore, the purity of
the enriched cells varied between 13.57 and 34.35 % (Fig. 3.15, right plot and 3.16, lower
right plot, respectively). The percentage of B cells that were stained unspecifically for HBV
increased when purifying control B cells by antigen tetramers (Fig. 3.16, upper right plot).
However, the purity of the HBV-specific population was higher and therefore specific.
Fig. 3.15 Purification of HBV-specific B cells from donors with low frequencies. PBMCs from donors
were stained for HBV-specific B cells among the CD19+ CD20+ B cell population with HBV-Biotin
tetramers. Representative flow cytometry analyses out of 5 independent experiments with non-
vaccinated donors (control, left plot) or vaccinated donors (middle and right plot) are shown. HBV-
specific B cells of vaccinated donors were purified by positive selection with HBV-Biotin tetramers
(right plot). Numbers indicate the percentage of HBV+ B cells.
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The overall purity of CD19+ CD20+ B cells varied between 4.24 % and 23.31 % for non-
vaccinated non-purified donors and 9.22 % and 20.53 % for vaccinated antigen-enriched
donors (Fig. 3.17).
3.1.4 Human Antigen-Specific B Cells Show a Class-Switched Phenotype
Analogous to murine antigen-specific B cells, the isolated HBV-specific B cells were
characterized by FACS analysis for several surface markers defining their activation status
and developmental state. Bar charts represent results of at least three independent
Fig. 3.17 B cell purity of HBV-
enriched B cells. PBMCs of
vaccinated and non-vaccinated
donors were purified by
positive selection with HBV-
Biotin tetramers and stained
for CD19+ CD20+ B cells. Results
of at least 4 donors are shown.
Fig. 3.16 Purification of HBV-
specific B cells from donors
with high frequencies. PBMCs
from donors were stained for
HBV-specific B cells among
the CD19+ CD20+ B cell
population with HBV-Biotin
tetramers. Representative
flow cytometry analyses out
of five independent
experiments with non-
vaccinated donors (control,
upper plots) or vaccinated
donors (lower plots) are
shown. PBMCs were either
stained immediately (left
plots) or were purified by
positive selection with HBV-
Biotin tetramers (right plots).
Numbers indicate the
percentage of HBV+ B cells.
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experiments. Expression levels of B cells of vaccinated donors were normalized to the
expression levels of B cells of non-vaccinated donors.
The expression of the B cell marker CD20 was significantly upregulated in HBV-specific CD19+
CD20+ B cells (222.1 % ± 21.43) compared to control B cells of non-vaccinated donors or
HBV-negative B cells of vaccinated donors (122.0 % ± 8.69; Fig. 3.18). The same was
observed for the B cell marker CD19, which was significantly upregulated in HBV-specific B
cells (174.0 % ± 9.70) compared to control B cells and HBV-negative B cells (107.5 % ± 2.70;
Fig. 3.19).
Fig. 3.18 CD20 expression in HBV-specific B cells. HBV-specific B cells from vaccinated donors were
stained for their expression of CD20 and analyzed by flow cytometry. (A) Representative analyses out
of 3 independent donors are shown. HBV-specific B cells (black line) were compared to B cells of a
non-vaccinated (control) donor (left plot, grey line) and HBV-negative B cells of the same donor (right
plot, grey line). Cells that were analyzed without antibody staining served as unstained control (filled
histogram). (B) The mean fluorescent intensity (MFI) of CD20 of HBV-specific (HBV+) and HBV-
negative (HBV-) B cells in vaccinated donors were normalized to the expression levels in B cells of
control donors. Bar charts show mean values ± SEM of three independent experiments. Significant
differences were calculated with ordinary one-way ANOVA are marked by an asterisk. ** p ≤ 0.01. 
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Fig. 3.19 CD19 expression in HBV-specific B cells. HBV-specific B cells from vaccinated donors were
stained for their expression of CD19 and analyzed by flow cytometry. (A) Representative analyses out
of 3 independent donors are shown. HBV-specific B cells (black line) were compared to B cells of a
non-vaccinated (control) donor (left plot, grey line) and HBV-negative B cells of the same donor (right
plot, grey line). Cells that were analyzed without antibody staining served as unstained control (filled
histogram). (B) The mean fluorescent intensity (MFI) of CD19 of HBV-specific (HBV+) and HBV-
negative (HBV-) B cells in vaccinated donors were normalized to the expression levels in B cells of
control donors. Bar charts show mean values ± SEM of three independent experiments. Significant
differences were calculated with ordinary one-way ANOVA are marked by an asterisk. ** p ≤ 0.01.
Interestingly, in contrast to murine antigen-specific B cells, the percentage of IgD+ and IgM+
HBV-specific CD19+ CD20+ B cells was almost as high (77.67 % ± 7.69 and 83.26 % ± 8.83,
respectively) as in control B cells (85.14 % ± 8.11 and 76.42 % ± 6.87, respectively) and HBV-
negative B cells (79.07 % ± 6.86 and 77.80 % ± 5.71, respectively; Fig. 3.20 and Fig. 3.21,
respectively). IgD+ B cells could be subdivided into two types by additional staining for CD27.
Classical IgD+ CD27- naïve B cells were significantly decreased in HBV-specific B cells (38.78 %
± 10.07) compared to control (73.48 % ± 21.58) and HBV-negative B cells (59.75 % ± 8.01,
Fig. 3.22). IgD+ CD27+ B cells were significantly increased in HBV-specific B cells (45.89 % ±
12.67) compared to control (12.59 % ± 11.32) and HBV-negative B cells (23.52 % ± 9.04). The
percentages of classical IgD- CD27+ memory B cells were more or less equal in the different
populations. As expected, significantly more HBV-specific B cells were positive for IgG1
(34.89 % ± 5.66) compared to control B cells (6.09 % ± 1.14) or HBV-negative B cells (3.32 % ±
0.01; Fig. 3.23).
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Fig. 3.20 IgD+ HBV-specific B cells. HBV-specific B cells from vaccinated donors were stained for their
expression of IgD and analyzed by flow cytometry. (A) Representative analyses out of 3 independent
donors are shown. HBV-specific B cells (black line) were compared to B cells of a non-vaccinated
(control) donor (left plot, grey line) and HBV-negative B cells of the same donor (right plot, grey line).
Cells that were analyzed without antibody staining served as unstained control (filled histogram). (B)
The percentage of IgD+ B cells among HBV-specific (HBV+), HBV-negative (HBV-) B cells in vaccinated
donors and B cells of control donors are shown. Bar charts show mean values ± SEM of three
independent experiments. Significant differences calculated with ordinary one-way ANOVA were not
detected.
Fig. 3.21 IgM+ HBV-specific B cells. HBV-specific B cells from vaccinated donors were stained for their
expression of IgM and analyzed by flow cytometry. (A) Representative analyses out of 3 independent
donors are shown. HBV-specific B cells (black line) were compared to B cells of a non-vaccinated
(control) donor (left plot, grey line) and HBV-negative B cells of the same donor (right plot, grey line).
Cells that were analyzed without antibody staining served as unstained control (filled histogram). (B)
The percentage of IgM+ B cells among HBV-specific (HBV+), HBV-negative (HBV-) B cells in vaccinated
donors and B cells of control donors are shown. Bar charts show mean values ± SEM of three
independent experiments. Significant differences calculated with ordinary one-way ANOVA were not
detected.
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Fig. 3.22 IgD CD27 expression in HBV-specific B cells. HBV-specific B cells from vaccinated donors
were stained for their expression of IgD and CD27 analyzed by flow cytometry. The percentages of
the different IgD and CD27 subtypes of HBV-specific (HBV+), HBV-negative (HBV-) and control B cells
are shown. Bar charts show mean values ± SD of five independent experiments. Significant
differences were calculated with two-way ANOVA are marked by an asterisk. ** p ≤ 0.01, **** p ≤ 
0.0001.
Fig. 3.23 IgG1+ HBV-specific B cells. HBV-specific B cells from vaccinated donors were stained for
their expression of IgG1 and analyzed by flow cytometry. (A) Representative analyses out of 3
independent donors are shown. HBV-specific B cells (black line) were compared to B cells of a non-
vaccinated (control) donor (left plot, grey line) and HBV-negative B cells of the same donor (right
plot, grey line). Cells that were analyzed without antibody staining served as unstained control (filled
histogram). (B) The percentage of IgG1+ B cells among HBV-specific (HBV+), HBV-negative (HBV-) B
cells in vaccinated donors and B cells of control donors are shown. Bar charts show mean values ±
SEM of three independent experiments. Significant differences were calculated with ordinary one-
way ANOVA are marked by an asterisk. ** p ≤ 0.01. 
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HBV-specific B cells show significantly higher expression of the MHC molecule II HLA-DR
(169.7 % ± 24.75; Fig. 3.24) compared to control B cells. The difference to HBV-negative B
cells of the same donor was not significant (142.8 % ± 12.10).
Fig. 3.24 MHC II expression in HBV-specific B cells. HBV-specific B cells from vaccinated donors were
stained for their expression of MHC II and analyzed by flow cytometry. (A) Representative analyses
out of 3 independent donors are shown. HBV-specific B cells (black line) were compared to B cells of
a non-vaccinated (control) donor (left plot, grey line) and HBV-negative B cells of the same donor
(right plot, grey line). Cells that were analyzed without antibody staining served as unstained control
(filled histogram). (B) The mean fluorescent intensity (MFI) of MHC II of HBV-specific (HBV+) and
HBV-negative (HBV-) B cells in vaccinated donors were normalized to the expression levels in B cells
of control donors. Bar charts show mean values ± SEM of three independent experiments. Significant
differences were calculated with ordinary one-way ANOVA are marked by an asterisk. * p ≤ 0.05. 
Moreover, the expression of the costimulatory molecule CD86 was significantly higher in
HBV-specific B cells (133.3 % ± 8.33; Fig. 3.25) than in control B cells or HBV-negative B cells
(94.44 % ± 3.67). Although HBV-specific B cells also upregulated the expression of CD80
(230.1 % ± 59.58; Fig. 3.26), the differences to control B cells or HBV-negative B cells (152.4
% ± 74.68) was not significant.
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Fig. 3.25 CD86 expression in HBV-specific B cells. HBV-specific B cells from vaccinated donors were
stained for their expression of CD86 and analyzed by flow cytometry. (A) Representative analyses out
of 3 independent donors are shown. HBV-specific B cells (black line) were compared to B cells of a
non-vaccinated (control) donor (left plot, grey line) and HBV-negative B cells of the same donor (right
plot, grey line). Cells that were analyzed without antibody staining served as unstained control (filled
histogram). (B) The mean fluorescent intensity (MFI) of CD86 of HBV-specific (HBV+) and HBV-
negative (HBV-) B cells in vaccinated donors were normalized to the expression levels in B cells of
control donors. Bar charts show mean values ± SEM of three independent experiments. Significant
differences were calculated with ordinary one-way ANOVA are marked by an asterisk. ** p ≤ 0.01.
Fig. 3.26 CD80 expression in HBV-specific B cells. HBV-specific B cells from vaccinated donors were
stained for their expression of CD80 and analyzed by flow cytometry. (A) Representative analyses out
of 3 independent donors are shown. HBV-specific B cells (black line) were compared to B cells of a
non-vaccinated (control) donor (left plot, grey line) and HBV-negative B cells of the same donor (right
plot, grey line). Cells that were analyzed without antibody staining served as unstained control (filled
histogram). (B) The mean fluorescent intensity (MFI) of CD80 of HBV-specific (HBV+) and HBV-
negative (HBV-) B cells in vaccinated donors were normalized to the expression levels in B cells of
control donors. Bar charts show mean values ± SEM of three independent experiments. Significant
differences calculated with ordinary one-way ANOVA were not detected.
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Interestingly, the percentage of CD138+ CD20+ CD19+ was increased in HBV-specific B cells
(16.57 % ± 1.7; Fig. 3.27) compared to control B cells (8.41 % ± 1.3) and HBV-negative B cells
(6.77 % ± 0.7).
Fig. 3.27 CD138+ HBV-specific B cells. HBV-specific B cells from vaccinated donors were stained for
their expression of CD138 and analyzed by flow cytometry. (A) Representative analyses out of 3
independent donors are shown. HBV-specific B cells (black line) were compared to B cells of a non-
vaccinated (control) donor (left plot, grey line) and HBV-negative B cells of the same donor (right
plot, grey line). Cells that were analyzed without antibody staining served as unstained control (filled
histogram). (B) The percentage of CD138+ B cells among HBV-specific (HBV+), HBV-negative (HBV-) B
cells in vaccinated donors and B cells of control donors are shown. Bar charts show mean values ±
SEM of three independent experiments. Significant differences were calculated with ordinary one-
way ANOVA are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01. 
3.2 Stimulation with the CD40 Ligand Activates Antigen-Specific B Cells
Through stimulation with the CD40L and IL-4, B cells upregulate costimulatory and MHC
molecules and develop into highly efficient APCs (Schultze et al. 1997, Liebig et al. 2010).
This in vitro culture system is established for human and murine polyclonal B cells and leads
to more than 90 % pure CD40B cell cultures after 14 days. In order to use antigen-specific B
cells as antigen-presenting cells for cancer immunotherapy, the purified cells were cultivated
in the CD40 culture system for up to 14 days.
3.2.1 Murine Antigen-Specific B Cells Show a Proliferative Disadvantage in the CD40L
System
OVA-specific B cells were isolated from spleens of immunized C57BL/6 mice and enriched by
positive selection. The enriched OVA-specific B cells (80 % B cell purity and > 60 % OVA
purity) were cultivated on murine CD40L feeder cells (tmuCD40L HeLa cells). B cells were
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harvested on day 3, 7, 11 and 14 and recultivated on fresh feeder cells. The absolute
increase of cells in culture was determined (Fig. 3.28) and pictures (Fig. 3.29) as wells as cells
for Pappenheim staining (Fig. 3.30) were taken on day 7, 11 and 14. CD19+ B cells isolated
from non-immunized mice (> 90 % pure) served as controls.
The number of cells in OVA-cultures decreased from day 0 to 7, while the control cultures
stayed stable (Fig. 3.28). However, from day 7 to day 11 both cultures highly proliferated
resulting in a 1.3 fold expansion of initial cultures on day 14.
Fig. 3.28 Absolute increase of murine cells in the CD40L culture over 14 days. Purified B cells of
immunized or control mice were cultivated on CD40L-expressing HeLa cells over a period of 14 days.
The number of viable cells was determined every 3-4 days by trypan blue exclusion test. The absolute
increase was determined by calculating the increase between two passages in percentage. One
representative growth curve of 5 independent experiments is shown.
Control cultures formed evenly shaped round clusters on day 7, which stayed stable in size
and morphology until day 14 (Fig. 3.29 a-c). Pappenheim staining of control cultures showed
a typical lymphocyte appearance with a dark nucleus and a granulated cytoplasm (Fig. 3.30
a-d). As expected, the cell size increased from day 0 to day 7 and the cell shape appeared
impaired on day 14.
OVA cultures also formed clusters on day 7. However, their shape was not as round and
even as in control cultures and the magnetic beads from the purification process were still
visible (Fig. 3.29 d-f). Nevertheless, on day 14 OVA cultures showed a similar morphology to
control cultures with large round clusters. In Pappenheim staining, cells of OVA cultures
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showed a dark nucleus and a granulated cytoplasm (Fig. 3.30, e-h). However, compared to
control cultures their shape was not as even due to attachment of microbeads. On day 7, 11
and 14 cells appeared similar to control cultures with an increase in size and an impaired cell
shape on day 14.
Fig. 3.30 Morphology of B cells in CD40L cultures. Purified B cells of immunized or control mice were
cultivated on CD40L-expressing HeLa cells over a period of 14 days. A Pappenheim staining was
performed on day 0, 7, 11 and 14 of culture and pictures were taken at a 63x magnification using a
Zeiss AxioPhot microscope. Representative pictures of 5 independent experiments are shown.
Control and OVA cultures were analyzed by FACS for the percentage of CD19+ B220+ B cells
and the percentage of OVA-specific among the CD19+ B220+ B cell population. Control
Fig. 3.29 Cluster formation of B
cells in CD40L cultures. Purified
B cells of immunized or control
mice were cultivated on CD40L-
expressing HeLa cells over a
period of 14 days. Pictures were
taken on day 7, 11 and 14 at a
10x magnification using a light
optical microscope fitted with a
digital camera. Representative
pictures of 5 independent
experiments are shown.
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cultures were > 90 % pure CD19+ B220+ B cells on day 0 and purity stayed stable until day 14
(Fig. 3.31). OVA cultures were about 80 % pure CD19+ B220+ B cells and increased to about
95 % until day 14. However, the percentage of OVA-specific cells among CD19+ B220 + B cells
decreased rapidly from more than 60 % on day 0 to about 10 % on day 7 and further
decreased until day 14 (Fig. 3.32).
Fig. 3.31 Increase of CD19+ B220+ B cells in CD40L cultures. Purified B cells of immunized or control
mice were cultivated on CD40L-expressing HeLa cells over a period of 14 days. Staining for CD19+
B220+ B cells was performed on day 0, 7, 11 and 14 and the percentage of B cells was determined by
flow cytometry analyses. Representative curves out of at least 10 independent experiments are
shown.
Since biotinylated OVA-antigen is used for the enrichment of OVA-specific B cells, the
question arose whether the observed decrease in the percentage of OVA-specific B cells is
Fig. 3.32 Decrease of OVA-specific B cells in
percentage among the CD19+ B220+ B cell
population in CD40L cultures. Purified B cells of
immunized mice were cultivated on CD40L-
expressing HeLa cells over a period of 14 days.
Staining for OVA-specific CD19+ B220+ B cells was
performed on day 0, 7, 11 and 14 and the percentage
of OVA-specific B cells was determined by flow
cytometry analyses. Representative bar charts of 3
independent experiments are shown.
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simply a failure of the staining method due to a blocked BCR. Therefore, mixed-lymphocyte
reactions were performed, in which OVA-specific CD40B cells from day 1, 7, 11 and 14 were
cocultured with OVA-specific OT-I T cells for 5 days. Proliferation of T cells was determined
by analyzing the decrease in CFSE labeling. B-to-T-cell ratios were kept constant for the
different time points. Therefore, induction of T cell proliferation by CD40B cells should
stay stable in case the percentage of OVA-specific B cells in culture was stable, but could
simply not be detected. Polyclonal CD40B cells were used as control. As expected,
proliferation of T cells decreased with decreasing B-to-T-cell ratios (Fig. 3.33). Moreover,
induction of proliferation decreased with increasing time in CD40B culture (day 7-14)
thereby confirming the decreasing percentages of OVA-specific B cells as determined by
FACS (Fig. 3.32).
Fig. 3.33 T cell proliferation induced by CD40-activated B cells. Purified B cells of immunized mice
were cultivated on CD40L-expressing HeLa cells over a period of 14 days. Cells from day 1, 7, 11 and
14 were cocultured in different ratios together with OT-I T cells for 5 days. Proliferation of T cells was
determined by flow cytometry analyses by a decrease in CFSE-staining. CD40B cells of non-
immunized mice served as control. Bar charts represent one independent experiment.
Another possible explanation for the decrease in the percentages of OVA-specific B cells
would be their differentiation into plasma cells and the subsequent loss of the BCR.
Therefore, OVA cultures were analyzed for their expression of the plasma cell marker
CD138+ over a period of 14 days (Fig. 3.34). Although the percentage of CD138+ B cells
increased in OVA cultures on day 7, it was not high enough to account for the decrease in
the percentage of OVA-specific B cells. Furthermore, in Pappenheim staining of OVA cultures
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(Fig. 3.29) no plasma cells could be detected, which would appear larger in size and with a
more distinct cytoplasm.
Fig. 3.34 Percentage of CD138+ B cells in CD40L cultures. Purified B cells of immunized or control
mice were cultivated on CD40L-expressing HeLa cells over a period of 14 days. Staining for CD138
was performed on day 0, 7, 11 and 14 and the percentage of CD138+ B cells was determined by flow
cytometry analyses. Representative bar charts of 3 independent experiments are shown.
Next, CD19+B220+ CD40B cells of control cultures and OVA+ or OVA- CD40B cells from OVA
cultures were stained for Annexin V as an indicator for cell apoptosis (Koopman et al. 1994).
OVA+ CD40B cells of OVA cultures showed a slight increase in Annexin V + staining (Fig. 3.35,
left column) compared to control CD40B cells with or OVA- CD40B cells (Fig. 3.35, right and
middle column, respectively). However, this difference was not high enough to explain the
decrease in the percentage of OVA-specific B cells.
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Fig. 3.35 Annexin V staining of CD19+ B220+ B cells in CD40L cultures. Purified B cells of immunized
or control mice were cultivated on CD40L-expressing HeLa cells over a period of 14 days. Staining for
Annexin V was performed on day 0, 7, 11 and 14 and the percentage of Annexin V+ OVA+ and OVA- B
cells of immunized mice or control B cells of non-immunized mice was determined by flow cytometry
analyses. Representative plots of 3 independent experiments are shown. Numbers indicate the
percentage of Annexin V+ B cells.
Having ruled out the explanations of an inaccurate staining, the differentiation into plasma
cells or an increased apoptosis, OVA-specific B cells were stained with CFSE in order to
analyze their proliferation behavior. CFSE segregates equally between daughter cells upon
cell division, thereby resulting in the sequential halving of cellular fluorescence intensity with
each successive generation. Interestingly, FACS analyses revealed that OVA-specific B cells
proliferated less (Fig. 3.36, black line) than B cells in control cultures (Fig. 3.36, filled line) or
OVA- B cells in OVA cultures (Fig. 3.36, grey line). Detailed analysis of the cultures by Flow
Jo’s proliferation tool (Flow Jo Version 10, Tree Star) revealed a much lower percentage of
dividing cells among OVA-specific B cells compared to control or OVA- B cells over the whole
culture period of 14 days (Table 3.1). Accordingly, the division index, which reflects the
Results
72
average number of cell divisions that a cell in the original population has undergone, was
between 20 and 30 fold smaller on day 7 and day 11 in OVA-specific B cells than in control or
OVA- B cells, respectively (Table 3.1). Although there was no difference between the three
populations in the proliferation index (Table 3.1), which only takes into account the divisions
of cells that actually respond, these data indicate a clear proliferative disadvantage of OVA-
specific B cells compared to OVA- B cells from the same cultures. The OVA-specific B cells
seem to stay in culture, but since they proliferate less than OVA- B cells their percentage in
the overall B cell population decreases constantly over a period of 14 days. Therefore, all
following experiments were performed with OVA-specific B cells that were cultivated in the
CD40 system for a maximum of 2 days.
Fig. 3.36 CFSE staining of B cells in CD40L cultures. Purified B cells of immunized or control mice
were stained with CFSE and cultivated on CD40L-expressing HeLa cells over a period of 14 days.
Proliferation of OVA+ (black line) and OVA- B cells (grey line) of immunized mice and control B cells
(filled) of non-immunized mice was determined on day 7, 11 and 14 measuring the decrease in CFSE
by flow cytometry analyses. Histograms represent one independent experiment.
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Table 3.1 Proliferation Analysis of B cells in CD40L culture. Purified B cells of immunized or control
mice were stained with CFSE and cultivated on CD40L-expressing HeLa cells over a period of 14 days.
Proliferation of OVA-specific and OVA-negative CD40B cells of immunized mice and control CD40B
cells of non-immunized mice was determined on day 7, 11 and 14 and analyzed with the Flow Jo
Proliferation Tool (Flow Jo Version 10).
3.2.2 Murine Antigen-Specific B Cells Upregulate Activation Markers upon CD40L
Stimulation
OVA-specific and polyclonal B cells that were kept in the CD40 culture for 1 day were
analyzed for the expression levels of several surface markers in order to confirm their
antigen-presenting phenotype. Bar charts represent results of at least three independent
experiments. Expression levels on day 1 of culture of the different CD40B cells populations
(OVA-specific and OVA-negative from immunized mice and control CD40B cells from non-
immunized mice) were normalized to the expression levels of the respective population on
day 0.
There was no difference in expression of the B cell marker B220 in any of the observed
CD40B cell populations on day 1 compared to their respective population on day 0 (Fig.
3.37). The B cell marker CD19 was upregulated in all CD40B cell populations from day 0 to
day 1 (Fig. 3.38), although the difference was only significant in control cells (121.2 % ±
47.59).
% Divided Cells Division Index Proliferation Index
Day 7
Control 56.6 1 1.77
OVA- 87.4 1.58 1.81
OVA+ 3.68 0.0534 1.45
Day 11
Control 69.4 1.19 1.71
OVA- 71.4 1.48 2.06
OVA+ 3.74 0.0784 2.1
Day 14
Control 3.69 0.04 1.08
OVA- 18.2 0.226 1.24
OVA+ 2.9 0.0417 1.44
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As expected, the percentage of IgG1+ B cells in the three CD40B cell populations increased
from day 0 to day 1 in culture. The increase was not significant for control CD40B cells (12.74
% ± 1.01), OVA-negative CD40B cells (74.20 % ± 0.81) or OVA-specific CD40B cells (90.52 % ±
1.23) on day 1 (Fig. 3.39).
Fig. 3.37 B220 expression in OVA-
specific CD40B cells on day 1 of
culture. The mean fluorescent
intensity (MFI) of B220 of control
CD40B cells, OVA-specific (OVA+) or
OVA-negative (OVA-) CD40B cells
on day 1 of the CD40 culture was
determined by flow cytometry and
values were normalized to the
expression levels in B cells of the
respective populations on day 0.
Bar charts show mean values ± SEM
of three independent experiments.
Significant differences calculated
with ordinary one-way ANOVA
were not detected.
Fig. 3.38 CD19 expression in OVA-
specific CD40B cells on day 1 of
culture. The mean fluorescent
intensity (MFI) of CD19 of control
CD40B cells, OVA-specific (OVA+) or
OVA-negative (OVA-) CD40B cells
on day 1 of the CD40 culture was
determined by flow cytometry and
values were normalized to the
expression levels in B cells of the
respective populations on day 0.
Bar charts show mean values ± SEM
of three independent experiments.
Significant differences were
calculated with ordinary one-way
ANOVA are marked by an asterisk.
* p ≤ 0.05. 
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Moreover, a significant difference in IgD+ CD40B cells was observed in control CD40B cells
(55.33 % ± 4.58) and OVA-negative CD40B cells (21.10 % ± 7.82) on day 1 (Fig. 3.40), but the
difference was not significant in OVA-specific CD40B cells (22.41 % ± 8.41). Interestingly,
IgM+ B cells were increased on day 1 in control CD40B cells (96.32 % ± 0.98), OVA-specific
CD40B cells (37.83 % ± 2.14) and OVA-negative CD40B cells (82.33 % ± 5.22; Fig. 3.41).
However, the differences were not significant. These data indicate that B cells further
undergo class-switch in the CD40 culture and on day 1 seems to be still in a transitional state
from IgD- IgMhigh IgG+ to IgD- IgMlow IgGhigh B cells.
Fig. 3.40 Percentage of IgD+ CD40B
cells on day 1 of culture. The
percentage of IgD+ B cells among
control CD40B cells, OVA-specific
(OVA+) or OVA-negative (OVA-)
CD40B cells on day 1 of the CD40
culture was determined by flow
cytometry and compared to the
percentages of the respective
populations on day 0. Bar charts
show mean values ± SEM of three
independent experiments.
Significant differences were
calculated with ordinary one-way
ANOVA are marked by an asterisk. *
p ≤ 0.05. 
Fig. 3.39 Percentage of IgG1+
CD40B cells on day 1 of culture.
The percentage of IgG1+ B cells
among control CD40B cells, OVA-
specific (OVA+) or OVA-negative
(OVA-) CD40B cells on day 1 of the
CD40 culture was determined by
flow cytometry and compared to
the percentages of the respective
populations on day 0. Bar charts
show mean values ± SEM of three
independent experiments.
Significant differences were
calculated with ordinary one-way
ANOVA are marked by an asterisk. *
p ≤ 0.05. 
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The expression of MHC I molecules was highly upregulated on day 1 (Fig. 3.42) in control
CD40B cells (1026.0 % ± 48.91), OVA-specific CD40B cells (507.1 % ± 10.81) and OVA-
negative CD40B cells (901.1 % ± 40.38). The same was observed for MHC class II molecules
(Fig. 3.43) for control CD40B cells (714.1 % ± 155.1), OVA-specific CD40B cells (342.9 % ±
11.42) and OVA-negative CD40B cells (757.0 % ± 188.7).
Fig. 3.41 Percentage of IgM+ CD40B
cells on day 1 of culture. The
percentage of IgM+ B cells among
control CD40B cells, OVA-specific
(OVA+) or OVA-negative (OVA-)
CD40B cells on day 1 of the CD40
culture was determined by flow
cytometry and compared to the
percentages of the respective
populations on day 0. Bar charts
show mean values ± SEM of three
independent experiments.
Significant differences calculated
with ordinary one-way ANOVA
were not detected.
Fig. 3.42 MHC I expression in OVA-
specific CD40B cells on day 1 of
culture. The mean fluorescent
intensity (MFI) of MHC I of control
CD40B cells, OVA-specific (OVA+) or
OVA-negative (OVA-) CD40B cells
on day 1 of the CD40 culture was
determined by flow cytometry and
values were normalized to the
expression levels in B cells of the
respective populations on day 0.
Bar charts show mean values ± SEM
of three independent experiments.
Significant differences were
calculated with ordinary one-way
ANOVA are marked by an asterisk.
**** p ≤ 0.0001. 
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Moreover, the expression of the costimulatory molecule CD86 (Fig. 3.44) was significantly
upregulated in OVA-specific CD40B cells (354.3 % ± 45.18) and OVA-negative CD40B cells
(315.6 % ± 81.78) and was even higher in control CD40B cells (425.8 % ± 57.90).
Although OVA-specific CD40B cells also upregulated the expression of CD80 (137.9 % ± 1.00;
Fig. 3.45) the difference to the expression on day 0 was not significant. No differences in
CD80 expression were observed in control CD40B cells (96.71 % ± 24.69) or OVA-negative
CD40B cells (76.81 % ± 15.77) from day 0 to day 1.
Fig. 3.43 MHC II expression in OVA-
specific CD40B cells on day 1 of
culture. The mean fluorescent
intensity (MFI) of MHC II of control
CD40B cells, OVA-specific (OVA+) or
OVA-negative (OVA-) CD40B cells
on day 1 of the CD40 culture was
determined by flow cytometry and
values were normalized to the
expression levels in B cells of the
respective populations on day 0.
Bar charts show mean values ± SEM
of three independent experiments.
Significant differences were
calculated with ordinary one-way
ANOVA are marked by an asterisk.
* p ≤ 0.05, ** p ≤ 0.01,  
**** p ≤ 0.0001. 
Fig. 3.44 CD86 expression in OVA-
specific CD40B cells on day 1 of
culture. The mean fluorescent
intensity (MFI) of CD86 of control
CD40B cells, OVA-specific (OVA+) or
OVA-negative (OVA-) CD40B cells
on day 1 of the CD40 culture was
determined by flow cytometry and
values were normalized to the
expression levels in B cells of the
respective populations on day 0.
Bar charts show mean values ± SEM
of three independent experiments.
Significant differences were
calculated with ordinary one-way
ANOVA are marked by an asterisk.
*** p ≤ 0.001, **** p ≤ 0.0001. 
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The percentage of CD138+ B cells was increased in all three populations from day 0 to day 1
(control CD40Bs: 4.67 % ± 1.28; OVA-specific CD40Bs: 11.08 % ± 3.11; OVA-negative CD40Bs:
3.41 % ± 0.35), although the differences were not significant (Fig. 3.46).
These data clearly indicate that B cells undergo class-switching when stimulated with the
CD40 ligand and that antigen-specific B cells upregulate costimulatory and MHC molecules,
which has already been shown for polyclonal CD40B cells (Ahmadi et al. 2008, Liebig et al.
2010).
3.2.3 Human Antigen-Specific B Cells are Activated by Stimulation with the CD40L
Purified HBV-specific B cells (~ 15 % B cell purity, ~ 30 % HBV-specific B cells) were kept in the
CD40 culture on CD40L-expressing NIH feeder cells for up to 14 days. B cells were harvested
Fig. 3.45 CD80 expression in OVA-
specific CD40B cells on day 1 of
culture. The mean fluorescent
intensity (MFI) of CD80 of control
CD40B cells, OVA-specific (OVA+) or
OVA-negative (OVA-) CD40B cells
on day 1 of the CD40 culture was
determined by flow cytometry and
values were normalized to the
expression levels in B cells of the
respective populations on day 0.
Bar charts show mean values ± SEM
of three independent experiments.
Significant differences calculated
with ordinary one-way ANOVA
were not detected.
Fig. 3.46 Percentage of CD138+
CD40B cells on day 1 of culture.
The percentage of CD138+ B cells
among control CD40B cells, OVA-
specific (OVA+) or OVA-negative
(OVA-) CD40B cells on day 1 of the
CD40 culture was determined by
flow cytometry and compared to
the percentages of the respective
populations on day 0. Bar charts
show mean values ± SEM of three
independent experiments.
Significant differences calculated
with ordinary one-way ANOVA
were not detected.
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on day 7, 11 and 14 and recultivated on fresh feeder cells. The absolute increase of cells in
culture was determined (Fig. 3.47) and pictures (Fig. 3.48) were taken on these days. PBMCs
isolated from non-vaccinated donors (~ 15 % B cells) served as controls.
The number of cells in HBV-cultures increased from day 0 to 7, while the number of cells in
control cultures decreased slightly (Fig. 3.47). From day 7 to day 11, the control cultures
started to proliferate, resulting in a 2 fold increase of the initial culture on day 14. While
proliferation of HBV-specific cultures stayed stable from day 7 to day 11, they highly
proliferated afterwards resulting in a 3.5 fold expansion of initial cultures.
Fig. 3.47 Absolute increase of human cells in the CD40L culture over 14 days. Purified B cells of
vaccinated (HBV) or PBMCs of non-vaccinated (control) donors were cultivated on CD40L-expressing
NIH cells over a period of 14 days. The number of viable cells was determined every 3-4 days by
trypan blue exclusion test. The absolute increase was determined by calculating the increase
between two passages in percentage. Growth curve represent 3 independent donors.
Control cultures formed clusters on day 7 and day 11 with larger and evenly shapes on day
14 in correlation with their proliferative behavior (Fig. 3.48, left column).
HBV cultures formed round and evenly shaped cluster on day 7, although magnetic beads
from the purification process were still apparent (Fig. 3.48, right column). However, from
day 11 on HBV cultures showed a less stable morphology with smaller and unevenly shaped
clusters.
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Control and HBV cultures were analyzed by FACS for the percentage of CD19+ CD20+ B cells
and the percentage of HBV-specific among the CD19+ CD20+ B cell population. B cell purity
constantly increased in control and HBV-specific cultures reaching a maximum on day 14 of
77 % and 97 % purity, respectively (Fig. 3.49). However, control cultures had started with a
lower B cells purity than HBV-specific cultures. However, the percentage of HBV-specific cells
among CD19+ CD20+ B cells decreased rapidly to about 1 % on day 14 as observed in murine
CD40B cultures (data not shown).
Fig. 3.49 Increase of CD19+ CD20+ B cells in CD40L cultures. Purified B cells of vaccinated (HBV) or
PBMCs of non-vaccinated (control) donors were cultivated on CD40L-expressing NIH cells over a
period of 14 days. Staining for CD19+ CD20+ B cells was performed on day 0, 7, 11 and 14 and the
percentage of B cells was determined by flow cytometry analyses. Results of 5 independent donors
are shown.
Fig. 3.48 Cluster formation of B cells
in CD40L cultures. Purified B cells of
vaccinated (HBV) or PBMCs of non-
vaccinated (control) donors were
cultivated on CD40L-expressing NIH
cells over a period of 14 days.
Pictures were taken on day 7, 11 and
14 at a 10x magnification using a
light optical microscope fitted with a
digital camera. Representative
pictures of 3 independent
experiments are shown.
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On day 7, 11 and 14 CD40B cells were analyzed for the expression levels of several surface
markers to confirm their antigen-presenting phenotype. The MFI of the molecules of interest
was normalized to the MFI of their respective culture on day 0.
Interestingly, the expression of MHC II molecules (HLA-DR) in HBV-specific cultures was
upregulated at first, but then decreased until day 14 to 59.60 % ± 7.66 (Fig. 3.50, red and
green line). Control cultures expressed significantly more HLA-DR on 14 days than HBV-
specific cultures, although the total increase was only minor (107.85 % ± 6.66; Fig. 3.49 blue
line).
Fig. 3.50 MHC II expression in HBV-specific CD40B cells in the CD40 culture. The mean fluorescent
intensity (MFI) of MHC II of Control CD40B cells, HBV-specific (HBV+) or HBV-negative (HBV-) CD40B
cells over a period of 14 days was determined by flow cytometry and values were normalized to the
expression levels in B cells of the respective populations on day 0. Curves show mean values ± SD of
three independent experiments. Significant differences were calculated with two-way ANOVA are
marked by an asterisk. ** p ≤ 0.01. 
The expression of the costimulatory molecules CD86 (Fig. 3.51, red and green line) was
highly upregulated in HBV-specific CD40B cultures, although the expression decreased from
day 11 to 14. CD86 was also upregulated in control cultures (2024 % ± 114), although there
was a significant difference to HBV-specific cultures (Fig. 3.51, blue line)
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Fig. 3.51 CD86 expression in HBV-specific CD40B cells in the CD40 culture. The mean fluorescent
intensity (MFI) of CD86 of Control CD40B cells, HBV-specific (HBV+) or HBV-negative (HBV-) CD40B
cells over a period of 14 days was determined by flow cytometry and values were normalized to the
expression levels in B cells of the respective populations on day 0. Curves show mean values ± SD of
three independent experiments. Significant differences were calculated with two-way ANOVA are
marked by an asterisk. *** p ≤ 0.001. 
HBV-specific CD40B cells (3046 % ± 807) and control B cells (2283 % ± 84) also highly
upregulated the expression of CD80 (Fig. 3.52, red and blue line, respectively). Interestingly,
the difference to HBV-negative CD40B cells in HBV cultures on day 14 was highly significant
(7760 % ± 594; Fig. 3.52, green line).
Fig. 3.52 CD80 expression in HBV-specific CD40B cells in the CD40 culture. The mean fluorescent
intensity (MFI) of CD80 of Control CD40B cells, HBV-specific (HBV+) or HBV-negative (HBV-) CD40B
cells over a period of 14 days was determined by flow cytometry and values were normalized to the
expression levels in B cells of the respective populations on day 0. Curves show mean values ± SD of
three independent experiments. Significant differences were calculated with two-way ANOVA are
marked by an asterisk. **** p ≤ 0.0001. 
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The percentage of CD138+ HBV-negative and control CD40B cells decreased from day 0 until
day 14 and there was no difference in the two populations (Fig. 3.53, green and blue line,
respectively). However, the percentage of CD138+ HBV-specific CD40B cells increased to
51.87 % ± 24.36 until day 14 (Fig. 3.53, red line). The difference to HBV-negative and control
CD40B cells was significant.
Fig. 3.53 Percentage of CD138+ B cells in the CD40 culture. The percentage of CD138+ B cells of
Control CD40B cells, HBV-specific (HBV+) or HBV-negative (HBV-) CD40B cells over a period of 14 days
was determined by flow cytometry. Curves show mean values ± SD of three independent
experiments. Significant differences were calculated with two-way ANOVA are marked by an asterisk.
**** p ≤ 0.0001. 
3.3 Murine Antigen-Specific CD40B Cells Efficiently Present Antigen to T Cells
In Vitro
To study the antigen-presenting function of murine OVA-specific CD40B cells, their ability to
stimulate an antigen-specific response of CD4+ or CD8+ T cells in vitro was investigated. For
this purpose, a mixed-lymphocyte reaction (MLR) assay was performed (Steinman and
Witmer 1978), in which protein-pulsed APCs are co-cultured together with CD4+ or CD8+ T
cells from OT-II or OT-I mice, respectively. T cell activation and proliferation is induced via
binding of the OVA-specific T-cell receptor to its antigen in the context of MHC presented on
APCs. Co-stimulatory signals complete the activation of T cells through binding of CD80 (B7-
1) and CD86 (B7-2) expressed on APCs to its receptor CD28 on the T cell surface (Galvin et al.
1992).
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OVA-specific B cells were purified from immunized C57BL/6 mice and activated in the CD40
system over night (OVA CD40Bs). In addition, they were incubated with 75 nM OVA-protein
for 24 hours prior to incubation with T cells. Polyclonal B cells from naïve C57BL/6 mice
served as control (control CD40Bs). The activation status of CD40B cells (80 % B cell purity
and > 60 % OVA purity) was confirmed by analyzing the upregulation of the expression
markers CD80, CD86, IAb (MHC II) and H2Kb (MHC I) by FACS (Fig. 3.42-3.45).
Bone-marrow derived dendritic cells served as alternative source of APCs and positive
control in MLRs, since they have long been viewed as the most potent APCs (Inaba et al.
1990). DCs were generated from bone-marrow derived CD34+ progenitor cells and matured
by addition of anti-CD40 antibody or LPS (herein after referred to as CD40 DCs or LPS DCs,
respectively). The two different stimuli were tested to cover the heterogeneity of DC subsets
(Shortman and Liu 2002). The phenotype and activation status of mature DCs was confirmed
by analyzing the > 90 % pure CD11b+ CD11c+ population (Fig. 3.54) for their upregulation of
the activation markers CD80, CD83, CD86 and IAb by FACS (Fig. 3.55).
Fig. 3.54 Purity of matured CD40 DCs and LPS DCs. Representative flow cytometry analyses of
CD40L-matured DCs (CD40 DCs, A) and LPS-matured DCs (LPS DCs, B) out of at least 5 independent
experiments are shown. Mature DCs were stained for CD11b+ CD11c+ cells. Numbers indicate the
percentages.
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Antigen-specific CD4+ or CD8+ T cells were isolated from OT-II or OT-I mice, respectively.
Antigen-specificity of the > 90 % CD3+ T cell population (Fig. 3.56, upper row) was
determined by analyzing the expression of TCR-chain Vβ5 on CD4+ or CD8+ T cells by FACS
(Fig. 3.56, lower row).
Fig. 3.55 Expression of activation markers
in mature DCs. Representative flow
cytometry analyses of CD40L-matured DCs
(CD40 DCs, A) and LPS-matured DCs (LPS
DCs, B) out of at least 5 independent
experiments are shown. Mature DCs were
stained for the activation markers CD80,
CD83, CD86 and IAb were indicated (black
line). Unstained cells served as control
(filled line).
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T cells were labeled with CFSE to measure their proliferation and were cultured together
with control CD40Bs (with or without protein), OVA CD40Bs (with or without protein), CD40
DCs or LPS DCs at various APC-to-T cell ratios (0:1, 3:1, 1:1, 1:5,1:10, 1:20, 1:50) for 5 days.
CFSE segregates equally between daughter cells upon cell division. When analyzed by FACS,
this sequential halving of fluorescence is visualized as distinct peaks in the histogram (Fig.
3.58).
Incubation of either CD4+ or CD8+ T cells with protein-pulsed control CD40Bs in a ratio 1:1
resulted in proliferation of a small proportion of T cells (8.43 % ± 3.45 and 4.61 % ± 2.45,
respectively; Fig. 3.57 A and B). However, this induction of proliferation was not significantly
higher than in non-pulsed control CD40Bs. Cocultures of protein-pulsed OVA CD40Bs with
either CD4+ or CD8+ T cells in a ratio of 1:1 resulted in high proliferation of the T cells (61.56
% ± 12.40 and 72.66 % ± 14.15, respectively). Although protein-pulsed OVA CD40Bs induced
more proliferation than OVA CD40Bs that received no additional OVA-protein (38.18 % ±
19.57 and 50.77 % ± 33.07, respectively), the difference was not significant. Moreover,
culture of T cells with CD40 DCs or LPS DCs in a ratio of 1:1 induced high proliferation of T
cells. Proliferation of CD4+ or CD8+ T cells was higher in CD40 DCs (77.11 % ± 6.02 and 97.62
% ± 1.09, respectively) than in LPS DCs (68.55 % ± 1.41 and 76.85 % ± 19.13, respectively).
However, the difference was not significant. Furthermore, there was no significant
Fig. 3.56 Purity of OT-I and OT-II T
cells. Representative flow
cytometry analyses of OT-II (CD4+ T
cells, left column) and OT-II (CD8+ T
cells, right column) T cells out of at
least 5 independent experiments
are shown. Purified T cells were
stained for CD3+ B220- cells (upper
row) and their expression of Vβ5.1 
TCR (lower row, black line).
Numbers indicate the percentages.
T cells from C57BL/6 mice served as
negative controls (grey line) and
unstained cells as staining control
(filled line).
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difference in induction of T cell proliferation between OVA CD40Bs and the two DC subtypes,
but proliferation was significantly lower in cocultures with control CD40Bs than with OVA
CD40Bs or DCs.
Fig. 3.57 T cell proliferation in co-cultures of APCs and OT-II or OT-I T cells in the ratio 1:1.
Polyclonal CD40B cells (Control CD40B cells), OVA-specific CD40B cells (OVA CD40B cells) CD40-
matured DCs (CD40 DCs) or LPS-matured DCs (LPS DCs) were left untreated (- OVA) or pulsed with
protein (+ OVA) over night. Afterwards, they were mixed with OT-I (A) or OT-II (B) T cells in a ratio of
1:1 and incubated for 5 days. Proliferation of T cells was determined by flow cytometry by a decrease
in CFSE labeling. Bar charts represent mean values ± SD of 4 independent experiments. Significant
differences were calculated with two-way ANOVA are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001. 
Performing four independent MLRs, it was observed that induction of proliferation by
peptide-pulsed OVA CD40Bs is dependent on APC-to-T-cell ratio. Increasing the ratio to 3:1
induced even more proliferation of CD4+ or CD8+ T cells (77.66 % ± 11.01 and 80.99 % ±
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17.17, respectively; Fig. 3.58 and Fig. 3.59). By decreasing the APC-to-T-cell ratio to 1:5 the
differences between protein-pulsed OVA CD40Bs cells (29.46 % ± 12.97 for CD4+ T cells and
34.12 % ± 20.15 for CD8+ T cells; Fig. 3.60) and OVA CD40Bs that did not receive additional
protein (14.20 % ± 9.68 for CD4+ T cells and 5.76 % ± 3.66 for CD8+ T cells) became more
obvious, although it was not significant. Induction of proliferation further decreased in an
OVA CD40Bs-to-T-cell ratio of 1:10 (7.81 % ± 4.53 for CD4+ T cells and 8.90 % ± 4.50 for CD8+
T cells; Fig. 3.61) and reduced to almost zero in ratios of 1:20 and 1:50 (data not shown).
CD40 DCs or LPS DCs were less affected by lower APCs-to-T-cell ratios. In CD40 DC cocultures
at a ratio of 1:10 induction of proliferation was still significantly higher than in control
CD40Bs (53.06 % ± 25.26 for CD4+ T cells and 89.40 % ± 4.06 for CD8+ T cells; Fig. 3.61).
Although induction of proliferation was lower in LPS DC cocultures (33.82 % ± 0.40 for CD4+ T
cells and 42.54 % ± 29.71 for CD8+ T cells) the difference to control CD40Bs was significant.
Even at low DC-to-T-cell ratios of 1:20 and 1:50, proliferation was still detected, although
differences to control CD40Bs were not significant anymore (data not shown).
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Fig. 3.58 T cell proliferation in
co-cultures of APCs and OT-II
or OT-I T cells in the ratio 3:1.
Polyclonal CD40B cells (control
CD40B cells), OVA-specific
CD40B cells (OVA CD40B cells)
CD40-matured DCs (CD40 DCs)
or LPS-matured DCs (LPS DCs)
were left untreated (- OVA) or
pulsed with protein (+ OVA)
over night. Afterwards, they
were mixed with OT-I (left
column) or OT-II (right column)
T cells in a ratio of 3:1 and
incubated for 5 days.
Proliferation of T cells was
determined by flow cytometry
by a decrease in CFSE labeling.
Representative flow cytometry
histograms out of 4
independent experiments are
shown. Numbers indicate
percentage of proliferated
T cells.
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Fig. 3.59 T cell proliferation in co-cultures of APCs and OT-II or OT-I T cells in the ratio 3:1.
Polyclonal CD40B cells (control CD40B cells), OVA-specific CD40B cells (OVA CD40B cells) CD40-
matured DCs (CD40 DCs) or LPS-matured DCs (LPS DCs) were left untreated (- OVA) or pulsed with
protein (+ OVA) over night. Afterwards, they were mixed with OT-I (A) or OT-II (B) T cells in a ratio of
3:1 and incubated for 5 days. Proliferation of T cells was determined by flow cytometry by a decrease
in CFSE labeling. Bar charts represent mean values ± SD of 4 independent experiments. Significant
differences were calculated with two-way ANOVA are marked by an asterisk. ** p ≤ 0.01, *** p ≤ 
0.001, **** p ≤ 0.0001. 
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Fig. 3.60 T cell proliferation in co-cultures of APCs and OT-II or OT-I T cells in the ratio 1:5.
Polyclonal CD40B cells (control CD40B cells), OVA-specific CD40B cells (OVA CD40B cells) CD40-
matured DCs (CD40 DCs) or LPS-matured DCs (LPS DCs) were left untreated (- OVA) or pulsed with
protein (+ OVA) over night. Afterwards, they were mixed with OT-I (A) or OT-II (B) T cells in a ratio of
1:5 and incubated for 5 days. Proliferation of T cells was determined by flow cytometry by a decrease
in CFSE labeling. Bar charts represent mean values ± SD of 4 independent experiments. Significant
differences were calculated with two-way ANOVA are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001. 
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Fig. 3.61 T cell proliferation in co-cultures of APCs and OT-II or OT-I T cells in the ratio 1:10.
Polyclonal CD40B cells (control CD40B cells), OVA-specific CD40B cells (OVA CD40B cells) CD40-
matured DCs (CD40 DCs) or LPS-matured DCs (LPS DCs) were left untreated (- OVA) or pulsed with
protein (+ OVA) over night. Afterwards, they were mixed with OT-I (A) or OT-II (B) T cells in a ratio of
1:10 and incubated for 5 days. Proliferation of T cells was determined by flow cytometry by a
decrease in CFSE labeling. Bar charts represent mean values ± SD of 4 independent experiments.
Significant differences were calculated with two-way ANOVA are marked by an asterisk. ** p ≤ 0.01, 
*** p ≤ 0.001. 
In addition, stimulation of T cell proliferation by either source of APC was accompanied by
an upregulation CD25 expression indicating T cell activation (Fig. 3.62- 3.65). In cocultures of
OVA CD40Bs and CD4+ or CD8+ T cells, upregulation of CD25 was high in ratios 3:1 (54.93 % ±
20.57 for CD4+ T cells and 85.54 % ± 5.80 for CD8+ T cells; Fig. 3.62) and 1:1 (46.45 % ± 16.39
for CD4+ T cells and 72.64 % ± 11.95 for CD8+ T cells; Fig. 3.63) and decreased in lower ratios
(Fig. 3.64 and Fig. 3.65 and data not shown) according to T cell proliferation. In ratios 3:1 and
1:1, the differences to control CD40Bs cells were significant and the influence of additional
protein pulsing became more obvious than in T cell proliferation. Although in cocultures with
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control CD40Bs upregulation of CD25 was detected in CD8+ T cells in ratios 3:1 and 1:1 (3.42
% ± 2.70 and 2.27 % ± 2.03, respectively), it dropped to almost zero in lower control CD40Bs-
to-CD8+ T-cell ratios (Fig. 3.64 and Fig. 3.65, and data not shown). CD4+ or CD8+ T cell
activation in a 3:1 ratio was high in CD40 DCs (60.72 % ± 20.48 and 84.54 % ± 5.80,
respectively) and LPS DCs (56.54 % ± 5.78 and 71.15 % ± 26.42, respectively;) and remained
above 10 % in all testes ratios.
Fig. 3.62 T cell activation in co-cultures of APCs and OT-II or OT-I T cells in the ratio 3:1. Polyclonal
CD40B cells (control CD40B cells), OVA-specific CD40B cells (OVA CD40B cells) CD40-matured DCs
(CD40 DCs) or LPS-matured DCs (LPS DCs) were left untreated (- OVA) or pulsed with protein (+ OVA)
over night. Afterwards, they were mixed with OT-I (A) or OT-II (B) T cells in a ratio of 3:1 and
incubated for 5 days. Activation of T cells was determined by staining for CD25 expression and
subsequent flow cytometry analysis. Bar charts represent mean values ± SD of 4 independent
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experiments. Significant differences were calculated with two-way ANOVA are marked by an asterisk.
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
Fig. 3.63 T cell activation in co-cultures of APCs and OT-II or OT-I T cells in the ratio 1:1. Polyclonal
CD40B cells (control CD40B cells), OVA-specific CD40B cells (OVA CD40B cells) CD40-matured DCs
(CD40 DCs) or LPS-matured DCs (LPS DCs) were left untreated (- OVA) or pulsed with protein (+ OVA)
over night. Afterwards, they were mixed with OT-I (A) or OT-II (B) T cells in a ratio of 1:1 and
incubated for 5 days. Activation of T cells was determined by staining for CD25 expression and
subsequent flow cytometry analysis. Bar charts represent mean values ± SD of 4 independent
experiments. Significant differences were calculated with two-way ANOVA are marked by an asterisk.
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Fig. 3.64 T cell activation in co-cultures of APCs and OT-II or OT-I T cells in the ratio 1:5. Polyclonal
CD40B cells (control CD40B cells), OVA-specific CD40B cells (OVA CD40B cells) CD40-matured DCs
(CD40 DCs) or LPS-matured DCs (LPS DCs) were left untreated (- OVA) or pulsed with protein (+ OVA)
over night. Afterwards, they were mixed with OT-I (A) or OT-II (B) T cells in a ratio of 1:5 and
incubated for 5 days. Activation of T cells was determined by staining for CD25 expression and
subsequent flow cytometry analysis. Bar charts represent mean values ± SD of 4 independent
experiments. Significant differences were calculated with two-way ANOVA are marked by an asterisk.
** p ≤ 0.01. 
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Fig. 3.65 T cell activation in co-cultures of APCs and OT-II or OT-I T cells in the ratio 1:10. Polyclonal
CD40B cells (control CD40B cells), OVA-specific CD40B cells (OVA CD40B cells) CD40-matured DCs
(CD40 DCs) or LPS-matured DCs (LPS DCs) were left untreated (- OVA) or pulsed with protein (+ OVA)
over night. Afterwards, they were mixed with OT-I (A) or OT-II (B) T cells in a ratio of 1:10 and
incubated for 5 days. Activation of T cells was determined by staining for CD25 expression and
subsequent flow cytometry analysis. Bar charts represent mean values ± SD of 4 independent
experiments. Significant differences were calculated with two-way ANOVA are marked by an asterisk.
** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
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3.4 Antigen-Specific CD40B Cells Migrate to Secondary Lymphoid Organs and
to the Tumor
For the induction of immunity, APCs need to encounter T cells. This process is particularly
regulated by chemokine gradients in the T-cell areas of secondary lymphoid organs (von
Andrian and Mempel 2003). By expressing molecules and receptors crucial for homing to
secondary lymphoid organs or attraction of T cells (von Bergwelt-Baildon et al. 2006, Guo et
al. 2009), they fulfill an important criterion for an efficient APC. However, little is known
about the in vivo migration of CD40-activated B cells. To assess their migration kinetics in
vivo, CD40B cells were generated from Luc+ C57BL/6 mice. B cells from Luc+ mice could be
stimulated with the CD40L without affecting their autofluorescence. Moreover, these cells
displayed the typical APC phenotype (Fig. 3.42-3.45). Polyclonal CD40B cells were injected
via two different routes and their location was tracked after different time points.
Administration routes were chosen to assess the following biological and clinical aspects:
first, possible paths of homing to peripheral lymph nodes, lymph or blood vessels; and
second, their relevance for clinical application. The general migration of polyclonal CD40B
cells after intravenous (i.v.) or subcutaneous (s.c.) injection was assessed by injecting 5 x 106
Luc+ CD40B cells (> 90 % pure) into C57BL/6 mice. Subcutaneous injection did not result in
migration to the secondary lymphoid organs at any of the observed time points (Fig. 3.66,
right column). However, after i.v. injection the Luc+ CD40B cells appeared in the spleen
within 12 hours and over a period of 5 day migrated to the abdominal lymph nodes (Fig.
3.66, left column). Luc+ CD40B cells could be detected in the abdominal lymph nodes for up
to 15 days (data not shown).
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To observe the migration behavior of OVA-specific CD40B cells in healthy mice, 1 x106 Luc+
OVA-specific CD40B cells (> 80 % B cells purity and > 60 % OVA purity) were injected i.v. into
C57BL/6 mice. Their migration behavior was similar to that of polyclonal CD40B cells. OVA-
specific CD40B cells appeared in the spleen within 12 hours and over a period of 5 days
migrated to the abdominal lymph nodes (Fig. 3.67). They could be detected for up to 15 days
(data not shown).
Tumor-infiltrating B cells in human breast cancer (Hansen et al. 2001) and B cells in the
tumor-draining lymph nodes in mice (Li et al. 2009) were shown to produce autoantibodies
against tumor targets, thereby suggestion an infiltration of tumors by antigen-specific B
Fig. 3.66 CD40B cells migrate to
spleens and lymph nodes in vivo. 5-
10 x 106 CD40B cells from Luc+ mice
were injected into C57BL/6 mice
subcutaneously (s.c.) or
intravenously (i.v.). 12 hours (12 h),
36 hours (36 h) or 5 days (5 d) after
injection, mice were analyzed for
the presence of the CD40B cells by
imaging in the IVIS 200 system.
Representative pictures out of 3
experiments are shown.
Fig. 3.67 OVA-specific CD40B
cells migrate to spleens and
lymph nodes in vivo. 1 x 106
CD40B cells from Luc+ mice were
injected into C57BL/6 mice
intravenously. 12 hours (12 h),
36 hours (36 h) or 5 days (5 d)
after injection, mice were
analyzed for the presence of the
CD40B cells by imaging in the
IVIS 200 system. Representative
pictures out of 3 experiments
are shown.
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cells. In order to test this hypothesis, the migration behavior of polyclonal and OVA-specific
CD40B cells was assessed in tumor-bearing mice. For this purpose, OVA-expressing E.G7
lymphoma cells were injected s.c. into the right flanks of C57BL/6 mice and tumors were
allowed to grow for 10 days until they became clearly apparent. EG.7 lymphoma cells were
analyzed for their expression of OVA-protein in the context of MHC II by FACS (Fig. 3.68).
1x106 Luc+ OVA-specific or polyclonal CD40B cells were injected i.v. into tumor-bearing mice
and their location was tracked for 14 days. Polyclonal CD40B cells showed the same
migration behavior as in healthy mice by traveling to the spleen and the lymph nodes and in
addition to the tumor draining lymph nodes. No Luc+ cells showed up in the tumor (Fig.
3.69).
Fig. 3.68 Expression of OVA-protein in the context of MHC II
on E.G7 lymphoma cells. Representative flow cytometry
analyses of E.G7 lymphoma cells out of at least 5 independent
experiments are shown. Cells were stained for the expression
of OVA-peptide in the context of MHC II (black line). EL4 cells
served as negative controls (grey line). Unstained cells served
as staining control (filled line).
Fig. 3.69 Polyclonal CD40B cells migrate to
lymphoid organs in tumor-bearing mice. 1 x 106
CD40B cells from Luc+ mice were injected into
C57BL/6 mice intravenously. 36 hours (36 h) or 5
days (5 d) after injection, mice were analyzed for
the presence of the CD40B cells by imaging in the
IVIS 200 system. Representative pictures out of 3
experiments are shown.
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OVA-specific CD40B cells migrated to the spleen and the lymph node over a period of 36
hours (Fig. 3.70). However, in contrast to polyclonal CD40B cells, they also appeared at the
tumor site in high amounts where they still could be detected on day 5. Some Luc+ cells
stayed in the spleen and the abdominal lymph nodes.
3.5 Antigen-Specific CD40B Cells Induce an Antigen-Specific Immune
Response In Vivo
When used as cellular adjuvant, polyclonal CD40B cells are able to present antigen to T
cells in order to induce an antigen-specific immune response in vivo (Wennhold et al. 2013)
and unpublished data). Moreover, OVA-specific CD40B cells migrate to the spleen and lymph
nodes when administered i.v. Based on the previous in vitro data, antigen-specific CD40B
cells should be more effective in inducing an antigen-specific immune response in vivo than
polyclonal CD40B cells. In order to test this hypothesis, in vivo cytotoxicity assays were
performed. For this purpose, different APCs were loaded with protein by protein-pulsing,
which is a common technique to deliver antigens to APCs (Inaba et al. 1990, Zitvogel et al.
1996). Protein pulsed APCs were injected according to a previously optimized vaccination
protocol (unpublished data) (Fig. 3.71): C57BL/6N mice were immunized i.v. three times in
Fig. 3.70 CD40B cells migrate to
lymphoid organs and the tumor in
tumor-bearing mice. 1 x 106 CD40B
cells from Luc+ mice were injected
into C57BL/6 mice intravenously. 36
hours (36 h) or 5 days (5 d) after
injection, mice were analyzed for the
presence of the CD40B cells by
imaging in the IVIS 200 system.
Representative pictures out of 3
experiments are shown.
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an interval of seven days with 5x106 APCs. On day 21, CFSE+ OVA-peptide pulsed target cells
were injected into immunized mice.
Fig. 3.71 Overview of the in vivo cytotoxicity assay. Different APCs loaded with protein were
injected three times in an interval of seven days. Peptide-pulsed CFSE-labeled target cells were
injected on day 21. On day 22, specific lysis of the target cells was analyses by flow cytometry.
The in vivo cytolytic activity of antigen-specific CD8+ T cells was determined by calculating
the specific lysis from the ratio of target cells in spleens. The specific lysis of immunized mice
was normalized to the specific lysis of negative controls.
Polyclonal and OVA-specific CD40B cells were generated from non-immunized or OVA-
immunized mice, respectively, by CD19+ selection and subsequent CD40-activation. Protein-
pulsed DCs served as standard to which CD40B cells were compared. Since isolated CD19+ B
cells of OVA-immunized mice consisted of 1-4 % OVA-specific B cells, DCs were either
injected at 93 % purity as a control (Fig. 3.54) or they were supplemented with 96-99 %
polyclonal CD40B cells (DCs+CD40Bs) to mimic OVA-specific B cell purity. All APCs showed
upregulation of activation markers before injection (Fig. 3.42-3.45+ 3.55). Positive controls
were immunized with OVA-protein and CpG in PBS and IFA. Negative controls were treated
with IFA and PBS only.
The antigen-specific response was significantly higher in mice that were immunized with
OVA-specific CD40B cells (27.51 % ± 14.57) than in mice that were immunized with
polyclonal control CD40B cells (11.12 % ± 4.92) (Fig. 3.72). Immunization with OVA-specific
CD40B cells, pure DCs, and positive controls resulted in similarly effective induction of
specific lysis. However, induction of immunity was significantly higher in mice immunized
with OVA-specific CD40B cells than in mice immunized with DCs+CD40Bs (8.17 % ± 3.12).
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Fig. 3.72 Antigen-specific CD40B cells induce specific lysis of target cells. C57BL/6N mice were
immunized with 5 x 106 APCs, i.e. polyclonal CD40B cells (Control CD40Bs), OVA-specific CD40B cells
(OVA CD40Bs), pure dendritic cells (CD40 DCs) or DCs + polyclonal CD40B cells (CD40DCs+B cells),
PBS+IFA as negative controls (Neg. Control), or IFA+PBS+OVA+CpG as positive controls (Pos. Control)
three times i.v. in an interval of seven days. The ratio of CFSE+ target cells in spleens was determined
by FACS (A) and the specific lysis was calculated by normalizing values to negative controls (B).
Representative FACS data of at least three independent experiments are shown (A). Bar charts show
mean values ± SD of specific lysis of three independent experiments with three mice per group (B).
Significant differences calculated with ordinary one-way ANOVA are marked by an asterisk. * p ≤ 
0.05, **** p ≤ 0.0001.  
3.6 Antigen-Specific B Cells Differentiate into Antibody-Secreting B Cells upon
Stimulation
The classic effector function of B cells is not the presentation of antigens to T cells, but the
secretion of antibodies upon differentiation into plasma cells. Although several monoclonal
antibodies are approved for the treatment of cancer in humans, they have several
drawbacks, e.g. their development is expensive and laborious (Chames et al. 2009, Weiner et
al. 2010) and even humanized monoclonal antibodies can be antigenic (Klee 2000).
Therefore, it seems plausible to transfer patient-derived plasma cells that produce
tumorantigen-specific antibodies (Moutai et al. 2014). Moreover, the combination of both
effector functions offers additional advantages for cancer immunotherapy.
Therefore, a protocol was developed to stimulate differentiation of antigen-specific B cells
into antibody secreting plasma cells using the well known stimulator of plasma cell
differentiation, IL-21 (Ozaki et al. 2004, Moutai et al. 2014), in combination with other
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stimulating cytokines and BCR antagonists. For this purpose, OVA-specific B cells were
isolated from immunized C57BL/6 mice (80 % B cell purity and > 60 % OVA purity) and were
incubated with the stimuli for 3 days. Plasma cell differentiation was determined by FACS
analyses for the percentage of CD138+ B cells. Polyclonal B cells from non-immunized mice
served as control.
The addition of IL-21 to OVA-specific B cell cultures increased the percentage of B220low
CD19+ CD138+ plasma cells from 13.28 % ± 7.70 to 18.27 % ± 6.94 (Fig. 3.73, left panel). In
addition of soluble CD40L the percentage of CD138+ plasma cells significantly increased to
44.24 % ± 0.76. However, IL-21 was crucial for this effect, since stimulation of OVA-specific B
cells with OVA-antigen, IL-4 and CD40L alone resulted in reduced percentage of CD138+ B
cells (16.89 % ± 13.55). OVA-specific B cells that were treated with IgM and IL-4 alone were
used as negative controls (12.22 % ± 7.22) and OVA-specific B cells that were treated with
LPS served as positive controls (58.09 % ± 23.28). LPS and IgM treated cells were not
additionally treated with OVA-antigen. However, the amount of OVA-antigen added during
the purification process is sufficient to results in stimulation as indicated by MLRs of
‘unpulsed’ OVA-specific B cells (chapter 3.3).
Control B cells from non-immunized mice, which showed a different phenotype upon
isolation, reacted differently to the stimuli than OVA-specific B cells (Fig. 3.73, right panel).
Treatment with OVA-antigen and IL-4 alone or in combination with IL-21 and treatment with
IgM and IL-4 almost similarly induced plasma cell differentiation (23.63 % ± 16.10, 22.69 % ±
14.44 and 25.42 % ± 13.70, respectively). In comparison, treatment with CD40L reduced the
differentiation into CD138+ plasma cells (15.71 % ± 2.56 with OVA+ IL-4+ IL-21+ CD40L and
10.79 % ± with OVA+ IL-4+ CD40L). However, stimulation with LPS resulted in the highest
percentages of CD138+ B cells (38.99 % ± 20.59).
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Fig. 3.73 Induction of plasma cell differentiation in antigen-specific and polyclonal B cells. OVA-
specific B cells (OVA) of immunized mice or CD19+ B cells of non-immunized mice (Control) were
stimulated with the indicated stimuli for 3 days and thereafter analyzed by flow cytometry for
expression of CD138. Bar charts show mean values ± SD of the percentage of CD138+ B cells in three
independent experiments. Significant differences calculated with two-way ANOVA are marked by an
asterisk. * p ≤ 0.05, ** p ≤ 0.01.  
Another possibility to enrich antigen-specific B cells is a memory isolation kit, which works by
specifically isolating IgG+ B cells. In order to confirm that stimulation with the specific
antigen is necessary for the differentiation into plasma cells from antigen-specific B cells,
KLH-specific B cells were purified by the memory isolation kit and stimulated with the same
stimuli as shown for OVA-specific B cells. However, instead of stimulating KLH-specific B cells
with their specific antigen, the non-specific OVA-protein was added. Unexpectedly, even
though the specific antigen KLH was not present, this experiment showed similar results as
OVA-specific B cells (Fig. 3.74 compared to Fig. 3.73). KLH-specific B cells seem to be
stimulated by anti-IgG antibodies contained in the memory isolation kit and therefore
respond by differentiation into plasma cells when stimulated with additional cytokines. In
OVA-specific B cells, purification with the memory isolation kit and additional treatment with
OVA-protein does not result in a higher differentiation into plasma cells than with OVA-
protein alone (data not shown). The lack of a method for the isolation of specific B cells
without stimulating the BCR, makes it difficult to determine the role of BCR signaling in
plasma cell differentiation.
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Fig. 3.74 Induction of plasma cell differentiation in antigen-specific B cells. KLH-specific B cells (KLH)
of immunized mice were stimulated with the indicated stimuli for 3 days and thereafter analyzed by
flow cytometry for expression of CD138. Bar charts show values of the percentage of CD138+ B cells
of one representative experiment.
Clearly the most important aspect when thinking about OVA-specific plasma cells for
immunotherapy is the actual secretion of OVA-specific antibodies. Therefore, the
supernatant of the differentiation cultures were collected and an OVA-specific Elisa was
performed. As expected, control B cells and KLH-specific B cells did not secrete any OVA-
specific IgG1 antibodies when treated with OVA-protein or any of the other stimuli (Fig.
3.75). In accordance with the observed changes in CD138+ B cells, OVA-specific B cells
secreted OVA-specific IgG1 antibodies when treated with OVA-protein and IL-4 (4.53 ng/ml),
OVA-protein + IL-4 + IL-21 (5.72 ng/ml) or OVA-protein + IL-4 + IL-21 + CD40L (6.44 ng/ml).
Moreover, stimulation with OVA-protein, IL-4 and CD40L without IL-21 led to a reduced
secretion of OVA-specific IgG1 antibodies (3.64 ng/ml). As expected, OVA-specific B cells
produced higher amounts of OVA-specific IgG1 antibodies when treated with LPS (25.52
ng/ml). In contrast to the low percentage of CD138+ B cells in OVA-specific B cells that were
treated with IgM and IL-4, the secretion of OVA-specific IgG1 antibodies was relatively high
(11.65 ng/ml).
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Fig. 3.75 Secretion of OVA-specific IgG1 antibodies in stimulated culture supernatants. OVA-specific
B cells (OVA) or KLH-specific B cells (KLH) of immunized mice or CD19+ B cells of non-immunized mice
(Control) were stimulated with the indicated stimuli for 3 days and supernatants were analyzed by
ELISA for the production of OVA-specific IgG1 antibodies. Bar charts show mean values ± SD of
antibody concentration in ng/ml of one independent experiment.
For in vivo experiments, OVA-specific B cells were stimulated with the combination of OVA-
protein, IL-4, IL-21 and CD40L, since differentiation into CD138+ cells and secretion of specific
antibodies were high and cells survived best over the culture period of 3 days (data not
shown).
3.7 The Combined Vaccination with Antigen-Specific CD40B Cells and Plasma
Cells Induces Anti-Tumor Immunity and Prolongs Survival
The experiments so far have confirmed the hypothesis that OVA-specific CD40B cells more
efficiently induce an antigen-specific T cell response than polyclonal CD40B cells in vitro and
in vivo. Therefore, the influence of a preventive immunization with tumor-antigen specific
CD40B cells on tumor establishment and growth was investigated. The E.G7 lymphoma cells
express OVA-protein in the context of MHC I and gives rise to H-2 Kb restricted cytotoxic
lymphocytes specific for the OVA 258-276 peptide and was therefore chosen as tumor
model. For preventive immunization, protein-pulsed APCs were injected into C57BL/6N mice
i.v. three times in an interval of seven days with APCs numbers varying between 0.1 and 0.6
x106 (Fig. 3.76). On day 21, immunized mice were inoculated with E.G7 tumor cells, which
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were analyzed for their expression of OVA-protein in the context of MHC I by FACS (Fig.
3.68). Tumor growth was observed the earliest on day 7 after tumor inoculation and daily
measured from there on.
Fig. 3.76 Overview of the tumor vaccination scheme. Different APCs loaded with protein were
injected three times in an interval of seven days. EG.7 lymphoma cells were injected on day 21.
Tumor growth was measured thereafter.
Polyclonal CD40B cells were isolated from non-immunized mice by CD19+ selection. OVA-
specific CD40B cells were isolated from immunized mice and purified by positive selection.
Both B cell populations were activated by CD40 stimulation for 2 days. On the day of
injection, polyclonal B cell cultures consisted of > 95 % CD19+ B cells and OVA-specific B cell
cultures consisted of > 80 % CD19+ > 60 % OVA-specific B cells. Protein-pulsed DCs served as
standard, to which CD40B cells were compared, and DCs were injected at 93 % purity (Fig.
3.54). The APC phenotype of B cells and DCs was confirmed by FACS analyses before
injection (Fig. 3.42-3.45+3.55). 0.1-0.6 x 106 cells were injected in 100 µl PBS. Positive
controls were immunized with OVA-protein and CpG in IFA. Negative controls were treated
with IFA and PBS only. For plasma cell differentiation, OVA-specific B cells were stimulated
with the combination of OVA-protein, IL-4, IL-21 and CD40L. Secretion of OVA-specific IgG1
antibodies was confirmed by ELISA (Fig. 3.77).
Fig. 3.77 Secretion of OVA-specific IgG1 antibodies. OVA-
specific B cells were stimulated with OVA-protein, IL-4, IL-21
and CD40L for 3 days in order to stimulate plasma cell
differentiation. The supernatant was collected and the
concentration of OVA-specific IgG1 antibodies was
determined by ELISA. Polyclonal CD19+ B cells served as
control. Bar charts represent one representative
experiment.
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Mice that were immunized with APCs before tumor inoculation showed a delayed tumor
growth compared to negative controls (IFA + PBS only) and positive controls (IFA + CpG+
OVA-Protein + PBS) (Fig. 3.78). On day 16 after tumor inoculation, the difference in tumor
volume of negative controls was significant to all other tested groups. Mice of the negative
control group died much earlier than the mice in all other groups and this difference was
significant to mice treated with CD40B cells alone or in combination with plasma cells (Fig.
3.79). Although tumors of positive controls grew faster and the mice died earlier than mice
that were treated with APCs, the differences were not significant.
Comparing the different APC treated groups, CD40B cells prolonged survival more efficiently
than did DCs. Tumors of mice that were treated with control CD40Bs grew faster than
tumors of mice treated with DCs. Nevertheless, mice of the control CD40B group died later
than mice that were treated with DCs. Both differences were not significant. Tumors of mice
that were treated with control CD40Bs grew also faster than tumors of mice that were
treated with OVA CD40Bs alone or combination with plasma cells. This difference was
significant on day 18. Moreover, mice treated with OVA CD40Bs alone or in combination
with plasma cells survived longer than control CD40B treated mice.
Tumors in DC treated mice grew faster and the mice died earlier than tumors of mice treated
with OVA CD40Bs alone or in combination with plasma cells. The difference was not
significant on day 24 to OVA CD40Bs alone, but to OVA CD40Bs in combination with plasma
cells.
The addition of plasma cells also resulted in a significant difference in tumor growth
between the mice treated with OVA CD40Bs and mice treated with CD40Bs in combination
with plasma cells.
The difference in survival of mice that were treated with OVA CD40Bs in combination with
plasma cells was significant to all other groups except for mice treated with OVA CD40Bs
alone or plasma cell alone.
Tumors of mice that were treated with plasma cells alone grew slower than tumors of
negative controls for the first 13 days, but afterwards in two of three mice the tumor volume
increased rapidly. However, one mouse stayed tumor free until the end of the experiment
and this difference was significant to negative controls.
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Fig. 3.78 Antigen-specific CD40B cells and plasma cells induce
anti-tumor immunity. C57BL/6N mice were immunized with
0.1-0.6 x 106 APCs, i.e. polyclonal CD40B cells (Control CD40Bs),
OVA-specific CD40B cells (OVA CD40Bs), pure CD40-activated
dendritic cells (CD40 DCs); PBS+IFA as negative controls (NC),
IFA+OVA+CpG as positive controls (PC); OVA-specific plasma
cells alone (OVA PCs) or in combination with OVA-specific
CD40B cells (OVA CD40Bs+ OVA PCs) three times i.v. in an
interval of seven days. On day 21, 0.4 x 106 E.G7 lymphoma
cells were injected into immunized mice and tumor growth was
measured every day thereafter. Growth curves show increase of tumor volume in mm3 of one
out of three representative experiments with three mice per group. Significant differences
calculated with two-way ANOVA are marked by an asterisk. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001, **** p ≤ 0.0001. Curves had to be terminated when one mouse of the group had to be 
sacrificed due to extensive tumor growth as indicated by †.
Results
110
Fig. 3.79 Antigen-specific CD40B cells and plasma cells prolong survival of tumor-bearing mice.
C57BL/6N mice were immunized with 0.1-0.6 x 106 APCs, i.e. polyclonal CD40B cells (Control
CD40Bs), OVA-specific CD40B cells (OVA CD40Bs), pure CD40-activated dendritic cells (CD40 DCs);
PBS+IFA as negative controls (NC), IFA+OVA+CpG as positive controls (PC); OVA-specific plasma cells
alone (OVA PCs) or in combination with OVA-specific CD40B cells (OVA CD40Bs+ OVA PCs) three
times i.v. in an interval of seven days. On day 21, 0.4 x 106 E.G7 lymphoma cells were injected into
immunized mice. Survival of mice was observed over a period of 40 days. Survival curves show one
out of three representative experiments with three mice per group. Significant differences were as
follows: * OVA PCs vs. Neg. Controls; * OVA CD40Bs vs. Neg. Controls; * Control CD40Bs vs. Neg.
Controls; * OVA CD40Bs+ OVA PCs vs. Neg. Controls/ Pos. Controls/ Control CD40Bs/ CD40 DCs.
Significant differences calculated with the Mantel-Cox test: * p ≤ 0.05.  
Discussion

Discussion
113
4. Discussion
The present study strongly underlines the potential of CD40B cells as APCs for cancer
immunotherapy and adds further advantages by combining induction of T cell immunity with
the secretion of specific antibodies, the B cell’s most prominent function in immune
response.
4.1 Murine Antigen-Specific B Cells are Class-Switched and Develop an APC
Phenotype when Stimulated with the CD40L
Several studies reported the detection of antigen-specific B cells in immunized mice (Julius et
al. 1976, Hayakawa et al. 1987, Hoven et al. 1989, Lalor et al. 1992, Townsend et al. 2001,
Newman et al. 2003), but only few focused on the isolation of those cells and some rather
relied on the use of mouse models with genetically modified B cells (Phan et al. 2003, Avalos
et al. 2014). None of the groups studied the antigen-presenting function of the antigen-
specific B cells.
In this study, antigen-specific B cells were isolated from mice and successfully enriched by
the use of antigen tetramers. Enrichment highly depended on the grade of biotinylation of
the antigen and the efficiency of immunization. This is in accordance with other studies
showing that a tetrameric antigen-labeling is crucial to include the whole antigen-specific B
cell repertoire (Franz et al. 2011). Detection of antigen-specific B cells in the mesenteric
lymph nodes varied, since they do not represent the only draining lymph nodes after i.p.
injection (Parungo et al. 2007). Therefore, lymph nodes were not included in the isolation of
antigen-specific B cells.
Compared to polyclonal B cells of non-immunized mice and immunized-mice, the antigen-
specific B cells showed a class-switched phenotype by downregulation of IgD and switch
from IgM to IgG. The enrichment of class-switched B cells is in agreement with antigen-
specificity of the isolated B cells, since it is well known that encounter of B cells with their
specific antigen results in isotype switching and somatic hypermutation (Good-Jacobson and
Shlomchik 2010). As expected for antigen-specific B cells that recently underwent activation,
MHC and costimulatory molecules were upregulated in OVA- and KLH-specific B cells
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(Lenschow et al. 1994, Nashar and Drake 2005, Rodriguez-Pinto 2005). In line with this, no
class-switch or activation was observed in OVA- or KLH-negative B cells in immunized mice.
The increase in the percentage of CD138+ antigen-specific B cells probably represents an
intermediate state of a part of the antigen-specific B cell population undergoing
differentiation into plasma cells (Lacotte et al. 2013). It was not expected that B220
expression stayed unchanged in antigen-specific B cell compared to control B cells. B220 is
suggested to regulate antigen-receptor mediated signal transduction by controlling
phosphorylation of multiple compartments (Brown et al. 1994). Moreover, downregulation
of B220 has been described previously in antigen-specific B cells of immunized mice (Lalor et
al. 1992, Smith et al. 1996) and after in vitro activation of B cells (Dustin et al. 1995).
However, the analyzed B cells in those studies were antibody-secreting CD138+ B cells. In
contrast, the B cells in the present study are mostly CD138- antigen-specific B cells and
therefore rather of the classical memory B cell phenotype that expresses B220 (McHeyzer-
Williams et al. 2000). The upregulation of CD19 in immunized mice was expected, since it
plays an important role in affinity maturation upon antigen encounter and the subsequent
antibody response (Del Nagro et al. 2005).
Stimulation with the CD40 ligand and IL-4 was shown to efficiently stimulate murine B
cells to proliferate and develop an antigen-presenting phenotype (Ahmadi et al. 2008, Liebig
et al. 2010). Accordingly, OVA-specific B cells proliferated when cultivated on CD40L-
expressing HeLa cells and showed the expected cluster formation and morphology (Liebig et
al. 2010). In addition, B cells could be highly enriched over a period of 14 days by stimulation
with the CD40L even when starting with a low B cell purity.
As expected from earlier studies on polyclonal CD40B cells (Ahmadi et al. 2008, Liebig et al.
2010), antigen-specific B cells further upregulate molecules that are involved in antigen-
presentation. Furthermore, they downregulate the expression of IgD and upregulate the
expression of IgM and IgG. This change was also observed in polyclonal B cells, thus
indicating an induction of class-switching and differentiation into memory B cells or
plasma cells (Good-Jacobson and Shlomchik 2010). The slight increase in the percentage of
CD138+ CD40B cells after one day in culture was expected, since it was shown that CD40
stimulation has an influence on the differentiation into plasma cells (Spriggs et al. 1992,
Grabstein et al. 1993, Maliszewski et al. 1993). B220 expression was slightly changed in
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control CD40B cells, OVA-specific and OVA-negative CD40B cells. However, this change was
not significant. The observed upregulation of CD19 after CD40L stimulation in antigen-
specific B cells was expected, since CD19 signaling decreases the threshold for BCR
stimulation (Depoil et al. 2008) and plays an important role in particular in class-switched B
cells, i.e. deficiency in CD19 signaling leads to an impaired affinity maturation and antibody
response (Kanegane et al. 2007, van Zelm et al. 2014).
Unexpectedly, antigen-specific murine B cells could not be expanded in the CD40 culture.
The percentage of OVA-specific B cells among the entire B cell population decreased rapidly,
even though the initial antigen-specific B cell purity was high. This observation is in line with
a study by Ahamdi et al. (Ahmadi et al. 2008), who cultivated B cells from antigen-
immunized mice on CD40L-expressing feeder cells and reported a drop in the percentage of
antigen-specific B cells in the first days of culture. They did in fact report a stabilization of
the percentages of antigen-specific B cells. However, these data were not shown in the
publication. Although the number of cells in culture decreased in the first seven days, the
loss of antigen-specific B cells due to apoptosis was only minor. Instead, antigen-specific
class-switched B cells seem to possess a proliferative disadvantage compared to the
polyclonal B cells that did not undergo class-switching. This hypothesis is supported by other
studies, which observed that the expansion capacity of murine IgG+ B was lower than that of
IgM+ B cells (Kometani et al. 2013). These results were different to studies with human B
cells, which do not show a dependence of proliferation on a class-switched phenotype
(Tangye et al. 2003).
The question arises why a strong activation occurs in antigen-specific CD40B cells as seen by
upregulation of MHC and costimulatory markers, although the proliferation is poor.
However, several experiments with soluble anti-CD40 antibodies indicate that the activation
of B cells is independent of the proliferation especially when using the CD40L for stimulation
(unpublished data).
Several factors might influence the outcome of antigen-specific B cell enrichment: from
varying immunization efficiency leading to low antigen-specific B cell frequency or low
affinity BCRs, over the grade of antigen biotinylation, to the strength of antigen-BCR cross-
linking during purification and the resulting activation signaling before culture (Avalos et al.
2014). Although it remains challenging to control these factors, in this study a reliable and
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efficient method was developed that provides antigen-specific B cell enrichment with stable
purity for the production of antigen-presenting B cells.
4.2 Human Antigen-Specific B Cells can be Isolated from PBMCs and Develop
an APC Phenotype when Stimulated with the CD40L
Various studies reported the detection of antigen-specific B cells in human PBMCs of
vaccinated donors , but only few focused on the isolation of those cells (Leyendeckers et al.
1999, Ward et al. 2008, Franz et al. 2011). Most studies relied on expansion and conversion
of memory B cells into antibody-secreting plasma cells to monitor B cell responses (Crotty et
al. 2003, Buisman et al. 2009, Fecteau et al. 2009, Corti et al. 2010). A recent approach
achieved the isolation of human tetanus toxoid-specific memory B cells by use of antigen-
tetramers (Franz et al. 2011) and further confirmed antigen-specificity by demonstrating
high affinity binding of the BCR antibodies to its antigen. However, the group did not
characterize the phenotype of the isolated B cells, nor did they stimulate their antigen-
presenting function.
In this study, antigen-specific B cells were isolated from vaccinated donors and enriched by
the use of antigen tetramers. The efficiency of the enrichment highly depended on initial
antigen-specific B cell frequency and the number of B cell available for purification.
Enrichment of HBV-specific B cells with high initial frequencies resulted in 30 % pure
populations, although the overall B cell purity could not be increased. The relatively low
frequency of B cells in PBMCs and the limitation of the number of PBMCs that can be
obtained from a donor, makes it challenging to increase the enrichment of antigen-specific B
cells. Higher B cell frequencies in spleens of mice and the overall higher number of available
splenocytes probably account for the differences observed in murine and human antigen-
specific B cell enrichment. Nevertheless, the here described enrichment technique achieved
higher purities of antigen-specific B cells than formerly described methods (Leyendeckers et
al. 1999, Ward et al. 2008).
The isolated antigen-specific B cells express several molecules defining their phenotype. As
expected, antigen-specific B cells upregulated IgG1 in comparison to non-specific B cells. At
first sight, the slight increase in IgD+ in antigen-specific B cells seems astonishing, since
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antigen-specific B cells would be expected to possess a classical memory B cells phenotype
(Coico et al. 1983, Ziegner et al. 1994). High expression of IgD would rather point towards a
naïve B cell phenotype. However, a closer analysis of the IgD+ subtypes revealed a lower
percentage of naïve IgD+ CD27- B cells in the antigen-specific B cell compartment compared
to control B cells and HBV-negative B cells. Moreover, another IgD+ B cell subpopulation has
been described that additionally expresses CD27 and thereby resembling neither the
classical naïve nor the classical memory B cell phenotype (Klein et al. 1999, van Zelm 2012).
These IgD+ CD27+ B cells appear to contain a high frequency of autoreactive cells (Koelsch et
al. 2007) and therefore are presumably antigen-specific. Interestingly, in the present study
the percentage of IgD+ CD27+ antigen-specific B cells was increased among the IgD+
subpopulation probably accounting for the observed overall increase in the percentage of
IgD+ B cells. The function of this antigen-specific subpopulation is however unclear.
Although antigen-specific B cells of the donors have not been recently activated, they
express higher levels of CD86 and MHC II than polyclonal B cells of the same donor. In this
context, human memory B cells were shown to express CD86, even after circulating in the
body for several years (Good et al. 2009) and unpublished data).
The percentage of CD138+ antigen-specific B cells was increased probably representing an
intermediate state of a part of the antigen-specific B cell population undergoing
differentiation into plasma blasts or plasma cells (Fink 2012). The upregulation of CD19
expression was expected in human antigen-specific B cells. Like in mice, CD19 is important
for affinity maturation and in addition for the development of memory B cells (van Zelm et
al. 2014). CD20 was upregulated in antigen-specific B cells. Although CD20 was the one of
the first B cell-specific differentiation antigen that was identified (Stashenko et al. 1980), its
specific function or ligand are still unknown. Nevertheless, a role in the regulation of B cell
activation and proliferation was demonstrated (Tedder et al. 1985) and CD20 was identified
to be a component of a multimeric cell surface complex that regulates Ca2+ transport across
the plasma membrane (Bubien et al. 1993, Kanzaki et al. 1997). However, its role in antigen-
specific B cells is even less well defined. On the one hand, CD20 was shown to be
downregulated upon CD40 signaling (Anolik et al. 2003) and to enable optimal B-cell
responses, specifically against T-independent antigens (Kuijpers et al. 2010). These
observations would be in contrast to the present data, since antigen-specific class-switched
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B cells usually develop through interaction with T cells and subsequent CD40 signaling
(Danese et al. 2004, Elgueta et al. 2009). On the other hand, in the context of BCR signaling,
CD20 induces calcium flux supporting BCR signaling (Walshe et al. 2008, Franke et al. 2011)
and anti-CD20 treatment results in a time-dependent inhibition of the BCR cascade (van de
Ven et al. 2012). This rather suggests an important role of CD20 in the BCR signaling and
therefore in antigen-specific B cells.
Stimulation with the CD40 ligand and IL-4 was shown to highly stimulate human B cells
proliferation and the development of an antigen-presenting phenotype (Schultze et al. 1997,
von Bergwelt-Baildon et al. 2004, Liebig et al. 2009). Accordingly, HBV-specific B cells
proliferated when cultivated on CD40L-expressing NIH cells and showed the expected cluster
formation and morphology (Liebig et al. 2009). B cell expansion over a period of 14 days was
not as high as expected from literature. This difference probably resulted from downsizing
the culture conditions in order to adjust to the low number of HBV-specific B cells. This has
been shown to impair B cell proliferation in preceding studies (unpublished data). Moreover,
the percentage of HBV-specific B cells stayed stable or decreased in culture (data not
shown). IgG+ antigen-specific B cells should not have a proliferative disadvantage as it was
observed for murine IgG+ B cells (Tangye et al. 2003). However, other factors might as well
contribute to the decrease of specific B cells in the culture: Initial HBV-purity was low, overall
proliferation was not high. Moreover, the percentage of CD138+ B cells increased
significantly in HBV-specific cultures from day 7 to day 14, which might indicate a
differentiation into plasma cells. Nevertheless, the overall B cells could be highly enriched
over a period of 14 days by stimulation with the CD40L even when starting with a low B cell
purity.
As expected from earlier studies on polyclonal CD40B cells (Lapointe et al. 2003, Liebig et al.
2009), antigen-specific B cells highly upregulate costimulatory molecules that are involved in
antigen-presentation. B cell activation in terms of CD86 and CD80 upregulation was shown
to be independent of B cell proliferation. Thus, the observed high activation despite the poor
proliferation was not contradictory. Unexpectedly, MHC II molecules stayed stable in
polyclonal B cells of non-vaccinated donors and where even downregulated in antigen-
specific and polyclonal B cells of vaccinated donors. This effect might also be explained by
insufficient culture conditions due to downsizing of the culture system. Whether the
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acquired antigen-presenting phenotype is effective enough to induce an antigen-specific T
cell response remains to be examined in human mixed-lymphocyte reactions.
4.3 Murine Antigen-Specific CD40B Cells Induce an Antigen-Specific T Cell
Response In Vitro and In Vivo
Murine and human CD40B cells were shown to present antigen to T cells, thereby inducing
an antigen-specific T cells response (Schultze et al. 1997, von Bergwelt-Baildon et al. 2002,
Ahmadi et al. 2008). In vitro induction of a T cell response in autologous MLRs requires TCR
signalling through binding to an autoantigen-MHC complex and T-cell activation through
costimulation by APCs. In our model, antigen-specific CD40B cells rapidly upregulate the
expression of the costimulatory molecules CD80 and CD86 and MHC I and II molecules.
Therefore, it was not astonishing that antigen-specific CD40B cells induce significant
proliferation and activation of both CD4+ and CD8+ antigen-specific T cells. In high B-to-T
cell ratios, OVA-specific CD40B cells were superior to polyclonal CD40B cells, thereby
supporting the hypothesis that the use of antigen-specific B cells improves antigen-
presentation by the B cells and thereby induction of a T cell response. The advantage of
antigen-specific B cells for the use as antigen-presenting CD40B cells over polyclonal B cells
lies in two characteristics provided by antigen uptake via their specific BCR. First, the BCR
affinity was shown to be directly proportional to the capacity of B cells to present antigen to
CD4+ T cells (Rodriguez-Pinto 2005), i.e. B cells with a very high affinity BCR (Ka of 5 x 1010 M-
1) could induce CD4+ T cell proliferation after being incubated with soluble antigen at
concentrations as low as 0.05 nM (Batista and Neuberger 1998). In the present study, the
antigen concentration for pulsing of APCs was 1500 times higher (75 nM). Nevertheless,
presentation after fluid-phase pinocytosis of antigen, as it occurs in polyclonal B cells,
required concentrations about 5000 times higher (Batista and Neuberger 1998).
Proliferation and activation by APCs was equally high in CD4+ and CD8+ T cells. One would
expect a higher response in CD4+ T cells, since presentation of exogenous antigens via MHC II
molecules is the classical pathway in professional APCs. However, the process of cross-
presentation has been described in dendritic cells and B cells (de Wit et al. 2010, Kurts et al.
2010), which allow professional APCs to process and present exogenously derived antigens
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on MHC class I molecules. Since CD40B cells were also observed to upregulate the
expression of MHC I molecules in the culture, it is no longer surprising that CD8+ T cells show
equally high responses. In lower B-to-T cell ratios OVA-specific CD40B cells were still more
potent in T cell induction than polyclonal CD40B cells. DCs are usually considered to be more
potent APCs than B cells (Salio et al. 2001). Therefore, it was astonishing that there was no
difference between OVA-specific CD40B cells and DCs in higher APC-to-T cell ratios. As
expected, differences between DCs and CD40B cells became apparent in lower APC-to-T cell
ratios. However, from a biological aspect it might be delusive to directly compare two such
fundamentally differing cell types. Murine DCs posses a 4.5 times higher surface than CD40B
cells (data not shown) and therefore express more costimulatory and MHC molecules on
their surface. Since both DCs and CD40B cells were shown to make contact with more than
one T cell at a time (Klein-Gonzalez et al. accepted 2015), a higher surface might lead to an
advantage in antigen presentation when the same numbers of APCs are compared in the
system. Nevertheless, from the aspect of clinical application it is of high relevance that
antigen-specific CD40B cells are equally potent APCs as DCs, especially when considering the
fact that, with regard to the clinical application as cellular adjuvant, CD40B cells in contrast
to DCs are available at almost unlimited numbers.
Very few studies have focused on the in vivo antigen-presenting capacity of CD40B cells. Two
independent reported that B cell activated with a soluble anti-CD40 antibody (HM40-3)
alone or in combination with CpG are weak inducers of cytotoxic T cell responses (Lee et al.
2008, Guo et al. 2009). However, two different studies contradicted these results by showing
that polyclonal CD40B cells induced LCMV-specific CD8+ T cell responses after i.p. vaccination
(Ritchie et al. 2004, Liebig et al. 2011). In the present study, OVA-specific CD40B cells
induced antigen-specific killing of target cells. Although antigen-specific B cells were only
enriched for CD19+ B cells and not for their antigen-specificity, therefore representing only 2
% of the B cell population, they induced a significantly higher cytotoxic T cell response than
polyclonal CD40B cells. Vaccination with enriched OVA-specific CD40B cells would probably
result in even stronger T cell responses. In order to match conditions of the antigen-specific
CD40B cells (i.e. 2 % OVA-specific B cells with 98 % polyclonal B cells), mature DCs were
mixed with polyclonal CD40B cells before injection. Interestingly, this combination did result
in only very weak CD8+ T cell induction, which was significantly lower than after vaccination
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with antigen-specific CD40B cells. Only when 95 % pure DCs were injected for vaccination,
equally high or higher specific lysis than with OVA-specific CD40B cells was observed.
Polyclonal CD40B cells might exert some inhibiting functions on DCs in the mixture (Tretter
et al. 2008), thereby accounting for the observed weak induction of T cell responses.
Taken together, these data provide evidence for the capacity of CD40B cells to induce T
cell responses in vitro and in vivo and that antigen-specific CD40B cells are indeed more
efficient APCs than polyclonal CD40B cells.
4.4 Tumorantigen-Specific CD40B Cells Home to Secondary Lymphoid Organs
and to the Tumor
An APC must physically encounter a T cell in order to induce an immune response. This takes
place in the secondary lymphoid organs. In the setting of the anti-tumor immune response
these interactions usually must occur in the tumor draining lymph nodes in order to achieve
a strong response. The in vivo migration experiments confirmed homing of polyclonal and
antigen-specific CD40B cells into the spleen and the abdominal lymph nodes. A five-day
period seems to be sufficient for the CD40B cells to arrive in the secondary lymphoid organs
after i.v. injection. This is in line with another study by Ahmadi et al., who could detect GFP+
CD40B cells of immunized mice in the spleen and lymph nodes seven days after injection by
flow cytometry analyses (Ahmadi et al. 2008). After s.c. injection polyclonal CD40B cells were
not detected by luciferase imaging. Therefore, s.c. injection was not included in subsequent
experiments. However, a recent study with GFP+ cells showed that a small number of
polyclonal CD40B cells homes to the secondary lymphoid organs after s.c. injection (Klein-
Gonzalez et al. accepted 2015). The luciferase detection method is probably not sensitive
enough to detect this small number of cells. In the lymphoid tissue, CD40B cells were
recently shown to accumulate in the B-cell follicles, but also to a small extend in the T-cell
zone or at the edge of the T-cell zone (Klein-Gonzalez et al. accepted 2015). These results
suggest that CD40B cells interact with T cells in the lymphoid organs. These findings imply a
clear advantage of CD40B cells over DCs, of which only 4 % of injected cells migrate to the
draining lymph nodes in mice and humans and rather stay at the site of injection (Steinman
and Banchereau 2007).
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As expected, polyclonal CD40B cells do not home to the tumor in E.G7 tumor-bearing mice,
but localize in the spleen, the abdominal lymph nodes and the tumor draining lymph nodes.
Excitingly, tumorantigen-specific CD40B cells appeared in the tumor three days after i.v.
injection while about half of the Luc+ CD40B cells remained in the spleen and the tumor
draining lymph nodes. Tumor-infiltrating B cells in human breast cancer (Hansen et al. 2001)
and B cells in the tumor-draining lymph nodes in mice (Li et al. 2009) were shown to produce
autoantibodies against tumor targets, thereby suggesting that at least some of the tumor
infiltrating B cells are antigen-specific. Tumor-infiltrating B cells also contribute to tumor cell
death by expression of granzyme B (Hagn et al. 2009) and TRAIL (Kemp et al. 2004), an
apoptosis inducing protein. Therefore, it was not completely unexpected to detect
tumorantigen-specific CD40B cells in the tumor. These findings offer new application
possibilities for CD40B cells in cancer immunotherapy. Loading of tumorantigen-specific
CD40B cells with magnetic beads that can be detected in MRI could allow early detection of
tumors. Moreover, tumorantigen-specific CD40B cells could be used as drug delivery vehicle
by loading them with oncolytic viruses.
4.5 Antigen-Specific B Cells can be Stimulated to Differentiate into Antibody-
Secreting Plasma Cells
Several protocols have been reported to differentiate B cells into antibody-secreting plasma
cells (Spriggs et al. 1992, Grabstein et al. 1993, Maliszewski et al. 1993, Kawabe et al. 1994,
Arpin et al. 1995, Callard et al. 1995, Han et al. 1995, Silvy et al. 1996, Randall et al. 1998,
Ozaki et al. 2004, Kometani et al. 2013). Most of these protocols have been focusing on B
cells in general rather than antigen-specific B cells, therefore leaving the class-switched
phenotype without consideration. However, at least one study reported the differentiation
of antigen-experienced IgG+ B cells into plasma cells after stimulation with the BCR ligand
(Kometani et al. 2013). In the present study, antigen-specific B cells were therefore
stimulated with crosslinked OVA-protein in order to trigger differentiation into plasma cells.
The combination of OVA-protein, IL-4, IL-21 and soluble CD40L induced expression of CD138,
a plasma cells marker, in about stimulated 50 % of B cells. The crucial influence of IL-21 was
not surprising, since this cytokines was reported in other studies to be essential for plasma
cell differentiation (Ozaki et al. 2004). However, the influence of CD40L was unexpected,
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because contradictory results have been reported on its role in plasma cell differentiation.
While several in vitro studies have suggested that CD40 signaling promotes B cell
differentiation and Ig secretion (Spriggs et al. 1992, Grabstein et al. 1993, Maliszewski et al.
1993), in vitro and in vivo studies in CD40-deficient mice have suggested that CD40
engagement may actively inhibit B cell differentiation into plasma cells (Kawabe et al. 1994,
Arpin et al. 1995, Callard et al. 1995, Han et al. 1995, Silvy et al. 1996, Randall et al. 1998).
However, those studies focused on differentiation of naïve B cells. In contrast, at least one
study supported the observation that CD40L stimulation is beneficial for differentiation of
antigen-experienced B cells into plasma cells (Kometani et al. 2013). Therefore, these
contradictory results might simply display the difference between naïve B cells and antigen-
experienced IgG+ B cells. Although LPS, which was used as positive control in differentiation
assays, induced stronger differentiation into CD138+ cells and higher antibody secretion than
other stimuli, it was not considered as stimulus for in vivo experiments. B cells that were
activated with bacterial stimuli were shown to possess regulatory functions (Tretter et al.
2008). Since only about 60 % of B cells in the assay differentiated into plasma cells when
stimulated with LPS, the risk was too high to induce immunosuppression rather than an anti-
tumor response when using LPS-differentiated cells for immunotherapy. Moreover, injection
of LPS is a known to induce a septic shock in humans and mice (Opal 2010).
Interestingly, beside LPS-treated cells the highest amount of OVA-specific IgG1 antibodies
was secreted by cells that were treated with IgM and IL-4. This was unexpected since only
about 12 % of IgM and IL-4 treated B cells differentiated into CD138+ cells. However, this
discrepancy can probably be explained by the existence of early antibody-secreting cells, so
called plasma blasts, that express MHC class II on their surface, but not yet CD138 (Manz et
al. 1998, Hoyer et al. 2004, Racine et al. 2011, Lacotte et al. 2013). However, this hypothesis
has to be confirmed by flow cytometry analyses of antibody-secreting cells in differentiation
assays. The secretion of IgG1, the most frequent antibody isotype in human serum and
probably the major effector of antigen clearance (Collins and Jackson 2013), by
differentiated cells could be established in this study. However, the secretion of other
antibody isotypes than IgG1 remains to be confirmed.
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4.6 Immunotherapy with Antigen-Specific CD40B Cells in Combination with
Plasma Cells Leads to Anti-Tumor Immunity and Prolongs Survival
So far antigen-specific CD40B cells proved to be superior APCs to polyclonal CD40B cells in
vitro and in vivo. Therefore, their ability to induce anti-tumor immunity in a preventive
vaccination approach was examined. With the expectation to enhance the anti-tumor
immune response, cellular and humoral immune functions of B cells were joined by
vaccinating mice with antigen-specific CD40B cells as APCs in combination with antibody-
secreting plasma cells. The vaccination with tumorantigen-specific CD40B cells induced anti-
tumor immunity, which resulted in the delayed growth of E.G7 lymphomas and a prolonged
survival of tumor-bearing mice. Excitingly, this response could be further improved with the
combinatorial vaccination of tumorantigen-specific CD40B cells and anti-tumor antibody-
secreting plasma cells. The differences in tumor growth and survival after combined
immunotherapy were significant to all other tested cell types and conditions. Polyclonal
CD40B cells were also shown to reduce tumor growth and prolong survival of tumor-bearing
mice. These data are supported by two studies that use CD40B cells for preventive
vaccination in LL-LCMV tumors or B16 melanomas (Ritchie et al. 2004, Liebig et al. 2011)
reporting a reduced tumor growth. In the later study, 1 x 107 CD40B cells were injected per
vaccination, which is 100 times more than were used here. It seems that even at low
numbers, CD40B cells overcome inhibitory mechanisms by the tumor. This idea is also
supported by a study on tumor-mediated immune suppression of CD40B cells. Phenotype,
migratory potential and antigen-presenting function of human CD40B cells were shown to
be resistant to PGE-2, IL-10, TGF-β and VEGF (Shimabukuro-Vornhagen et al. 2012). Tumor 
growth in mice vaccinated with peptide-pulsed DCs was reduced and survival prolonged,
however, not as efficiently as in mice that were treated with antigen-specific CD40B cells
alone or in combination with plasma cells. This was unexpected, since so far in vivo CD40B
cells have never been shown to be equal or superior to DCs as cellular adjuvants for
immunotherapy.
Whether antigen-specific CD40B cells or the combined immunotherapy with plasma cells will
be efficient when used in a therapeutic approach remains to be examined. Guo et al.
reported failure of 1 x 105 OVA-peptide pulsed CD40B cells to reduce tumor growth of E.G7
lymphomas in a therapeutic setting (Guo et al. 2009). Furthermore, Lee et al. showed no
Discussion
125
reduction of tumor growth when treating B16 melanoma-bearing mice with 4 x 105 RNA and
costimulatory-transfected CD40B cells (Lee et al. 2008). However, these studies used a
soluble anti-CD40 antibody (HM40-3) for the activation of B cells, which was demonstrated
to result in a weaker CD40 stimulus than activation by CD40L-expressing feeder cells
(Fanslow et al. 1994, Neron et al. 2011). When comparing the APC phenotype of the CD40B
cells in the studies of Lee et al. and Guo et al. with those obtained here, it becomes apparent
that stimulation with anti-CD40 antibodies does not result in the high upregulation of MHC
and costimulatory molecules that were observed in the present study. Therefore, it is likely
that in a therapeutic setting antigen-specific CD40B cells will prove to induce anti-tumor
immunity anyhow.
4.7 Concluding Remarks
Taken together, this study took the first step towards a use of human antigen-specific CD40B
cells as cellular adjuvant in cancer immunotherapy. Isolation and expansion of CD40B cells is
simple and fast resulting in high numbers of CD40B cells for adoptive transfer. Thus, they
provide several advantages over dendritic cell vaccines. Although human antigen-specific B
cells could not yet be expanded in the CD40 culture system, they were highly activated and
acquired an antigen-presenting phenotype. Moreover, a mixture of highly expanding
polyclonal B cells and few tumorantigen-specific CD40B cells is probably still advantageous
for T cell induction, since polyclonal B cells on their own where shown to be efficient
antigen-presenting cells. Although the combined preventive vaccination with antigen-
specific CD40B cells and plasma cells resulted in prolonged survival of mice, it remains to be
proven that they have an influence on tumor growth in a therapeutic setting. Treatment
with CD40B cells could also be combined with checkpoint blockade, i.e. anti-PD-L1 or anti-
CXCL4 antibodies, to further enhance the anti-tumor immunity. The next steps that need to
be taken into the direction of a clinical application are the isolation of tumorantigen-specific
B cells from cancer patients. One major challenge for the application of CD40B cells in the
clinic was recently solved by the development of a soluble CD40L that induces both
proliferation and activation of human B cells (Garcia-Marquez et al. 2014).
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Another exciting property of human and murine CD40B cells, which might be related to their
APC function, was recently discovered. CD40B cells form long extensions to T cells and other
CD40B cells when incubated together in a 3D-matrixgel (Fig. 4.1).
Fig. 4.1 Human CD40B cells form nanotubes. CD40B cells (green) were incubated in 3D-matrigel
together with human IL-2-stimulated CD3+ T cells (red). Images were taken with a confocal
microscope using a ×63 objective and an appropriate filter set.
These kind of extensions were observed in other types of immune cells including T cells
(Sowinski et al. 2008), NK cells (Chauveau et al. 2010), EBV-transfected B cells (Rainy et al.
2013) and others (Zhang 2011) with varying functions. A role of nanotubes in antigen-
presentation has not yet been shown. However, the fact that CD40B cells establish these
connections with T cells and that the shape of the connection point resembles the shape of
an immunological synapse (Robbiati and Guadagnini unpublished data) hints very much to
the involvement in antigen-presentation. However, more detailed analyses need to be
performed in order to reveal their function in B cell-T cell interaction.
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